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Ethnopharmacological relevance: Due to the location of Russia between West and East, Russian
phytotherapy has accumulated and adopted approaches that originated in European and Asian
traditional medicine. Phytotherapy is an ofﬁcial and separate branch of medicine in Russia; thus, herbal
medicinal preparations are considered ofﬁcial medicaments. The aim of the present review is to
summarize and critically appraise data concerning plants used in Russian medicine. This review
describes the history of herbal medicine in Russia, the current situation and the pharmacological effects
of speciﬁc plants in the Russian Pharmacopoeia that are not included in the European Pharmacopoeia.
Materials and methods: Based on the State Pharmacopoeia of the USSR (11th edition), we selected plant
species that have not yet been adopted in Western and Central Europe (e.g., selected for inclusion in the
European Pharmacopoeia) and systematically searched the scientiﬁc literature for data using library
catalogs, the online service E-library.ru, and databases such as Medline/Pubmed, Scopus, and the Web of
Science regarding species, effectiveness, pharmacological effects, and safety.
Results: The Russian Federation follows the State Pharmacopoeia of the USSR (11th edition), which
contains 83 individual plant monographs. Fifty-one of these plants are also found in the European
Pharmacopoeia and have been well studied, but 32 plants are found only in the Pharmacopoeia of the
USSR. Many articles about these medicinal plants were never translated in English, and much of the
information collected by Russian scientists has never been made available to the international
community. Such knowledge can be applied in future studies aimed at a safe, evidence-based use of
traditional Russian medicinal plants in European and global phytopharmacotherapy as well as for the
discovery of novel leads for drug development.
Conclusion: The review highlights the therapeutic potential of these Russian phytopharmaceuticals but
also highlights cases where concern has been raised about product safety and tolerability, which would
aid in supporting their safe use.
& 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).
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1. Introduction
Approximately 350,000 higher plants are estimated to exist
(Heywood 2011). Relatively speaking, very few medicinal plants
have been studied scientiﬁcally. Russia's large size and varied soils,
topography and climate favor the growth of an extensive number
of herbs, trees, and other plants. This had led to an active interest
in locally grown plants, which has stimulated serious study by
traditional healers and early ofﬁcial physicians alike. Herbal and
natural remedies are the product of hundreds of years of careful
observation of their therapeutic effects and risks; thus, their
properties and side effects are quite well known. In one approach,
scientists isolated one or more of the medicinal principles from
individual herbs in the laboratory (and possibly enhanced them
chemically) to create new medications that were often more
powerful than the original plant. This approach eventually led to
the development of a number of new herb-based medicines and
the creation of synthetic pharmaceuticals that duplicate the active
medicinal element of the original plant. Aspirin, codeine, digoxin,
and other drugs have their origins in herbal medicine (Yarnell,
2000). However, not all of these efforts were successful. Scientists
have often found that the herbs themselves, which possess unique
combinations of chemical components, are more effective than the
chemical derivatives (Li, 2002). As a result, medical science has
also focused on the medicinal values of the herbs themselves and
how they could best be incorporated into medical practice.
Although synthetic medicine continues to progress, the value of
medicinal plants (especially those in the highly developed and
unique Russian herbal medical tradition) remain largely unknown
in the West.
Nevertheless, information about plants that are referenced in
the Russian Pharmacopoeia and their applications remain
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fragmentary. The aim of the present review is to ﬁll this gap by
summarizing the data concerning plants used in Russian ofﬁcinal
medicine. This review describes the history of herbal medicine in
Russia, the current situation and the pharmacological effects of
plants that appear in the Russian Pharmacopoeia but are not
included in the European Pharmacopoeia. Such knowledge can be
applied to expanding the use of these plants in the pharmacother-
apy of European and other countries and in the development of
new drugs.
2. The history of herbal medicine in Russia
In many regions of the world and in a very generic way, the use
of herbal medicines can be classiﬁed into two main strands: popular
orally transmitted traditions that are passed on from generation to
generation and dogmatic or “ofﬁcial” traditions that today are often
based more on scientiﬁc investigation (Zevin et al., 1997).
Until the tenth century, popular Russian healing traditions had
a limited exchange of ideas between the various regions, at the
time when the herbal and medical literature was ﬁrst introduced.
At this time, copies of several Greek herbals found their way into
Russia through the monasteries and were eventually translated
into Russian. Unlike the herbal practice in other countries, how-
ever, the Russian herbal tradition was strong and well-established.
The ﬁrst pharmacy (potion store) (Rus¼ зелейная лавка) was
opened in Russia in the hospital of Kiev-Pechora Lavra in 1005–
1010 by the monk Makoveit from Athos; this event is likely to have
strengthened the Greek inﬂuence on Russian medicine. According
to the chronicles of the old city of Novgorod, Russian herbalists
(called "knowledgists") were able to cure infected wounds with
"banya mold" (Solovieva, 2005). In the thirteenth century, these
herbalists discovered the properties of the mold, which was used
to poultice wounds. This predates the development of penicillin in
England by seven centuries. Thus, these chronicles give a good
indication of the level of Russian popular medicine during this
period.
Starting in the mid-thirteenth century and for over three
hundred years, Russia was occupied by Tartars and Mongolians.
These people brought their own herbal traditions, which were
incorporated into healing praxis by local herbalists.
Although practically no information is available regarding the
following centuries, from the 15th to the 16th century, the Russian
empire expanded. Among its neighbors, Russia counted countries
in Western Europe and Asia, and herbalists began to accumulate
and adapt the Asian-Arabic and West European herbal traditions.
This led to the development of the unique features and advantages
of the Russian herbal system, combining autochthonous and
introduced knowledge and practice.
State-control over medicine in Russia can be traced back to the
end of sixteenth century. The ﬁrst enterprise to hold responsibility
for medical affairs was the Apothecary's Chamber, which was
opened in Moscow in 1581 by Tsar Ivan the Terrible (Ivan Grozny).
In 1620, this enterprise was reformed as the Apothecary's Order
(Blinova, Yakovlev, 1990). The ﬁrst head of the Apothecary's Order
was oprichnik (a member of an organization established by Tsar
Ivan the Terrible to govern the division of Russia known as the
Oprichnina), Knjaz Afanasy Vjazemsky. Apothecary James Frenc-
ham from Great Britain is generally regarded as the founder of the
ﬁrst Moscow Court Pharmacy - the progenitor of the Russian
medico-apothecary system. The exact date of its foundation is
uncertain but is likely to be in the years before 1581 (Appleby
1983). The Moscow Court Pharmacy in the Apothecary's Chamber
served the exclusive needs of the Tsar and his family (Appleby,
1983).
The ﬁrst public pharmacy was opened within a public hospital
on March 20, 1672 in Moscow. One famous herbalist manuscript,
"Cool vineyard" (rus¼ Прохладный вертоград) was published
in 1672. The main part of manuscript was "about the overseas and
Russian potions and about wood and herbs" (Sokolov, 2000).
In the eighteenth century, Tsar Peter the Great initiated major
reforms to the system. One of those reforms was the Apothecary's
Reform, which ﬁxed European normative and European type of
the pharmaceutical service. Under a decree by Peter the Great,
Korpisaari Island in Saint-Petersburg was designated in 1714 as the
location of the Apothecaries' Chancery and the principal Phar-
macy. At the same time, the local Apothecary's Garden was
founded.
Establishing of the State Academy of Science (1724) opened
new horizons in the systematization of knowledge and in surveys
of the rich Russian ﬂoral resources. New medicinal plants were
documented in the four-volume work, "Flora of Siberia", the result
of a Siberian expedition by I.I. Gmelin (1732-1743). After exploring
Siberia and the Volga river regions, academician P.S. Pallas pub-
lished the classical text, "Description of herbs of Russian State with
pictures". Prof. I.I Lepehin (1740-1802) promoted the utilization of
local ﬂora and argued that the importation of medicinal plants
should be decreased (Muraviova, 1991).
Russia was among the ﬁrst countries to compile a pharmaco-
poeia. In 1778, the Pharmacopoeia Rossica was published in St.
Petersburg by the Russian Academy of Science. This work contains
770 monographs, including 316 texts relating to herbal medicinal
preparations, 147 relating to chemical substances, and 29 relating
to the preparation of medicines from animal sources and complex
mixtures. Each entry is written mostly in Latin, but the Russian
name of the botanical simple or preparation is provided. Entries
for medicinal plants include their name, geographical origin,
odor, taste, therapeutic qualities, uses, doses, and preparation
(Tshibilaev et al., 2006). However, Russia's ﬁrst National Pharma-
copoeia written in Russian was published nearly a century later,
in 1866.
In the nineteenth century, European physicians had completely
forgotten about the herbal traditions that had once predominated
in their countries, whereas Chinese healers had almost no aware-
ness of the medical developments in the West. Russian doctors
were unique because they knew of both their own folk-herbal
tradition and of modern Western medicine.
The nineteenth century was marked by the beginning of the
study of the chemical composition of medicinal plants. Starting
with the isolation of atropine (1833), it became apparent during
the early 19th century that the pharmaceutical properties of plants
result from speciﬁc compounds that can be isolated and charac-
terized (Heinrich et al., 2012). For example, Prof. G.G. Dragendorff
(1879) published a series of articles on the "Relationship between
the chemical constituents and botanical features of plants" in the
Pharmaceutical Journal.
By the early twentieth century, Russian scientists had gener-
ated much scientiﬁc data regarding medicinal plants. However,
after the October revolution in 1917, the Soviet Union became
closed off from the rest of the world, and this research progress
was not shared for a long time. Luckily, the Soviet Union govern-
ment did not discard Russian medicine and herbalism. Many
institutes and academies for the study of medicinal plants were
established in all regions of the Soviet Union.
A new era of the intensive study of medicinal plants was
initiated in the middle of the twentieth century. On March 4,
1943, Joseph Stalin signed Order No 4654-p of the People’s
Commissars Council of the Union of Soviet Socialist Republics
"… to study limonnik (Schisandra chinensis (Turcz.) Baill. (Schisan-
draceae) with the purpose of ﬁnding tonic substances” for both
soldiers and persons working in the USSR defense industry during
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the SecondWorld War. In 1945, the stimulant effects of Schisandra on
nervous muscular excitability in humans were published (Panossian,
Wikman, 2008). As a result of intensive work by scientists in all parts
of the country, the concept of herbal substances that would increase
“the state of non-speciﬁc resistance” under conditions of stress was
developed, and the term “adaptogen” was formalized between 1947
and 1960. The term adaptogen was introduced in 1947 by N.V.
Lazarev while working on a synthetic compound, dibazol, which was
found to stimulate nonspeciﬁc resistance of organisms (Lazarev et al.,
1959). Later, the term ‘adaptogen’ was deﬁned more precisely by the
famous herbalists I.I. Brekhman and I.V. Dardymov. An adaptogen
must produce a nonspeciﬁc response, i.e., increase the power of
resistance against multiple (physical, chemical or biological) stres-
sors; have a normalizing effect, irrespective of the nature of the
pathology; and be nontoxic, innocuous and not inﬂuence normal
body functions more than required (Brekhman, Dardymov, 1969;
Panossian et al., 1999).
3. Current situation
The results of recent survey show that 14% of the Russian
population regularly uses phytopreparations for treatment and
44% uses them from time to time (Shikov et al., 2011). Phytother-
apy is a separate branch of medicine in Russia, and herbal
medicinal preparations (HMPs) are considered ofﬁcial medica-
ments. A herbal medicinal preparation is the ﬁnished product, and
this terms refers to a medical preparation containing herbal
materials and/or herbal preparations as its active ingredients.
More than 600 HMPs have been registered for use as medications
and are included in the Governmental Register of Medicinal
Preparations (Register Russia, 2012).
All aspects relating to the development, preclinical, and
clinical studies, evaluation, state registration, standardization and
quality control, manufacturing, preparation, storing, transporting,
importing and exporting, advertising, releasing, selling, using, and
disposing of pharmaceutical preparations (including HMPs) are
regulated by Federal Law No. 61 FZ (dated 12.04.2010) “Regarding
the circulation of drugs”.
4. Classiﬁcation of HMPs
Depending on the processing method used, herbal pharmaceu-
tical formulations can be classiﬁed into the following categories
(Severtsev et al., 2003):
(1) Medicinal plant materials are usually dried; however, freshly
gathered parts of medicinal plants (rarely, entire plants) are
sometimes used for the production of medical drugs. Medical
species are mixtures of several kinds of crushed or integral
plant materials with salts and ethers as additives.
(2) Summarized non-reﬁned or galenic formulations contain a
number of related substances together with the biologically
active substances. In the course of production, inactive ingre-
dients are removed from galenic formulations. Galenic for-
mulations include herb infusions and decoctions, tinctures,
extracts, and elixirs.
 Infusions and decoctions are liquid medicinal preparations
representing aqueous extracts from medicinal plant raw
materials, as well as aqueous solutions of dried material or
liquid extractions (concentrates).
 Tinctures are medicinal formulations in the form of alco-
holic and aqueous/alcoholic extracts of medicinal plant
materials (1:5 or 1:10) produced without heating or
removal of the extractant.
 Extracts are concentrated extractions from medicinal plant
materials in liquid (1:1), semi-solid (moistureo25%), or
dried (moistureo5%) forms.
 Elixirs are liquid medicinal formulations in the form of a
transparent mixture of alcoholic/aqueous extractions from
medicinal plant materials to which medical drugs, sugars,
and ﬂavors are added.
(3) Novo-galenic formulations are phyto-preparations containing
a mixture of biologically active substances that are free from
inert and concomitant ingredients. These formulations contain
a mixture of alkaloids, coumarins, etc. Novo-galenic prepara-
tions also include such substances as ﬂamine (a dried extract
of Helichrysum arenarium L ﬂowers containing ﬂavonoids),
ergotal (a mixture of ergot alkaloid phosphates), adonisid
(extract from Coronaria aerial parts), etc.
(4) Active pharmaceutical ingredients (APIs) are individual
compounds isolated from plants (serotonin, morphine, rutin,
lysergin, etc.). These compounds act directly, and most are
used to prepare injection formulations.
(5) Combined phyto-preparations combine the substances
extracted from plants with synthetic, endocrine and other
types of ingredients such as "Allokhol" (based on dry extracts
from garlic and nettle with coagulated active coal as an
additive), "Cholagolum" (which contains an extract of
Curcuma longa, emodin from the bark of Frangulaе alni,
magnesium salicylate, peppermint essential oil, eucalyptus
essential oil, olive oil, menthol, and ethanol), and "Valocor-
myde" (which is based on a tincture of valerian, lily of the
valley, and belladonna, and contains sodium bromide and
menthol as additives).
5. Information found in pharmacopoeia monographs
The Russian Federation follows the State Pharmacopoeia of
the USSR (11th edition). Last issued in 1987 (part 1) and 1990
(part 2), this Pharmacopeia includes 83 individual monographs
for plants.
Each monograph of the State Pharmacopoeia of the USSR
contains information including plant name (both Russian and
Latin), plant part, recommended collection time, macroscopic
evaluation (for whole and pulverized plant material), microscopic
observation, quantitative data (loss of material on drying, con-
centration of chemical constituents or biological activity), ash
content, ash content that is insoluble in 10% HCl, broken parts,
organic and mineral adulteration, qualitative assay (chemical
reactions or chromatography), fraction sieve analysis (for pul-
verised material), packaging, storage conditions, shelf life, and
pharmacological group. (Table 1).
Various plant parts are described in the Pharmacopoeia:
20 aerial parts (herb), 15 leafs, 13 fruits, 14 roots and rhizomes,
8 ﬂowers, 3 barks, 3 seeds, 2 buds, 1 mushroom, 1 cone, 1 alga,
1 column with stigmas, and 1 shoot.
Based on the main therapeutic indications, there are 13 expec-
torants, 8 diuretics, 7 astringents, 6 anti-inﬂammatory agents,
5 bitter agents (appetite stimulants), 5 laxatives, 3 tonics, 3 car-
diotonic agents, 3 cholinolytics, 3 diaphoretics, 2 cardiovascular
agents, 2 choleretics, 2 haemostatics, 2 antihelmintics, 2 poly-
vitamins, 2 sedatives, 1 antiseptic, 1 ambient, and 1 spasmolytic.
Three plants have no direct indications in the Pharmacopoeia or
in the online State Register of Medicinal Preparations. The term
"medicine of natural origin" indicates that a plant has a pharma-
cological application. Eleven plants have no pharmacological
indications in the Pharmacopoeia but have uses claimed in the
online State Register of Medicinal Preparations. Among these 11
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Table 1
Monographs for medicinal plants included in the State Pharmacopoeia of the USSR,
11th edition.
Monograph title Latin name of plant,
family (as in the State
Pharmacopoeia of the USSR)
Pharmacological
group
1. CORMUS LEDI
PALUSTRI
Ledum palustre L., Ericaceae Expectorant
2. CORTEX FRANGULAE
ALNI
Frangula alnus Mill.,
Rhamnaceae
Laxative
3. CORTEX QUERCUS Quercus robur L. Astringent
Querqus petrae Liebl.,
Fagaceae
4. CORTEX VIBURNI Viburnum opulus L,
Caprifoliaceae
Diuretic
5. FLORES
CALENDULAE
Calendula ofﬁcinalis L.,
Asteraceae
Antiseptic and anti-
inﬂammatory
6. FLORES
CENTAUREAE CYANI
Centaurea cyanus L., Asteraceae Diuretic
7. FLORES
CHAMOMILLAE
Chamomilla recutita (L.)
Rauschert (Matricaria recutita
L., M. chamomilla L.),
Asteraceae
Anti-inﬂammatory,
spasmolytic
8. FLORES CRATAEGI Crataegus sanguinea Pall.; Cardiovascular
С. laevigata (Poir.) DC.
[syn. С. oxyacantha sensu
Pojark.]
С. korolkowii L. Henry
С. altaica (Loud.) Lange
С. chlorocarpa Lenne et С. Koch
С. dahurica Koehne ex Schneid.
С. monogyna Jacq.
С. alemanniensis Cin.
С. orientobaltica Cin.
С. curvisepala Lindm.
С. Х curonica Cin.
С. Х dunensis Cin.
С. pentagyna Waldst. et Kit.,
Rosaceae
9. FLORES HELICHRYSI
ARENARII
Helichrysum arenarium (L.)
Moench, Asteraceae
Choleretic
10. FLORES SAMBUCI
NIGRAE
Sambucus nigra L.,
Caprifoliaceae
Diaphoretic
(sudoriﬁc)
11. FLORES TANACETI Tanacetum vulgare L.,
Asteraсеае
Antihelminthic and
choleretic
12. FLORES TILIAE Tilia cordata Mill.
T. platyphyllos Scop.,
Tiliaceae
Diaphoretic
(sudoriﬁc)
13. FOLIA
BELLADONNAE
Atropa bella-donna L.,
Solanaceae
Cholinolytic
(spasmolytic)
14. FOLIA DIGITALIS Digitalis purpures L.,
D. grandiﬂora Mill. (syn.
D. ambigua Murr.),
Scrophulareaceae
Cardiotonic
15. FOLIA EUCALYPTI
VIMINALIS
Eucalyptus viminalis Labill.,
Myrtaceae
Anti-inﬂammatory
16. FOLIA FARFARAE Tussilago farfara L.,
Asteraceae
Expectorant
17. FOLIA HYOSCYAMI Hyoscyamus niger L.,
Solanaceae
Cholinolytic
(spasmolytic)
18. FOLIA MENTHAE
PIPERITAE
Mentha piperita L., Lamiaceae Spasmolytic and
choleretic
19. FOLIA
MENYANTHIDIS
TRIFOLIATAE
Menyanthes trifoliata L.,
Menyanthaceae
Bitterness (appetite
stimulant) and
choleretic
20. FOLIA PLANTAGINIS
MAJORIS
Plantago major L.,
Plantaginacea
Expectorant
21. FOLIA
ORTHOSIPHONIS
STAMINEI
Orthosiphon stamineus Benth.,
Lamiaceae
Diuretic
22. FOLIA SALVIAE Salvia ofﬁcinalis L.,
Lamiaceae
Anti-inﬂammatory
23. FOLIA SENNAE Cassia acutifolia Del., Fabaceae Laxative
24. FOLIA STRAMONII Datura stramonium L.,
Solanaceae.
Cholinolytic
(spasmolytic)
25. FOLIA URTICAE Urtica dioica L., Urticaceae Haemostatic
26. FOLIA UVAE URSI Arctostaphylos uva-ursi (L.)
Spreng., Ericaceae
Diuretic
Table 1 (continued )
Monograph title Latin name of plant,
family (as in the State
Pharmacopoeia of the USSR)
Pharmacological
group
27. FOLIA VITIS-IDAEA Vaccinium vitis-idaea L.,
Ericaceae.
Diuretic
28. FRUCTUS ALNI Alnus incana (L.) Moench Astringent
A. glutinosa (L.) Gaertn.,
Betulaceae
29. FRUCTUS ANETHI
GRAVEOLENTIS
Anethum graveolens L.,
Apiaceae
Not claimed,
Spasmolyticn
30. FRUCTUS ANISI
VULGARIS
Pimpinella anisum L.
(Anisum vulgare Gaertn.),
Apicae
Not claimed,
Expectorantn
31. FRUCTUS CARVI Carum carvi L. Apiaceae Not claimed,
Spasmolyticn
32. FRUCTUS CRATAEGI Crataegus laevigata (Poir.) DC. Cardiovascular
(C. oxyacantha sensu Pojark.)
С. korolkovii L., Henry
С. altaica (Lond.) Lange
C. chlorocarpa Lenne
С. dahurica Koehne ex Schneid.
С. monogina Jacq.
С. alemanniensis Cin.
С. pentagyna Waldst. et Kit.
С. orientobaltica Cin.
С. curvisepala Lindm.
С. х curonica Cin.
С. х dunensis Cin.,
Rosaceae
33. FRUCTUS
FOENICULI
Foeniculum vulgare Mill.,
Apiaceae
Not claimed,
Spasmolyticn
34. FRUCTUS JUNIPERI Juniperus communis L.,
Cupressaceae
Diuretic
35. FRUCTUS MYRTILLI Vaccinium myrtillus L.,
Ericaceae
Astringent
36. FRUCTUS PADI Padus avium Mill. Astringent
P. asiatica Kom., Rosaceae
37. FRUCTUS RHAMNI
CATHARTICAE
Rhamnus cathertica L.,
Rhamnaceae
Laxative
38. FRUCTUS ROSAE Rosa majalis Herrm. Polyvitamin
(R. cinnamomea L.)
R. acicularis Lindl.
R. davurica Pall.
R. beggeriana Schrenk
R. fedtschenkoana Regel
R. canina L.
R. corymbifera Borkh.
R. micrantha Smith,
R. kokanica (Regel) Regel ex
Juz.,
R. psammophila Chrshan.,
R. tomentosa Smith,
R. zangezura P. Jarosch.,
R. rugosa Thunb.,
Rosaceae
39. FRUCTUS SORBI Sorbus aucuparia L.,
Rosaceae
Polyvitamin
40. FRUCTUS VIBURNI Viburnum opulus L.,
Caprifoliaceae
Diaphoretic, anti-
inﬂammatory
41. GEMMAE BETULAE Betula pendula Roth Diuretic
B. pubescens Ehrh.,
Betulaceae.
42. GEMMAE PINI Pinus silvestris L., Pinaceae Expectorant
43. HERBA ADONIDIS
VERNALIS
Adonis vernalis L.,
Ranunculaceae
Cardiotonic
44. HERBA ARTEMISIAE
ABSINTHII, FOLIA
ARTEMISIAE
ABSINTHII
Artemisia absinthium L.,
Asteraceae.
Bitterness (appetite
stimulant) and
choleretic
45. HERBA BIDENTIS Bidens tripartita L., Asteraceae. Anti-inﬂammatory
for external use
46. HERBA BURSAE
PASTORIS
Capsella bursa - pastoris (L.)
Medik., Brassicaceae
Not claimed,
Haemostaticn
47. HERBA CHELIDONII Chelidonium majus L.,
Papaveraceae
Anti-inﬂammatory
for external use
48. HERBA CENTAURII Centaurium erythraea Rafn
[syn.: C. minus Moench, C.
Bitterness (appetite
stimulant)
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plants, 4 are claimed as spasmolytics, 2 as haemostatics, one is an
expectorant, one is a hypotensive, one is a diuretic, one is a tonic,
and one is a metabolism regulator.
Approximately 60% of plants are referenced in the European
Pharmacopoeia and have been well studied in Europe, whereas 32
plants are included in the Pharmacopoeia of the USSR only.
In the following section, we discuss the plants that are included
only in the Pharmacopoeia of the USSR and focus on their
pharmacological effects and on safety, and clinical data.
5.1. Anti-inﬂammatory agents
5.1.1. HERBA BIDENTIS
The annual Bidens tripartita L. (Compositae) is 30–100 cm in
height with yellow ﬂowers (common names include threelobe
beggarticks, water agrimony, and burr marigold). In Russian
traditional medicine, an infusion of the aerial part of B. tripartita
L. is widely used in the treatment of catarrhal rhinitis, angina,
acute respiratory infection, and as an anti-inﬂammatory in
colitis, gout, and infantile rickets (Sokolov, 2000). This plant is
also used in oriental medicine as a diaphoretic and a diuretic in
nephrolithiasis (Sezik et al., 2004), as an antiseptic and as a bath
for children to treat diathesis (antiallergic action) (Blinova,
Yakovlev, 1990).
The safety of this plant has been studied in mice. An aqueous-
ethanol extract (1:1) of the aerial parts administered intraperito-
neally to mice had a median lethal dose of 750 mg/kg (Bhakuni
et al., 1971). No adverse effects were reported in rats after oral
Table 1 (continued )
Monograph title Latin name of plant,
family (as in the State
Pharmacopoeia of the USSR)
Pharmacological
group
umbellatum Gilib., Erythraea
Centaurium (L.) Borkh]
C. pulchellum (Sw.)
Druce [syn.: Erythraea
pulchella (Sw.) Hornem],
Centianaceae
49. HERBA
CONVALLARIAE,
FOLIA
CONVALLARIAE,
FLORES
CONVALLARIAE
Соnvallaria majalis L.,
C. transcaucasica Utkin ex
Grossh. C. keiskei Mig.
Liliaceae
Cardiotonic
50. HERBA EQUISETI
ARVENSIS
Equisetum arvense L.,
Equisetaceae
Diuretic
51. HERBA GNAPHALII
ULIGINOSI
Gnaphalium uliginosum L.,
Asteraceae
Not claimed,
Hypotensive, anti-
inﬂammatory,
cholereticn
52. HERBA HYPERICI Hypericum perforatum L. Astringent, antiseptic
H. maculatum Crantz
(H. quadrangulum L.),
Hypericaceae
53. HERBA MILLEFOLII Achillea millefolum L., Asteracea Not claimed,
Haemostatic,
anti-inﬂammatory
54. HERBA LEONURI Leonurus cardiaca L. Sedative
(L. cardiaca L. subsp. villosus
(Desf.) Jav.
Leonurus quinquelobatus Gilib.,
Lamiaceae.
55. HERBA ORIGANI Origanum vulgare L.,
Lamiaceae
Expectorant
56. HERBA POLYGONI
AVICULARIS
Polygonum aviculare L.,
Polygonaceae
Not claimed,
Diureticn
57. HERBA POLYGONI
HYDROPIPERIS
Polygonum hydropiper L.,
Polygonaceae
Haemostatic
58. HERBA POLYGONI
PERSICARIAE
Роlygonum persicaria L.,
Polygonaceae.
Not claimed,
medicine of natural
origin
59. HERBA
THERMOPSIDIS
LANCEOLATAE
Thermopsis lanceolata R. Вr.,
Fabaceae
Not claimed,
medicine of natural
origin
60. HERBA SERPYLLI Thymus serpyllum L.,
Lamiaceae.
Expectorant
61. HERBA THYMI
VULGARIS
Thymus vulgaris L., Lamiaceae Expectorant
62. HERBA VIOLAE Viola tricolor L. Expectorant
V. arvensis Murr., Violaceae
63. INONOTUS
OBLIQUUS
Inonotus obliquus (Pers.) Pil.,
Hymenochaetaceae
Not claimed,
Regulation of
metabolism, anti-
inﬂammatoryn
64. RADICES ALTHAEAE Althaea ofﬁcinalis L. Expectorant
A. armeniaca Ten.,
Malvaceae.
65. RADICES ARALIAE
MANDSHURICAE
Aralia elata (Miq.) Seem. Not claimed, Tonicn
(A. mandshurica Rupr. et
maxim.), Araliaceae.
66. RADICES GINSENG Panax ginseng С. А. Меу.,
Araliaceae
Tonic
67. RADICUS ONONIDIS Ononis arvensis L., Fabaceae Not claimed,
medicine of natural
origin
68. RADICES RHEI Rheum palmatum L. var
tanguticum Maxim.,
Polygonaceae
Laxative
69. RADICES TARAXACI Taraxacum ofﬁcinale Wigg.,
Asteraceae
Bitterness (appetite
stimulant) and
choleretic
70. RHIZOMATA
BERGENIAE
Bergenia crassifolia (L.)
Fritsch, Saxifragaceae.
Astringent, for
external use
71. RHIZOMATA
BISTORTAE
Polygonum bistorta L. Astringent
Table 1 (continued )
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72. RHIZOMATA
CALAMI
Acorus calamus L., Аrасеае Bitterness (appetite
stimulant) and
choleretic
73. RHIZOMATA ET
RADICES INULAE
Inula helenium L., Asteraceae Expectorant
74. RHIZOMATA CUM
RADICIBUS
POLEMONII
Polemonium caeruleum L.,
Polemoniaceae.
Expectorant
75. RHIZOMATA ET
RADICES RHODIOLAE
ROSEAE
Rhodiola rosea L., Crassulaceae Tonic
76. RHIZOMATA ЕТ
RADICES RUBIAE
Rubia tinctorum L. R. iberica
(Fish. ex DC). С. Koch,
Rubiaceae
Not claimed,
Spasmolyticn
77. RHIZOMATA CUM
RADICIBUS
VALERIANAE
Valeriana ofﬁcinalis L.,
Valerianaceae
Sedative
78. SEMINA
CUCURBITAE
Cucurbita pepo L.,
C. maxima Duch.
C. moschata (Duch.) Poir.,
Cucurbitaceae
Antihelminthic
79. SEMINA LINI Linum usitatissimum L.,
Linaceae
Ambient
80. SEMINA
SCHISANDRAE
Schisandra chinensis (Turcz.)
Baill., Schisandraceae
Tonic
81. STROBILI PICEAE
ABIETIS
Picea abies (L.) Karst., Pinaceae Anti-inﬂammatory
82. STYLI CUM
STIGMATIS ZEAE
MAYDIS
Zea mays L., Роасеае Choleretic
83. THALLI
LAMINARIAE
Laminaria saccharina (L). Lam.,
Laminariaceae
Laxative
n Pharmacological group according to the on line State Register of Medicinal
preparations.
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acute administration of aqueous infusion (10 g in 200 mL of
water) of B. tripartita at doses up to 20 mL/kg (Pozharitskaya
et al., 2010). Table 2 summarizes the pharmacological studies
that have been undertaken on B. tripartita and reported in the
literature.
In an open clinical trial without the use of a control group, a
70% EtOH extract of the aerial parts of the plant and an ointment
containing 2.5% of the extract were administered to 53 patients
with psoriasis. After oral administration of the extract (20 drops
three times daily) and simultaneous application of the ointment to
the affected areas of the skin once a day, the combination was
found to have anti-inﬂammatory activity as well as the ability to
stimulate adrenal function. After one week of treatment, desqua-
mation of the skin was decreased, and a decoloration of the
Table 2
Summary of Pharmacological Studies for B. tripartite.
Activity tested Model used Plant
part
used
Extract type Admin Dosage/
duration
Control Results Reference
Anticancer in vitro. Mouse
leukemia cells
L1210,
Not
speciﬁed
Methylene chloride
extract, soxhlet
96 well plate 10 μg per well Positive control
Methotrexate
Negative control
100% growth inhibition Goun et al.,
2002
Anti-
inﬂammatory
in vivo.
Carrageenan-
induced
edema in rats
Aerial
part
Crude aqueous infusion
(1:20 w/v). Active
compounds: (7)-
catechin, chlorogenic
acid, caffeic acid,
luteolin-7-O-glucoside,
chicoric acid,
rosmarinic acid,
luteolin,
hydroxycinnamic acid,
glycoside of luteolin,
polyacetylenes
Per oral 4, 10,
20 mL/kg 12 h
and at 2 h
before, and
immediately
after, injection
of carrageenan
Negative,
Indomethacin,
5 mg/kg
51.1% inhibition of
edema at the dose of
20 mL/kg, comparable
to indometacin.
Antipyretic effect
(normalization of paw
temperature) in 1 h
Pozharitskaya
et al., 2010
Antimicrobial in vitro. Broth
microdilution
method
in vitro. Disc
diffusion test
Dry
ﬂower
heads
and
herbs
Aqueous, MeOH/water,
acetone/water and
MeOH. MeOH extract
partitioned between
diethyl ether, EtOAc
and n-BuOH.
Dominating ﬂavonoid
in herb: cynaroside; in
ﬂower heads –
ﬂavanomarein
Essential oils by
hydrodistyllation
in vitro. No data Gram-positive:
Bacillus subtilis,
Micrococcus luteus,
Staphylococcus aureus.
Gram-negative:
Escherichia coli, E. coli
(β-lactamaseþ),
Klebsiella pneumoniae
(ESBLþ),
Pseudomonas
aeruginosa, Fungi:
Candida albicans, C.
parapsilosis,
Aspergillus fumigatus,
A. terreus
Weak activity against
Gram-positive bacteria
(MIC41.5 mg/mL) no
effect on Gram-
negative. Oil from
ﬂower heads activity
four-time higher than
from the herb.
Fungistatic effect of
oils, highest gainst C.
albicans and C.
parapsilosis
Tomczykowa
et al., 2008
Antioxidant in vitro. DPPH
assay
Dry
ﬂowers
and
herb
Aqueous, MeOH/water,
acetone/water and
MeOH crude extracts
in vitro. Radical scavenging for
MeOH/water extract of
ﬂowers - 68% ; for
acetone/ water extract
of herb -66%
Wolniak et al.
2007
in vitro. DPPH
assay
Aerial
part
Isoookanin 7-O-
glucoside, luteolin 7-O
glucoside, luteolin
in vitro. Radical scavenging :
25% for luteolin 7-O
glucoside, 41% for
luteolin
Wolniak et al.
2007
Antithrombin in vitro.
Thrombin
solution from
bovine plasma
Not
speciﬁed
Methylene chloride
extracts, soxhlet
96 well plate 50 μL Negative control 100% thrombin
inhibition
Goun et al.,
2002
Antiulcer in vivo.
Aspirin-
induced ulcer.
Indomethacin-
induced ulcer
of rats
Aerial
part
Crude MeOH and
aqueous extracts
Intragastric 500 mg/kg No data Antiulcer activity
against aspirin-
induced, but not
against indomethacin-
induced ulcers.
Muto et al.,
1994
Hepatoprotective in vivo. CCl4
induced
hepatitis of
rats
Aerial
part
Crude EtOH extract
(20-96%), crude
chloroform extract
Per oral 200 mg/kg,
6 days
Negative, Carsil,
100 mg/kg
EtOH extract (40%) was
most effective.
Decrease of ALT (51%),
ALP (40%), TG (53%),
increase of glycogen
(117%) in liver
Mikaelian et
al., 2006
Hypotensive in vivo.
Outbreed rats
Aerial
part
Crude EtOH extract (40,
96%), crude chloroform
extract
Intraperitoneal 100 mg/kg,
single
administration
Negative control Decrease of systolic
blood pressure in 35%
after 50 min (40% EtOH
extract). Decrease of
blood pressure 20%
during 5-60 min of
experiment
(chloroform extract)
Stepanova et
al., 2006
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psoriatic plaques was observed. Clinical recovery was recorded in
29 of the patients; an improvement in condition was recorded in
22 patients; and a failure of treatment was recorded in 2 patients
(Faraschuk, 1972; Levin et al., 1974).
Bidens tripartita was used in a clinical trial to treat 500 cases of
dysentery, 65 cases of acute enteritis, and 248 cases of chronic
enteritis. Different forms of the herb were used to prepare the
medicine; the daily amount was divided into three doses and used
in the following ways: 200 grams of fresh whole herb in decoction,
taken as three divided doses; 100 grams of dried herb in decoc-
tion, taken as three divided doses; granules of aqueous extract,
taken 5 grams each time, three times daily; 0.5 gram tablets of
aqueous extract, taken 10 tablets each time, three times daily;
injections of 2 mL each time, administered 2–3 times daily. The
granules and tablets prepared from granules were administered as
a total dose of 15 g/day (derived from approximately 75 g of dried
herb). The herbal materials in various forms were usually admi-
nistered for 3–10 days; to patients who had already suffered from
diarrhea, the herbs were administered for 7–15 days. In 500 cases
of dysentery, 387 cases were reported cured, of whom 13 did not
respond in 3 days. In 313 cases of enteritis, all were cured (12
chronic cases relapsed later). The author of the study noted that
there had been an epidemic of dysentery in Shandong Province for
many years and that practitioners at village clinics and at the
county hospital in Jianan County had used bidens as a remedy for
approximately 10,000 patients (Zhang, 1989).
Bidens tripartita is recommended for internal administration at
the dose of 1 tablespoon of the infusion (10 g in 200 mL of water)
taken 3–4 times a day and as one glass of an infusion of 10 g of cut
herb together with 100 g of cooking salt or sea salt per bath for
external use (Sokolov, 2000).
Bidens tripartita is a popular herb in Russia, and its safety and
efﬁcacy has been conﬁrmed through long use. The special mono-
graph Herba Bidentis was included in the World Health Organiza-
tion (WHO) monographs on medicinal plants commonly used in
the Newly Independent States (NIS) in 2010. However, there is a
lack of information in the public literature regarding its efﬁcacy. By
revealing more information about Bidens, broad studies of this
plant can lead to an improved appreciation of the extent of the
applications of this herb in medicine.
5.2. Diaphoretic and anti-inﬂammatory agents
5.2.1. FRUCTUS VIBURNI
Viburnum opulus L., also known as guelder rose, water elder,
European cranberrybush, cramp bark, and the snowball tree, is a
deciduous shrub of the Caprifoliaceae family and grows to 4–5m tall.
In Russian traditional medicine, an infusion of the fruit has been
used for the treatment of hemorrhoids, and the fruit juice has been
used as a laxative and for the treatment of colds, either alone or
mixed with honey (Utkin, 1931). The berries are recommended as a
source of vitamins and for use as a tonic, and a diuretic (Turova,
Sapozhnikova, 1989) and as hypotensive, choleretic, anti-inﬂamma-
tory, and sedative agents for use in hypertension, insomnia, con-
vulsions, and hysteria (Yelina, 1993). The berries are astringent;
therefore, they are seldom consumed directly. However, the juice is
one of the best-known products on the food market. People living
in the Middle Anatolia region of Turkey drink the juice to prevent
some stomach and kidney problems (Soylak et al., 2002).
The fruits are non-toxic (Ehrlen, Eriksson, 1993). The dry fruits
of V. opulus are safe at the recommended dose of 65 mL of
decoction (10 g of fruits in 200 mL of water) for use 3–4 times
per day and are available in pharmacies without a prescription
(Sokolov, 2000). Table 3 summarizes the pharmacological studies
that have been undertaken on V. opulus fruits and that are
reported in the literature.
No clinical data was found regarding V. opulus fruits in the
available literature. The fruits of V. opulus are recommended for
internal administration at the dose of 1/3 of a glass of the infusion
(10 g in 200 mL of water) 3–4 times a day (Sokolov, 2000).
V. opulus fruits can therefore be regarded as a promising and
under-explored fruit that has been used as food in Europe and
Asia and that might ﬁnd wider application for medicinal purposes.
However, the pharmacological effects of this fruit are not
well documented, and further study of this subject might prove
interesting.
5.3. Hypotensive, anti-inﬂammatory, and choleretic agents
5.3.1. HERBA GNAPHALII ULIGINOSI
Gnaphalium uliginosum L. (syn Filaginella uliginosa (L.) Opiz), a
member of the Compositae also known as Marsh cudweed, is an
annual plant widely used in Russian phytotherapy (Blinova, Yakovlev,
1999). In Russian and Bulgarian phytotherapy, this plant is used in the
treatment of hypertension and ulcers (Buturlin, 1953; Shchepotin et al.,
1984; Ivancheva, Stantcheva, 2000). Decoctions and infusions of the
aerial parts of G. uliginosum are known to possess anti-inﬂammatory,
astringent, and antiseptic properties (Sokolov, 2000). Some informa-
tion is available regarding the application of marsh cudweed for the
treatment of thrombophlebitis and phlebothrombosis (Turova,
Sapozhnikova, 1989; Shikov et al., 2010a). The hypotensive effect of
marsh cudweed is associated with a decrease in systolic blood
pressure due to a decrease in cardiac output and the inhibition of
baroreceptor sensitivity (Turischev, 2008). Oil extracts are used both
internally and externally for the treatment of laryngitis, upper
respiratory catarrh and tonsillitis (Gammerman et al., 1984). According
to Voronina (1952), the aerial parts of the plant are used to treat
nervous disease. The aerial parts of G. uliginosumwere included in the
VIIIth Pharmacopoeia of the USSR in 1952.
The herb G. uliginosum is generally considered safe when used
as infusions at the daily dose of 180–300 mL and is available in
pharmacies without a prescription (Sokolov, 2000). The 40% EtOH
crude extract did not suppress the growth of human lymphoblas-
toid Raji cells at concentrations of up to 200 μg/mL (Spiridonov et
al., 2005). Table 4 summarizes the pharmacological studies that
have been undertaken on G. uliginosum and that are reported in
the literature.
An original method for the treatment of patients with peptic
ulcers involving the combined administration of infusions of
Polemonium caeruleum and G. uliginosum has been reported
(Panchenkov, 1950) and is discussed in the part of the article
regarding P. caeruleum. No other clinical data were found. The
aerial parts of P. caeruleum are recommended for internal admin-
istration at the dose of 1/2 -1/3 of a glass of the infusion (10 g in
200 mL of water) 2–3 times per day for anti-inﬂammatory and
hypothensive use (Sokolov, 2000).
The safety and efﬁcacy of G. uliginosum have been conﬁrmed
during its long history of use. However, publications regarding its
chemistry, pharmacological effects, and safety remain fragmen-
tary. Further study of this herb might prove interesting.
5.4. Bitterants (appetite stimulants)
5.4.1. HERBA CENTAURII
In a monograph in the Pharmacopoeia of the USSR, Herba
centaurii was described as the aerial parts of Centaurium erythraea
Rafn [syn.: C. minus Moench, Erythraea Centaurium (L.) Borkh] and
C. pulchellum (Sw.) Druce, (Centianaceae), as collected during
the ﬂowering season. In the European Pharmacopoeia, C. majus
(H. et L.) Zeltner and C. suffruticosum (Griseb.) Ronn. (syn.: Eryth-
raea centaurium Persoon; C. umbellatum Gilibert; C. minus Gars.)
are also described in the monograph, Herba centaurii. Because the
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Table 3
Summary of Pharmacological Studies for V. opulus fruits.
Activity tested Model used Plant
part
used
Extract type Admin Dosage/
duration
Control Results Reference
Anticancer in vivo. Mice, 1,2-
dimethyl-
hydrazine (DMH)-
induced colon
cancer
Fruit Juice (65% pulp, 45% water) Per oral Drinking of juice
instead of water.
30 weeks after
ﬁrst DMH
injection), 18
after last DMH
injection
Negative control Higher number of low-grade dysplasia
and lower number of other type
lesions (high-grade dysplasia,
intramucosal carcinoma and invasive
carcinoma) in treated groups indicate
that juice prevents progress of
established tumors but not chemical
induction of colonic tumors.
Ulger et al.,
2012.
Antimicrobial in vitro. Agar well
diffusion method
Fruit Fresh juice, standardized by phenolics
and anthocyanins.
in vitro. Wells with 50 μL
of juice
Gram-positive: S. aureus, S.
epidermidis, B. subtilis, Listeria
monocytogenes, Enterococcus faecalis,
Micrococcus luteus. Gram-negative:
P. aeruginosa, E. coli, Salmonella
typhimurium, S. agona Yeast:
Debaryomyces hansenii, Trichosporon
cutaneum, Kluyveromyces marxianus
var. lactis, Torulaspora delbrueckii,
Saccharomyces cerevisiae, Candida
parapsilosis
Strong inhibition of S.typhimurium
(inhibition zone 25.3-30.3 mm), S.
agona (23.3-27.7 mm), L.
monocytogenes (26.570.35 mm), E.
faecalis (25.7 mm), and S. aureus
(24.1 mm). Most resistant: P.
aeruginosa, M. luteus, S. epidermidis.
No or little antifungal activity was
observed
Česoniene et
al., 2012
Antimicrobial in vitro. Agar well
diffusion method
Fruits MeOH extract (10 and 15%) in vitro. No data Negative control. Most sensitive: Aeromonas hydrophila,
most resistant Yersinia enterocolitica
Sagdic et al.,
2006
Antioxidant in vitro. DPPH
assay
Fruit Flesh, standardized by malic, oxalic,
citric acids, total phenolic, total
ﬂavonoid, and total anthocyanin
contents
in vitro. No data Negative control. EC50¼24.56 mg/mg Cam et al.
2007
in vitro. DPPH
assay
Fruit Seeds, standardized by malic, oxalic,
citric acids, total phenolic, total
ﬂavonoid, and total anthocyanin
contents
in vitro. No data Negative control. EC50¼2.35 mg/mg Cam et al.
2007
in vitro. ABTS
assay, DPPH assay,
NO scavenging,
superoxide anion
scavenging,
inhibition of lipid
peroxidation
Fruit Fruit extract (25%) standardized by
total phenolic and ascorbic acid
contents
in vitro. No data Negative control. Inhibition of NO (21.89-25.44%),
superoxide anion (25.13-28.50%), and
lipid peroxidation (11.20–13.90%). In
DPPH test 8.6-9.8 ascorbic acid
equivalent/kg of fresh fruits (AAE/kg
FM) and 9.1-11.1 AAE/kg FM in ABTS
test
Rop et al.,
2010
Gastroprotective in vivo. Rats, water
immersion
restraint stress
Dry
fruits
Proanthocyanidins, no composition Intragastric 25, 50, 75 mg/kg Negative control Potent gastroduodeno-protective
activity via an increase in endogenous
NO generation, suppression of lipid
peroxidation and mobilization of
antioxidant activity and changes in
glycoconjugate content of the
gastroduodenal mucosa of rats
Zayachkivska
et al., 2006
Immuno-
stimulating
in vitro. Peritoneal
cells of rats.
Fruit Water-soluble polysaccharide fractions
from the squeezed fruits. Acidic
polysaccharides with α-l,4-1inked
residues of D-galacturonic acid,
galactose, arabinose, and rhamnose.
Neutral polysaccharides composed of
galactose and mannose.
96 well plate Activity
of myeloperoxidase in
the macrophages Petri
dishes, phagocytic
index of the
macrophages by light
microscopy
Polisacharides,
10 μg/mL
Negative control Increase the phagocytic index in 31%
and the secretion of lysosomal
enzymes with peritoneal
macrophages in 68%
Ovodova et
al., 2000
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Table 4
Summary of Pharmacological Studies for G. uliginosum.
Activity tested Model used Plant
part
used
Extract type Admin Dosage/ duration Control Results Reference
Anticancer in vitro. Mouse
leukemia cells L1210,
Aerial
part
Methylene chloride and MeOH extracts, soxhlet 96 well
plate
10 μg per well Positive control
Methotrexate
Negative control
45% growth inhibition by methylene chloride
extract, 38% growth inhibition by MeOH extract
Goun et al.,
2002
Antidiabetic in vivo. Rats,
epinephrine induced
hyperglycemia. Rats,
alloxan induced
diabetes
Aerial
part
Crude aqueous decoction (1 g in 10 mL) Intragastric 25 mL/kg, 6 days Negative control The level of glucose was decreased 25%, and
glycogen in liver was increased 1.7 fold compared to
control the glucose tolerance test (epinephrine
induced hyperglycemia). Decrease of glucose 19%
but no effect on blood insulin level (alloxan induced
diabetes).
Molokovskii
et al., 2002
Antithrombin in vitro. Thrombin
solution from bovine
plasma
Not
speciﬁed
Methylene chloride and MeOH extracts, soxhlet 96 well
plate
50 μL Negative control 75% thrombin inhibition by methylene chloride
extract
Goun et al.,
2002
Gastroprotective in vivo. Experimental
gastric dystrophy by
stomach alteration in
reserpinized or
immobilized mice
Not
speciﬁed
Isolated gnaphaloside A ([7-(6''-O-caffeoyl]-O-β-
D-glucopyranosido-5,4'-dihydroxy-6,3'-
dimethoxyﬂavone)
Per oral 50 mg/kg
Immediately
before and 5 h
after
immobilization or
reserpine injection
Negative control Decrease total number of stomach lesions (by
1.6 fold), including small pulverized (l.7 fold) and
large bandlike (2.3 fold) lesions compared with
control (reserpinized mice). Decrease of number of
lesions of any type (by 2.6 to 3.l fold) and number of
animals with various gastric lesions (2.5 fold)
compared with control (immobilized mice).
Barnaulov et
al., 1984
Hypotensive in vivo. SHR rats Aerial
part
Crude aqueous extract. gnaphaloside A; 6"-caffeyl-
7-β-D-glucopyranosyloxy-4',5-dihydroxy-3',6'
dimethoxyﬂavone; 3',4',5,7-tetrahydroxy-6-
methoxyﬂavone 7-0-(6"-O-caffeyl-β-D-
glucopyranoside); 6-methoxyluteolin,
6-hydroxyluteolin 7-O- β -D-glucopyranoside
Per oral 50 mg/kg, 14 days Negative
control. Positive
control:
enalapril, 2 mg/
kg, atenolol
10 mg/kg
Decrease of systolic pressure by 12% and 19% after
3 and 6 h each day. Decrease of diastolic pressure by
34% and 37% after 3 and 6 h each day. Cumulative
affect after 10 days.
Makarova,
Makarov,
2010
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Table 5
Summary of Pharmacological Studies for A. incana.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Anticancer in vitro, Human cervix
adenocarcinoma HeLa
cell
Catkins MeOH extract,
soxhlet with
381.377.2 mg
gallic acid
equivalents/g
extract
96 well plate 200, 100, 50, 25,
and 12.5 μg/mL,
Negative control. Positive
control:
Cisplatin
IC50¼39.9 μg/mL Stević et al., 2010
Anti-inﬂammatory in vivo Rats,
chloroquine induced
irritation of mucous
membrane
accompanied with
emotional-painful
stress
Catkins Polyphenolic
extract (ellagic and
gallic acid)
Per oral 1 mg/kg, 30 days Negative control Positive effect on structures of
vessels of the microcirculatory
bloodstream, subepithelial
connective tissue and
integumentary epithelium of tunica
mucosa. Effect by endocellular
regeneration in combination with
expressed compensatory
hypertrophy of part epithelium
integument cells.
Moiseyеv et al.,
2008
Anti-inﬂammatory
(photoprotective)
in vivo. Guinea pigs;
ultraviolet-induced
erythema
Catkins Polyphenolic
extract (ellagic and
gallic acid)
Intragastric 1 mg/kg, 40 min
before and 2 h
after UV irradiation
Negative control. Positive
control: methyluracil, sea
buckthorn oil
Decrease of erythema (61%)
accompanied with decrease of lipid
conjugated dienes and increase of
superoxide (39%)dismutase and
catalase (16%) compared to control
group
Zvyagintseva
et al., 2009
Anti-inﬂammatory
(radioprotective)
in vivo. Rats, ionizing
radiation of skin (dose
80 Gy)
Catkins Polyphenolic
extract (ellagic and
gallic acid)
Intragastric 1 mg/kg, 40 min
before and
during 10 days
after irradiation
Negative control. Positive
control: methyluracil
Decrease of malonyl-dialdehyde
and lipid conjugated dienes,
increase of antioxidant enzymes
activity and quick epithelization
and healing of skin comparing
with control group
Myronchenko
and Zvyagintseva,
2008
Antimicrobial in vivo. Newborn rat.
Gastroenterocolitis
induced by Klebsiella
pneumoniae
Catkins Polyphenolic
extract (ellagic and
gallic acid)
Per oral 1.0, 2.5, 5.0, 10.0,
20.0 mg/kg 14 days
Negative control Bacteriostatic effect at 1.0 and
2.5 mg/kg (31.5 % and 62.5%
survival of rats resp.) Bactericidal
effect at 10.0 and 20.0 mg/kg;
100% survival of rats. No effect
on normal microﬂora at
1.0-20.0 mg/kg
Rikalo, 2005
Antimicrobial in vitro. Broth
microdilution method
Catkins MeOH extract,
Soxhlet with ca.
381.3 mg of gallic
acid equivalents/g
of extract
96 well plate No data E. coli, Salmonella
typhimurium, Enterobacter
cloacae, P. aeruginosa, P.
tolaasii, Proteus mirabilis,
Gram-positive S. aureus, S.
epidermidis, Streptococcus
faecalis, B. subtilis
Micrococcus luteus, M.
ﬂavus, Sarcina lutea, Listeria
monocytogenes; yeast: C.
albicans. Negative control,
streptomycin, nystatin
MIC¼0.117-0.129 mg/mL Stević et al., 2010
Antioxidant in vitro. DPPH assay,
phospholipid
degradation
Catkins MeOH extract,
Soxhlet with
ca.381.3 mg of
gallic acid
equivalents/g of
extract
in vitro. 100 μL Negative control. Positive
control: Trolox
IC50¼18.9 μg/mL (DPPH),
IC50¼48.6 μg/mL (phospholipid)
Stević et al., 2010
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pharmacological effects of the plants found in the European
Pharmacopoeia are similar to those of C. pulchellum, this review
will not discuss the pharmacological effects of C. pulchellum.
5.5. Astringents
5.5.1. FRUCTUS ALNI
Fructus alni consists of the catkins of Alnus incana (L.) Moench
(grey alder or speckled alder) or A. glutinosa (L.) Gaertn. (European
black alder; Betulaceae), a small to medium tree that is 15-20 m in
height. Alder catkins are collected during late autumn and winter.
Decoctions of alder catkins are used in Russian traditional medi-
cine for the treatment of stomach pain, diarrhea, and dysentery
(Nosal, Nosal, 1960).
In 1942, A. incana catkins were introduced in ofﬁcinal medicine
by Prof. D.M. Rossijsky Rossijsky, 1942; Vereschagin et al., 1959),
and a dry extract of A. glutinosa catkin was developed by V.E.
Shatadze (Turova, Sapozhnikova, 1989). Due to their astringent
properties, extracts of these catkins have been recommended for
the treatment of ailments of the gastrointestinal tract. Recently, it
was shown that Fructus alni has anti-inﬂammatory and UV- and
radioprotective properties (Sokolov, 2000).
The acute and chronic toxicity of a polyphenolic extract of A.
glutinosa catkins has been studied in rodents after oral adminis-
tration. The LD50 values measured in acute toxicity studies were
5,420 mg/kg in mice and 8,500 mg/kg in rats, respectively. In the
chronic toxicity study, the extract used exhibited hepatotoxicity in
rats after 6 months of administration at the dose of 50 mg/kg; the
recommended dose for therapeutic use is 1 mg/kg (Maloshtan,
Serbina, 1999). MeOH extracts of A. incana exhibited very low
toxicity and did not cause signiﬁcant brine shrimp (Artemia salina)
mortality, even when used at 200 μg/mL (Stević et al., 2010).
Table 5 summarizes the pharmacological studies that have been
undertaken on Fructus alni that are reported in the literature.
A group of 50 patients (32 females and 18 males, 19–78 years)
suffering from salmonellosis was included in a clinical trial. Group
1 (25 patients) was treated with drug therapy (control) and group
2 was treated with a polyphenol-rich extract of A. glutinosa catkins
at a dose of 20 mg, 3 times per day for 8 days. The publication did
not give a full description of the controls, making it difﬁcult to
assess the results of this trial. The levels of malonyl-dialdehyde
and lipid-conjugated dienes and the activity of superoxide dis-
mutase in the blood serum of the patients were statistically
signiﬁcantly decreased (33%, 44% and 10%, respectively) and were
similar to normal levels found in healthy persons. The levels of
malonyl-dialdehyde, lipid-conjugated dienes and superoxide dis-
mutase in group 1 decreased by 16%, 17% and 30%, respectively,
compared to untreated levels. Based on the results, the extract was
recommended for the treatment of patients with salmonellosis
(Popova, 2002).
Considering the literature data and the results of applications
of Fructus alni in the USSR and Russia, this material may be
considered safe and effective. Fructus alni is recommended for
internal administration at the dose of 1/2 - 1/3 of a glass of the
infusion (10 g in 200 mL of water) 2–3 times a day for use as an
astringent (Sokolov, 2000). "Altan" tablets, which include 0.01 g of
a polyphenolic extract of A. glutinosa catkins, are registered in
Ukraine as an over-the-counter medicine. Future study of alnus
catkins should contribute to increasing their medicinal
application.
5.5.2. HERBA HYPERICI
In a monograph in the Pharmacopoeia of the USSR, Herba
hyperici is described as the aerial parts of Hypericum perforatum L.,
H. maculatum Crantz (syn. H. quadrangulum L.), Hypericaceae, asTa
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collected during the ﬂowering season. Because the pharmacologi-
cal effects of H. maculatum are similar to those of H. perforatum,
which is included in the European Pharmacopoeia, the pharma-
cological effects of H. maculatum will not be discussed in this
review.
5.5.3. RHIZOMATA BERGENIAE
Bergenia crassifolia (L.) Fritsch (Saxifragaceae), commonly known as
badan, Siberian tea, Mongolian tea, leather bergenia, or elephant's ears,
is an evergreen perennial plant with rhizomes up to 1 meter long, 10–
50 cm long leather-like large leaves, and pink ﬂowers.
Infusions of Bergenia rhizomes have been used in Russian
traditional medicine for the treatment of colds, gastritis, entero-
colitis, headache, diarrhea, and fever (Gammerman et al., 1984). In
Russian ethnomedicine, the leaves are widely used as a beverage.
Buryats and Mongols are known to have used B. crassifolia leaves
to make tea. However, in Altai, old blackened wintered leaves,
known as chagirsky tea, are preferred for this purpose because the
green leaves contain higher amounts of tannins (Vereschagin et al.
1959). In ofﬁcinal medicine, the rhizomes are claimed as haemo-
static, astringent, anti-inﬂammatory, and antimicrobial agents.
Infusions are recommended in gynecology for excessive menstrua-
tion, bleeding after abortions, and cervical erosion treatment
(Turova, Sapozhnikova, 1989). The rhizome is claimed to
strengthen capillary walls, to exhibit local vasodilatation activity,
to decrease arterial blood pressure and to increase heart rate
(Sokolov, 2000). Bergenia rhizomes are used to treat the following
oral diseases: periodontal disease, stomatitis, gingivitis, and bleed-
ing gums (Lukomsky, 1955). Bergenia crassifolia appears to meet
the criteria required for consideration as an adaptogen (Suslov et
al., 2002; Panossian, 2003).
The rhizomes of B. crassifolia are safe at the daily dose of 50–
100mL of decoction (10 g in 200 mL of water) and are available in
pharmacies without a prescription (Sokolov, 2000). Infusions of both
the black and fermented leaves of B. crassifolia (10 g in 100 mL of
water) have been found to be safe in mice after 7 days of continuous
per oral administration at the dose of 9 mL/kg (Shikov et al., 2010b).
At a single oral dose (50 mg/kg per day) of dry extracts of black and
green leaves, no signs of toxicity were observed in rats after one week
(Shikov et al., 2012). Bergenin and norbergenin, the main coumarins
of Bergenia, were found to be safe up to 2,000 mg/kg weight in mice
after per oral acute administration, and no sign of mortality or change
in behavioral patternwas observed (Nazir et al., 2007). The bergenan -
pectic polysaccharide from B. crassifolia green leaves was found to be
nontoxic and failed to inﬂuence the body weight or the length and
weight of the intestine (Popov et al., 2005). The LD50 for sulfated
pectin derivatives of B. crassifolia after a single intraperitoneal injec-
tion was more than 1,000 mg/kg (Vityazev et al., 2012). Table 6
summarizes the pharmacological studies that have been undertaken
on B. crassifolia and that are reported in the literature.
In the available literature, no clinical data for B. crassifolia were
found. Rhizomes of B. crassifolia are recommended for internal
administration at the dose of 1–2 tablespoons of the decoction (10
g in 200 mL of water) taken 3 times per day as an astringent, a
haemostatic, or an anti-inﬂammatory agent (Sokolov, 2000).
Claims of antimicrobial activity are not supported by antimicrobial
assays, which only show activity at very high concentrations. Anti-
inﬂammatory activity might be associated with high concentra-
tions of polyphenols, polysaccharides, and α-bisabololoxide B
(Popov et al., 2005; Chernetsova et al., 2012; 2014).
It is interesting that the black leaves and rhizomes have been
used in traditional medicine, but the use of rhizomes is only
referred to in the Pharmacopoeia of the USSR. The safety and
efﬁcacy of B. crassifolia (both leaves and rhizomes) are conﬁrmed
by their long period of traditional application. However,
publications regarding their chemistry, pharmacological effects
and safety remain fragmentary. This plant should be an interesting
subject for further investigations, especially with respect to its
adaptogenic properties.
5.6. Choleretic agents
5.6.1. FLORES HELICHRYSI ARENARII
Helichrysum arenarium (L.) Moench (Compositae), also known
as dwarf everlast, is a perennial grows to an average height of 15–
40 cm.
The inﬂorescence of H. arenarium has been used in the popular
medicine of Russia for its choleretic, diuretic, anti-inﬂammatory,
and detoxifying properties and has been applied in the form of
infusions for treating cystitis, arthritis, rheumatism, and gout; for
stimulating gastric secretion; and for the treatment of gallbladder
disorders (Shass, 1952; Vereschagin et al., 1959). The choleretic,
cholagogue, hepatoprotective, and detoxifying activity of the
inﬂorescence of H. arenarium has been recognized for a long time
in Europe (Kroeber, 1951; Szadowska, 1962; Wagner, 1993).
The administration of H. arenarium at recommended dose
(decoction, 1:20, 100 mL, 2–3 times per day) or the use of "Flamin"
tablets (puriﬁed ﬂavonoids) at a therapeutic dose of 50 mg, 3 times
per day for 40 days, is safe. However, longer administration may
lead to the development of bile congestion (Sokolov, 2000).
Helichrysi ﬂos has cholagogue and choleretic activity and
stimulates the secretion of gastric juice (Krivenko et al., 1989;
Litvinenko et al., 1992). "Flamin" tablets are used in cases of
cholecystopathy and affect the chemical composition of bile (by
increasing the cholesterol cholate coefﬁcient), regulate the func-
tion of the gastrointestinal tract, and increase diuresis (Petrovsky
et al., 1953; Skakun, Stepanov, 1988). Table 7 summarizes the
pharmacological studies that have been undertaken on H. arenar-
ium and that are reported in the literature.
Increased bile secretion and decreased bilirubin and cholesterol
levels were observed in patients with cholecystitis, cholangitis,
gallstones, and hepatitis when treated with H. arenarium. Heli-
chrysum arenarium prevents the stagnation of bile, improves the
metabolic function of the liver, and decreases the viscosity and
relative density of bile. This plant also promotes the leaching of
sand and small stones in patients with chronic calculous chole-
cystitis (Sokolov, 2000). However, no more details are available.
The aerial parts of H. arenarium are recommended for internal
administration at the dose of 100 mL of the decoction (10 g in 200
mL of water), 2–3 times per day as a choleretic. "Flamin" tablets
containing 0.05 g of ﬂavonoids are recommended for internal
administration at the dose of 1 tablet 3 times daily for 10–40 days
in patients with cholecystitis (Sokolov, 2000).
A special monograph on Flos Helichrysi arenarii was included in
the WHO monographs on medicinal plants commonly used in the
Newly Independent States (NIS) in 2010. However, publications
regarding the chemistry and pharmacological effects of this plant
are fragmentary, and no special publication is available regarding its
safety. This plant is an interesting subject for further investigations.
5.7. Antihelmintic and choleretic agents
5.7.1. FLORES TANACETI
Tanacetum vulgare L., (common name, tansy) is a ﬂowering
herbaceous plant (Compositae) with ﬁnely divided compound
leaves and yellow, button-like ﬂowers; the plant is 50–150 cm tall.
In Russian traditional medicine, tansy has been used to treat
intestinal worms (ascaris and enterobius), diarrhea and digestive
problems and has been used as an antipyretic and as a diaphoretic
(Nosal, Nosal, 1960). Tansy has been proposed for use as an insect
repellent. Powdered aerial parts of this plant cause 100% paralysis in
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Table 6
Summary of Pharmacological Studies for B. crassifolia.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Adaptogenic in vivo. Mice, forced
swimming test.
Leaves, black and
fermented
Aqueous infusion
(1:10, w/v),
ﬁngerprint by
arbutin, bergenin,
ellagic, gallic,
protocatechuic
acids,
hydroquinone.
Per oral 9.0 mL/kg, 7 days Negative control. Positive
control: Rhodiola rosea
extract
2 fold Enhanced swimming time,
increased glucose utilization and
decreased lactate levels compared
to control . Increased fat utilization
and a decreased body weight of 15–
18% in groups treated with black
and fermented leaves.
Shikov et al.,
2010b
Anticancer in vitro. Human
lymphoblastoid Raji
cells
Rhizomes, green
leaves
Crude EtOH (40%)
extract
in vitro 10, 50, 200 μg/mL Positive control:
methotrexate ﬂuorouracil,
cyclophos-phamide,
vinblastine. Negative
control
99% inhibition at 200 μg/mL by
rhizomes extract; 82% inhibition by
leaves extract.
Spiridonov et al.,
2005
Antimicrobial in vitro. Liquid dilution
method
Rhizomes, leaves EtOH (80%) extract in vitro. No data B. cereus, E. coli, P.
aeruginosa, S. aureus,
C. albicans. Positive control:
erythromycin, gentamicin,
amphotericin B
MIC (mg/mL) for leaves/rhizomes:
B. cereus: 62.50 / 15.63; E. coli:
62.50/15.63; P. aeruginosa, 15.63/
62.50; S. aureus: 62.50/62.50; C.
albicans: 250.00/ 15.63
Kokoska et al.,
2002
Anti-inﬂammatory in vivo. Mice, adjuvant-
induced arthritis
Not speciﬁed Bergenin (main
coumarine) of plant
Per oral 5, 10, 20, 40, 80 mg/
kg
Positive control:
prednisolone
Inhibition production
proinﬂammatory Th1 cytokines
(IL-2, IFN-γ and TNF-α).
Nazir et al., 2007
Anti-inﬂammatory in vivo. Mice,
immobilization stress
or cyclophosphamide
injections
Rhizomes Dry extract
standardized by
arbutine min 18%.
Per oral 50 mg/kg, 5 days Negative control. Positive
control: enalapril, 2 mg/kg,
atenolol 10 mg/kg
Extract normalized content
antibody-forming cells in spleen
after stimulation by antigen in both
immunodepression models. Extract
decreased expression inﬂammatory
processes under delayed
hypersensitivity reaction
conditions, by preventing
accumulation of T-lymphocytes in
the inﬂammation focus and
reducing the ability of cells to
produce anti-inﬂammatory
cytokines
Churin et al.,
2005
Antiobesity in vivo. Rats with high-
calorie diet- induced
obesity
Leaves, black and
fermented
Crude aqueous
extract
standardized by
arbutin, bergenin,
ellagic, gallic,
protocatechuic
acids,
hydroquinone.
Per oral 50 mg/kg, 7 days Negative control. Positive
control: sibutramine
hydrochloride
Daily dietary intake reduced to 40%
compared with control.
Improvement in glucose tolerance
after 7 d treatment. Black leaves
extract reduced serum triglyceride
level by 45% compared to control in
rats.
Shikov et al., 2012
Antioxidant in situ. DPPH assay after
HPTLC separation.
Leaves, green,
brown, black.
MeOH extract, with
arbutin, bergenin,
ellagic, gallic acids,
hydroquinone.
in vitro. 1 mg/mL Negative control. Positive
control: ascorbic acid
ID50 (nmol) gallic acid 0.49; ellagic
acid 0.94; arbutin 0.88;
hydroquinone 1.23.
Pozharitskaya
et al. 2007
in vitro. DPPH assay. Rhizomes EtOH (70%) extract,
(þ)-catechin 3,5-
di-O-gallate,
(þ)-catechin 3-O-
gallate
in vitro. 10 mg/mL Negative control. Positive
control: gallic acid,
catechin, 2,6-di-tertbutyl-4-
methylphenol
SC50 (μg/mL) 3.7 for extract, 1.0 for
(þ)-catechin 3,5-di-O-gallate,
1.3 for (þ)-catechin 3-O-gallate.
Ivanov et al., 2011
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ﬂies within 15 minutes (Zemlinsky, 1949). This plant is also mentioned
regarding its use in treating hysteria, migraine, neuralgia, rheumatism,
kidney weakness, stomach problems, and fever. Tanacetum vulgare has
antihelminthic, carminative, antispasmodic, stimulant (to the abdom-
inal viscera), tonic, emmenagogue, antidiabetic, diuretic, and antihy-
pertensive properties. In larger doses, the plant can be used to induce
abortion. Externally, tansy is used as a poultice on swellings, sprains,
gout, contusions, and some eruptive skin diseases and to kill lice and
ﬂeas and treat scabies (Abad et al., 1995; Sokolov, 2000). Tanacechols,
a puriﬁed complex extract of ﬂavonoids and phenolcarbonic acids
extracted from tansy ﬂowers (0.05 g/ tablet), is registered in Russia as
a choleretic and as a spasmolytic agent for chronic cholecystitis and
biliary dyskinesia (Sokolov, 2000).
The acute and chronic toxic effects of a lyophilized aqueous extract
of tansy were studied in rodents. The no-observed-adverse-effect
levels (NOAELs) of crude aqueous tansy extract in mice when given
by the oral and intraperitoneal routes are 7.0 g/kg and 1.0 g/kg,
respectively, and the lowest-observed-adverse-effect levels (LOAELs)
are 9.0 g/kg and 1.5 g/kg, respectively. Mortality increased with
increasing dosage; the LD50 values were 9.9 g/kg and 2.8 g/kg for the
oral and intraperitoneal modes of administration, respectively. The
LD50 values were lower for female mice (oral dose: 8.70 g/kg;
intraperitoneal dose: 2.25 g/kg) than for male mice (oral dose:
11.30 g/kg; intraperitoneal dose: 3.25 g/kg). In the chronic study in
rats, daily oral administration of the crude aqueous extract of tansy up
to 600 mg/kg for 90 days did not result in death or signiﬁcant changes
in the biological (except for hypoglycemia) or hematological para-
meters (Lahlou et al., 2008a).
The safety of Tanacechols has been tested in rats, mice, dogs,
and guinea pigs. The LD50 was 1.27 g/kg in rats after intraperito-
neal administration and 7.42 g/kg in mice after intragastric admin-
istration. This drug was not toxic, and no histopathological effects
were detected after 90 days of administration in rats and dogs
at the dose of 100 mg/kg. No allergenic effects were observed in
guinea pigs (Vichkanova et al., 2009). Table 8 summarizes the
pharmacological studies that have been undertaken on T. vulgare
and that are reported in the literature.
The effects of oral treatment with Tanacechols have been
studied in 291 patients with chronic cholecystitis. Patients were
treated with Tanacechols tablets (0.05 g) at the dose of 2 tablets
3 times per day, 20–30 min before ingestion of food, for 25 days.
The report did not fully describe the controls used, which makes it
practically difﬁcult to assess the outcome of this trial. A positive
effect was registered in 74.9% of the patients studied. The treat-
ment led to a decrease in bitter taste in the mouth and nausea
after 6–7 days, reduced pain in the right-upper quadrant after 9–
10 days, and dyspepsia disappeared after 15–20 days. No side
effects were observed (Vichkanova et al., 2009).
The ﬂowers of T. vulgare are recommended for internal adminis-
tration at the dose of 1 tablespoon of the decoction (10 g in 200 mL of
water), 3 times per day, as a choleretic and an antihelmintic.
Tanacechols tablets containing 0.05 g of a puriﬁed complex extract
of ﬂavonoids and phenolcarbonic acids are recommended for internal
administration at the dose of 1–2 tablets, 3–4 times per day, for 20–30
days in patients with biliary system and liver diseases (Sokolov, 2000).
However, publications regarding the pharmacological effects and
clinical trials of these tablets are far too limited to allow conclusions
regarding its therapeutic potential. This botanical drug is clearly an
interesting subject for further investigations, especially within a
clinical context.
5.8. Expectorants
5.8.1. CORMUS LEDI PALUSTRI
Ledum palustre L. (syn. Rhododendron tomentosum Harmaja),
commonly known as marsh Labrador tea, northern Labrador tea or
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Table 7
Summary of Pharmacological Studies for H. arenarium.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Antibacterial in vitro, agar-well
diffusion method
Aerial part MeOH extract, Soxhlet with gallic, p-
hydroxybenzoic, chlorogenic, caffeic,
syringic, p-coumaric, ferulic,
rosmarinic acids, catechin,
epicatechin, rutin, resveratrol,
hesperidin, apigenin- 7-glucoside,
eriodictyol, quercetin, naringenin,
luteolin, apigenin, and acacetin.
in vitro. 100, 50, 25, 10 μg/
mL
Aeromonas hydrophila,
Bacillus brevis, B. cereus, B.
subtilis, E. coli, Klebsiella
pneumoniae, Morganella
morganii, Mycobacterium
smegmatis, Proteus mirabilis,
P. aeruginosa,
S. aureus, Yersinia
enterocolitica, C. albicans,
Saccharomyces cerevisiae.
Positive control: amoxicillin,
and 11 other antibiotics.
No activity against E. coli, B. subtilis,M.
morganii, M. smegmatis, P. mirabilis, Y.
enterocolitica, S. cerevisiae. Inhibition
diameter (mm at 100 μg/mL): A.
hydrophila (28.0), B. brevis (22.5), B.
cereus (22.5), K. pneumoniae (17.0), P.
aeruginosa (28.0), S. Aureus (23.5).
Albayrak et al.,
2010
Anticancer in vitro. Mouse leukemia
cells L1210,
Aerial part Methylene chloride and MeOH
extracts, soxhlet
96 well
plate
10 μg per well Positive control Methotrexate
Negative control
96% growth inhibition by methylene
chloride extract, 85% growth
inhibition by MeOH extract
Goun et al., 2002
Anticoagulant in vitro. Clotting assays of
activated partial
thromboplastin time
(APTT) and of
prothrombin time (PT)
Flowers Crude extract with polyphenolic-
polysaccharide fraction
in vitro. 0.1–12.5 mg/mL Negative control APTT4600 sec at 12.5 mg/mL and
479 sec at 6.25 mg/mL. Pt 81.7 sec at
12.5 mg/mL
Pawlaczyk et al.,
2009
Anti-inﬂammatory in vitro, TNF-α, 1 ng/mL
induced cytotoxicity in
L929 cells
Flowers MeOH extract, 50 constituents
including new ﬂavanone and
chalcone glycosides named
arenariumosides I, II, III, IV.
96-well
microplate
3–100 μM Negative control. Positive
control: sylibin, piperine.
20.8-40.7 % inhibition of TNF-α
-induced cytotoxicity in L929 cells at
30 μM by naringenin 7-O-β-D-
glucopyranoside, apigenin 7-O-β-D-
glucopyranoside, apigenin 7-O-
gentiobioside, apigenin 7,4'-di-O-β-D-
glucopyranoside.
Morikawa et al.,
2009
Antioxidant in vitro. DPPH assay,
reducing iron(III), H2O2:
OH– luminol–micropero-
xidase system
Inﬂo-rescences Crude aqueous infusion (5 g in
200 mL), lyophilizates (ﬁngerprint by
TLC: apigenin, naringenin,
kaempferol, luteolin, quercetin,
caffeic acid, helichrysin, apigenin-7-
O-glucoside, luteolin- 7-O-glucoside,
quercetin-3-O-glucoside, chlorogenic
acid)
in vitro 1 mg/mL Negative control. Positive
control: silibinin
For lyophilizates: IC50 ¼0.14 mg
(DPPH), 380-1049 asc. acid
equivalents/mg, IC90 ¼0.154 μg
(H2O2/OH luminol-microperoxidase
system)
Czinner et al.,
2000
in vitro. DPPH assay,
phospho-molybdenum
method
Aerial part MeOH extract, Soxhlet with gallic, p-
hydroxybenzoic, chlorogenic, caffeic,
syringic, p-coumaric, ferulic,
rosmarinic acids, catechin,
epicatechin, rutin, resveratrol,
hesperidin, apigenin- 7-glucoside,
eriodictyol, quercetin, naringenin,
luteolin, apigenin, and acacetin.
in vitro 1 mg/mL Negative control. Positive
control: butylated hydroxy-
toluene, ascorbic acid
IC50¼23-48 μg/mL (DPPH) 106–
162 mg asc. acid equivalents/g
Albayrak et al.,
2010
in vitro. Lipid
peroxidation in rats liver
microsomes
Inﬂores-cences. Lyophilized water extracts
standardized by polyphenols and
ﬂavonoids
in vitro 0.01–0.02 mg/mL Negative control. Positive
control: sylibin.
MDA production was decreased in 23-
50%, cytochrome c reductase activity
was increased in 20-50%
Czinner et al.,
2001
Antiviral in vitro. Agar diffusion,
method. HeLa cells
Flowers 10% aqueous extract Petri dishes 0.02 mL Herpes virus Hominis HVP 75
(type 2), inﬂuenza virus A2
(Manheim 57), Vaccini virus,
poliovirus type 1. Negative
control.
Virusatic effect with inhibition zone
15-30 mm for all viruses, inactive
against poliovirus type 1.
May, Willuhn,
1978
Hypothensive in vivo. Rats, dogs Aerial part Ether, EtOH, aqueous extracts Intravenous 50 mg/kg (dogs),
500 mg/kg (rats)
Negative control Hypotensive effect Szadowska, 1962
Spasmolytic in vivo. Rats Aerial part Aqueous solutions of naringenin-5-
glucoside, kaempferol-3-glucoside),
apigenin dissolved in phosphate-
buffered sodium hydroxide. EtOH
extract containing all ﬂ avonoids and
aqueous extract containing no
ﬂavonoids.
Intravenous 4 mg/100 g bw
50 mg/100 g bw
Negative control. Positive
control: dehydrocholic acid
Spasmolytic activity and choleretic
effects (approximately 33% of that of
dehydrocholic acid) for individual
compounds. The ﬂavonoids extract
demonstrated spasmolytic activity
similar to individual compounds. The
ﬂavonoids free extract elicited a
spastic response in smooth muscles
from rat intestine and gall-bladder.
Szadowska, 1962
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wild rosemary, is a low shrub growing to 50 cm (rarely up to
120 cm) tall with evergreen leaves, belonging to the Ericaceae.
In Russian traditional medicine, the shoots are used as an aqueous
infusion or decoction. This infusion has been used to treat a wide
range of respiratory and lung disorders including bronchitis, tuber-
culosis, (whooping) cough, and asthma, as well as for lowering blood
pressure and preventing seizures (Shass, 1952; Vereschagin et. al.,
1959); the decoction is used as an anthelmintic (Utkin, 1931), and an
ointment is prepared using an animal fat base, which is used
topically for eczema, scabies, and insect stings (Vereschagin et. al.,
1959). In Swedish traditional medicine, this plant has been used to
treat headache, toothache, pain, and shingles (Tunón et al., 1995). The
leaves are also used as marsh tea, which is considered to act as an
abortifacient, diaphoretic, diuretic, emetic, expectorant, and lactago-
gue (Jin et al., 1999). In the Norwegian Sami community, a decoction
of dried "guohcarassi" ("stinking plant") was considered a good
remedy for cold and whooping cough, for rheumatism as a pain
reliever, for frost damage of the joints, to lower blood pressure,
and for bladder catarrh and diphtheria (Alm, Iversen, 2010).
Ledum palustre leaves and shoots are used in China to treat coughs
and asthma, to decrease blood pressure, and as an antifungal agent
(Li, 2002).
Ledum palustre is regarded as poisonous due to the presence of
toxic volatile compounds, especially the sesquiterpenoid ledol. Ledol
can affect the central nervous system, initially leading to psychomo-
tor stimulation, then to seizures and cramps, ﬁnally to paralysis,
breathing problems and even death (Dampc, Luczkiewicz, 2013). As
has been suggested, chronic and extended exposure to ledol and
presumably its overdosage is crucial to causing serious adverse
reactions, such as dizziness, exhaustion, nausea, vomiting and loss
of consciousness (Dampc, Luczkiewicz, 2013). The essential oil of
wild rosemary when applied orally can irritate the kidneys, urinary
tract, and the gastrointestinal tract, causing vomiting and diarrhea
(Aronson, 2009; Habermehl, 1998). However, the only side effects
reported for "Ledin", an USSR medicine for coughs containing 50 mg
of ledol per tablet, when used at the recommended total daily dose of
50–100 mg divided over 3–5 administrations per day for 3–10 days,
are allergic reactions (Mashkovskii, 2002). The maximal tolerated
dose of L. palustre extract in mice after oral administration is greater
than 30 g/kg. At doses of 2.5, 5.0 and 10.0 g/kg, the extract had no
observable genotoxicity in mice and was found to inhibit cyclopho-
sphamide, a well-known anti-tumor drug, and induced genotoxicity
in mice (Jing et al., 2011).
The acute toxicities of a 40% EtOH extract of L. palustre shoots and
of chloroform and hexane fractions of the EtOH extract were studied
in mice. The LD50 for the 40% EtOH extract was 2,800–3,200 mg/kg
after intraperitoneal administration, and no mortality of mice was
observed after intragastric administration of the extract at the dose
of 10g/kg. The LD50 values for the chloroform fraction were 350 mg/
kg (intraperitoneal) and 2,600 mg/kg (intragastric), and the LD50
values for the hexane fraction were 420 mg/kg (intraperitoneal) and
5,100 mg/kg (intragastric), respectively (Basova, 2004).
The acute toxicity of ursolic acid as extracted from L. palustre
was tested in mice. The LD50 after oral administration was
determined to be 9.26 g/ kg. The frequencies of micronuclei in
mice administered with high, medium and low doses of the ursolic
acid extract were 2.0, 2.0 and 1.8, respectively. No signiﬁcant
differences in the frequency of micronuclei were observed
between mice administered with the ursolic acid extract and
untreated mice. Chromosomal aberration rates in mice adminis-
tered with high, medium, and low doses of the ursolic acid
extracts were 1.2%, 1.2% and 1.0%, respectively, and were not
signiﬁcantly different from those found in normal mice. The
results suggest that the ursolic acid extract from L. palustre is safe
and has low acute toxicity and no genetic toxicity (Jing et al.,
2009).
The pharmacological properties of L. palustre shoots depend on
the essential oil, which are partially excreted after intragastric
administration through the mucous membranes of the respiratory
system. Volatile compounds of L. palustre, which are eliminated
through the bronchi, have a moderate effect on the local irritation
of mucous membranes, increasing the secretion of the bronchial
glands and increasing the activity of the ciliated airway epithe-
lium. A spasmolytic effect of L. palustre on airway smooth muscle
has been observed (Sokolov 2000). It has been reported that the
expectorant and antitussive effects of L. palustre are caused by
ledol (Belousov et al., 1998). Table 9 summarizes the pharmacolo-
gical studies that have been undertaken on L. palustre and that are
reported in the literature.
The traditional applications of L. palustre shoots in various
countries are mostly for coughs, bronchitis, lung disorders, and
lowering blood pressure. The effects and safety of L. palustre has
been demonstrated in a number of experiments, and this material
is recommended in Russian ofﬁcinal medicine as an effective
expectorant for the treatment of bronchitis and other lung
diseases that are accompanied with cough in the form of an
infusion (10 g in 200 mL of water) at the dose of ¼ of a glass, 2–3
times per day (Sokolov, 2000). The ﬁlm-coated tablets “Ledin”
(which contain 50 mg of ledol) are recommended for acute and
chronic bronchitis, pneumonia and bronchitis that is caused by
chemicals, gases, fumes and vapors and for asthma, pulmonary
tuberculosis, cystic ﬁbrosis and frequent, mostly dry coughs at the
dose of 1–2 tablets, 3–5 times a day, for 3–10 days (Mashkovskii,
2002). However, additional studies regarding its safety (in parti-
cular, its chronic toxicity) and efﬁcacy are needed.
5.8.2. FOLIA FARFARAE
Tussilago farfara L. (Compositae), commonly known as coltsfoot,
is a perennial herbaceous species that grows 10–30 cm in height.
The leaves of T. farfara are traditionally used in Russia to treat
respiratory illnesses such as asthma, bronchitis, or the common
cold as an expectorant and as a sedative. Additional uses of this
material include the improvement of digestion, the treatment of
diarrhea, its topical application for furunculosis, and its use as an
analgesic (Vereschagin et al., 1959). The leaves are components of
pectoral and diaphoretic teas (Gammerman et al., 1984). In China,
the dried ﬂower buds of T. farfara are used to treat coughs,
bronchitis, and asthmatic conditions (Committee for the
Pharmacopoeia of People’s Republic of China, 2010).
The safety of T. farfara is extensively discussed in the literature.
In addition to the presence of acidic polysaccharides, which are
considered responsible for the cough-relieving effect (Franz, 1969),
T. farfara contains (generally comparatively low levels of) pyrroli-
zidine alkaloids, which are known to be toxic to the liver. The main
alkaloid is senkirkine, and traces of senecionine are also present.
The content of senkirkine in samples of T. farfara ﬂowers was
found to vary from 19.5 ppm to 46.6 ppm (Jiang et al., 2009). The
concentration of senkirkine in commercial samples of coltsfoot
leaves was 2.5–11.2 ppm, as determined using capillary zone
electrophoresis, depending on the method of extraction used.
The level of senecionine in the leaves was either below the
detection limit (by gas chromatography) or less than 0.9 ppm
when measured using capillary zone electrophoresis (Lebada et al.,
2000).
A small lifetime study was performed in rats that were fed 32%
young, pre-blooming ﬂowers of coltsfoot in their diet for 4 days,
and subsequently, as 16% of their diet until 380 days after the
beginning of treatment. All of the rats survived beyond 380 days
after the start of feeding, but 8 out of 12 developed hemangio-
endothelial sarcoma in the liver (Hirono et al., 1976). In the
absence of epidemiological data, the International Agency for
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Table 8
Summary of Pharmacological Studies for T. vulgare.
Activity tested Model used Plant part
used
Extract type Admin Dosage/ duration Control Results Reference
Anticancer in vitro. Mouse
leukemia cells L1210,
Aerial part Methylene chloride
and MeOH extracts,
soxhlet
96 well plate 10 μg per well Positive control
Methotrexate
Negative control
99% growth inhibition by methylene
chloride extract, 95% growth inhibition
by MeOH extract
Goun et al., 2002
Antihelminthic in vitro. Egg hatching
assay (Ascaris suum),
larval migration
inhibition (L3 larvae
from Trichostron-gylus
colubriformis)
Aerial part EtOH (80%) extract. 96 well plate. 62.5-2000 mg/mL Negative control.
Positive control:
albendazole
46% ovicidal effect on A. suum eggs at
2000 mg/mL; 49.5% larval migration
inhibition at 2000 mg/mL
Urban et al., 2008
Anti-inﬂammatory in vivo, mouse-ear
edema induced by 12-
0-tetradecano-
ylphorbol 13-acetate;
carrageenan-induced
mouse paw edema
Aerial part Dichlormethane,
MeOH, chloroform
extracts;
parthenolide,
methoxyﬂavones
jaceosidin,
eupatorin,
chrysoeriol,
diosmetin.
Topical
application in
ear. Per oral.
0.5 mg/ear 100 mg/kg per oral Negative control.
Positive control:
indometacin,
phenylbutazone
93% edema inhibition ID50¼0.18 μmol/
ear by parthenolide; 92% inhibition by
chloroform extract; 80% inhibition with
ID50¼0.50 μmol/ear by jaceosidin. 24%
paw edema reduction after 1 h. by
parthenolide.
Schinella et al.,
1998
in vivo, Rats, formalin
induced edema
Inﬂore-scence Polysacharide
complex
(ammonium
oxalate extract)
Intragastric 0.3 g/kg, 7 days Negative control.
Positive control:
indometacin.
61.9% oedema inhibition after 4 h, 100%
inhibition after 3 days of treatment.
Concentration leucocytes and
erythrocyte sedimentation rate was
equivalent to control group after 7 days.
Kirichenko et al.,
2012
Antioxidant in vitro. DPPH assay, Aerial part MeOH crude
extract, 3,5-O-
dicaffeoylquinic
acid, axillarin,
luteolin
in vitro. 1 mg/mL Positive control:
quercetin
EC50¼ 37 mg/mL (MeOH extract);
IC50¼9.7 mmol for 3,5-O-dicaffeoylquinic
acid
Juan-Badaturuge
et al., 2009
Antithrombin in vitro. Thrombin
solution from bovine
plasma
Aerial part MeOH extracts,
soxhlet
96 well plate 50 μL Negative control 87% thrombin inhibition Goun et al., 2002
Antiviral in vitro, antiviral and
time-of-addition assay
Aerial part Crude MeOH
extract,
fractionation using:
petroleum ether,
chloroform, EtOAc,
BuOH, water; 3,5-
O-dicaffeoylquinic
acid, axillarin,
luteolin,
parthenolide.
96 well plate 5–500 μg/mL Herpes simplex
viruses HSV-1,
HSV-2. Positive
control: acyclovir
CE50¼31.1 μg/mL, 69.9 μg/mL, 95.7 μg/mL
for 3,5-O-dicaffeoylqu-inic acid,
petroleum ether and EtOAc extracts
respectively against HSV-1.
CE50¼42.7 μg/mL, 47.0 μg/mL, 58.4 μg/
mL, 61.1 μg/mL for axillarin, 3,5-O-
dicaffeoylquinic acid, EtOAc, and
petroleum ether extracts respectively
against HSV-2.
Alvarez et al.,
2011
Choleretic in vivo. Rats, CCl4
induced hepatitis
Aerial part Tanacechols Per oral. 50, 100 mg/kg, single
administration
Negative control. Effect in rats treated with 50 mg/kg
observed during 3 h. After administration
of 100 mg/g bile volume increased 80.9%
after 1 h, and 76.2% after 2 h.
Concentration of bile acids increased in
2.7, 2.1 and 1.8 fold compared to control
after 1, 2, and 3 h.
Vichkanova et al.,
2009
Gastroprotective in vivo. Rats, EtOH-
induced gastric ulcer
Aerial part Chloroform
extracts;
parthenolide
Per oral. 2.5–80 mg/kg (chloroform extract),
5–40 mg/kg parthenolide, single
dose.
Negative control. 100% inhibition of damage for extract
(10 mg/kg) and parthenolide (40 mg/kg).
Administration extract (80 mg/kg) or
parthenolide (40 mg/kg) 24 h before
EtOH treatment restored numbers
Tournier et al.,
1999
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Research on Cancer listed senkirkine as an agent that was not
classiﬁable as carcinogenic to humans (Group 3) (Barceloux, 2008).
Roulet et al. (1988) reported a case of a newborn female infant
from Switzerland with fatal hepatic vaso-occlusive disease. Her
mother revealed the occasional consumption of cannabis and
hallucinogenic mushrooms some months before the actual preg-
nancy and the daily consumption of a single cup of herbal tea
representing a toxic amount of senecionine (0.60 mg/kg dry
weight) during her entire pregnancy. The exact composition of
the incriminated cough tea was obtained from the manufacturer;
of the 10 different plants used in this preparation, T. farfara leaves
comprised 9% (w/w). In a comment responding to this article,
Rod̈er assumed that the herb containing pyrrolizidine alkaloids
was not Tussilago but petasites, because the typical leading
alkaloid of Tussilago, senkirkine, was not found by the authors
(Rod̈er, 1988). Rod̈er argued that petasites leaves had most likely
been confused with Tussilago because both plants grow wild in
alpine regions and can be easily confused when gathered after the
ﬂowering period. The results of later research showed that the
cough tea, contrary to the representation made in the publication
of Roulet, contained not only leaves and ﬂowers of T. farfara, but
also the roots of Petasites hybridus (L.) G. Gaertn., B. Mey. & Scherb.
(described as Petasites ofﬁcinalis by Moench) (Spang, 1989).
Another report, published in 1995, concerned an 18-month-old
boy from the Southern Tyrol with reversible hepatic veno-
occlusive disease caused by over 15 months consumption of herbal
tea, which contained large amounts of seneciphylline (approxi-
mately 60 μg/kg body weight per day). Adenostyles alliariae
(alpendost) leaves were mistaken for those of T. farfara (coltsfoot)
by the parents; these two plants can easily be confused, especially
after the ﬂowering period. The child was given conservative
treatment only and recovered completely within 2 months (Sperl
et al., 1995). Both clinical cases were due to the adulteration of
coltsfoot with other, more toxic plants.
However, to avoid any risk for consumers, the German public
health authorities (Bundesgesundheitsamt, 1992) have limited the
daily intake of toxic pyrrolizidine alkaloids to 1 μg.
Intravenous injection of the alcoholic extracts or decoctions of
T. farfara to cats induced a primary blood pressure depression effect,
which was followed by a more rapid acute rise in mean blood
pressure and ﬁnally a sustained pressor response for several minutes.
No tachyphylaxis was observed. This blood pressure response was
associated with increases in heart rate and respiratory stimulation. It
was suggested that the mechanism of action of Tussilago on blood
pressure might be due to stimulation of the vasomotor center of the
medulla and the vascular α-receptor and to constriction of the
peripheral blood vessels (Wang, 1979). The juice prepared from fresh
T. farfara leaves (at dilutions of 1:10 and 1:100) was observed to
exhibit signiﬁcant antimutagenic activity against the genotoxic com-
pound nalidixic acid in an SOS chromotest (Karamova et al., 2010).
Water-soluble polysaccharides present in coltsfoot reduce the toxic
effect of paclitaxel on the blood system in mice that have Lewis lung
carcinoma (Safonova et al., 2010). Table 10 summarizes the pharma-
cological studies that have been undertaken on T. farfara and that are
reported in the literature.
Mixtures with T. farfara have been found efﬁcaceous in the
complex treatment of rhinosinusitis in miners with chronic bron-
chitis (Lavrenov et al., 1988). However, no details were provided by
the authors.
The leaves of T. farfara are used in Russian traditional medicine
and were included in the VIIIth Pharmacopoeia of the USSR in
1952. Since this time, no adverse effects or toxicity have been
reported in Russian publications. Considering the long history of
the application of this plant in traditional medicine, infusions of
T. farfara leaves (5 g in 300 mL of water) can be considered safe at
the recommended therapeutical dose of 1/2-1/3 of a glass, 2–3
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times per day, for use as an expectorant (Sokolov, 2000). The
possibilities of adulteration must, however, be carefully monitored
(Roulet et al. 1988, Sperl et al. 1995). Publications reporting the
chemistry and pharmacological effects of this plant remain frag-
mentary, and further study of this plant would provide useful
results.
5.8.3. FOLIA PLANTAGINIS MAJORIS
Plantago major L. is a perennial plant that belongs to the family
Plantaginaceae. The leaves of P. major have long been used in
Russia for wound healing and as an expectorant, antiphlogistic,
pain-relieving herb (Turova, Sapozhnikova, 1989; Sokolov, 2000).
Whole or fragmented dried leaves and scapes of Plantago lanceo-
lata L. are approved by the European Pharmacopoeia.
Because the pharmacological effects of P. major are similar to
those of Plantago lanceolata, the pharmacological effects of P. major
are not discussed in this review.
5.8.4. GEMMAE PINI
Gemmae pini consist of the buds of Pinus silvestris L. (of the
Pinaceae family), which are collected during early spring. Pine
buds are widely used in Russian traditional medicine as an
expectorant and a weak diuretic for the treatment of chronic
bronchitis and tuberculosis. This material can be used for aromatic
baths that improve skin conditions and support the treatment of
arthritis (Vereschagin et. al., 1959; Gammerman et al., 1984).
Pine buds are safe, available without a prescription, and are
recommended for use as a decoction (10 g of buds in 200 mL of
water) or by inhalation. The decoction is used at a dose of
60-100 mL, 2–3 times per day, as an expectorant (Sokolov,
2000). Pine buds are used as the raw material for the steam
distillation of an essential oil. Pini sylvestris aetheroleum is
included in the European Pharmacopoeia and will therefore not
be discussed further here.
5.8.5. RHIZOMATA ET RADICES INULAE
Elecampane (Inula helenium L.), also called horse-heal, is a
perennial plant from 90 cm to 150 cm high belonging to the
Compositae family. In Russia, elecampane roots are used as an
expectorant for treating chronic respiratory diseases, including
bronchitis, tracheitis, tuberculosis, and bronchitis with lots of
mucus (Turova, Sapozhnikova, 1989). A decoction made from
elecampane roots is often prescribed as an antiphlogistic and as
a haemostatic for treating problems of the gastrointestinal tract.
This root increases stomach and intestinal secretions, thus stimu-
lating the appetite and improving digestion (Zevin et al., 1997).
Preparations of the roots are used in the folk medicine of several
ethnic groups to treat a variety of ailments including asthma,
(whooping) cough, bronchitis, lung disorders, tuberculosis, indi-
gestion, chronic enterogastritis, and infectious and helminthic
diseases (List and Hor̈hammer, 1976; Cantrell et al., 1999; Huo
et al., 2008).
The safety of elecampane has been evaluated in mice, rats,
rabbits, and other animals. The LD50 of infusions, tinctures, and
liquid extracts of I. helenium roots were found to be greater than
5,000 mg/g in both mice and rats. The median lethal dose of the
tincture was found to be 14,043 mg/kg for mice and 12,684 mg/kg
for rats. The median lethal dose of the liquid extract was found to
be 13,230 mg/kg for mice and 12,285 mg/kg for rats (Gurskaya
et al., 2009a). The safety of the infusion, tincture, liquid and dry
extracts of I. helenium was evaluated in irritation tests on guinea
pigs, rabbits, sheep and piglets. There was no irritating effect after
the transdermal application of all forms of I. helenium. The
irritating activity of the infusion after application to the eye
conjunctiva was evaluated as light, whereas the effect of the dry
extract (10-20% suspension in water) was estimated as limited and
disappeared in 24 hours. The irritating activities of the tincture
and liquid extract (70% EtOH) were evaluated as pronounced and
did not disappear within 24 hours (Gurskaya et al., 2009b).
Table 11 summarizes the pharmacological studies that have been
undertaken on I. helenium and that are reported in the literature.
A clinically tested and approved extract of I. helenium root
(standardized based on the total amount of sesquiterpene lac-
tones), which has been marketed in Russia under the name
"Alanton" since 1979, is prescribed for the treatment of acute
and chronic infectious and inﬂammatory diseases of the respira-
tory system that are accompanied by a persistent cough with thick
viscous mucus, to stimulate blood circulation in the stomach and
to accelerate the healing of stomach ulcers (Mashkovskii, 2002). In
an open clinical trial without a control group, "Alanton" tablets
were administered to 24 patients with peptic ulcers. After oral
administration of the tablets (0.1 g, three times daily, for 3 weeks),
clinical recovery was recorded for all of the studied patients. The
level of blood serum protein, primarily albumin, and γ-globulins,
was increased. Decreases in pyrosis, nausea, and vomiting were
registered after 7–10 days, patient appetite was improved, and
body weight was increased by approximately 3 kg. The treatment
resulted in regeneration of the gastric epithelium and decreased
the size of the ulcers. It was concluded that "Alanton" has anti-
inﬂammatory activity and contributes to mucus production and
mucus membrane regeneration (Luchkova, 1978).
Inula helenium roots are recommended for internal adminis-
tration at a dose of 100 mL of the decoction (16:200), 2–3 times
per day, for use as an expectorant in upper respiratory tract
infections. "Alanton" tablets that contain 0.1 g of total sesquiter-
pene lactone content are recommended for internal administra-
tion at the dose of 1 tablet, 3 times per day, for 6–8 weeks by
patients with inﬂamed or scarred stomach ulcers (Sokolov, 2000).
The extracts and isolated compounds of I. helenium have been
determined to have interesting biological activities, suggesting
that Radix Inulae could lead to the development of further drugs.
5.8.6. RHIZOMATA CUM RADICIBUS POLEMONII
Polemonium caeruleum L., (Jacob's ladder or Greek valerian;
Polemoniaceae) is a hardy perennial ﬂowering plant, which grows
to a height of approximately 35–140 centimeters; this plant has
been used in Russian traditional medicine as a sedative that is
similar to valerian and to treat tuberculosis and whooping cough.
In Ukraine, this plant was used to prepare childrens’ baths. An
infusion of the roots is used as a drink to treat fever (Turova,
Sapozhnikova, 1989, Sokolov, 1990). In modern medicine, this
plant is recommended as an expectorant for bronchitis, neurosis,
and stomach and intestinal ulcers in combination with Gnapha-
lium uliginosum L. (Mashkovskii, 2002).
Varlakov ﬁrst studied this plant in 1932 in connection with the
medicinal ﬂora of Eastern Sayan and proposed its use as an
expectorant to replace imported Polygala senega L. (Varlakov,
1943). In experiments on rabbits with cholesterol-induced athero-
sclerosis, it was shown that saponins of P. caeruleum have a
hypocholesterolemic effect, decrease the development of athero-
sclerosis and reduce lipid levels in the skin, aorta and liver
(Sokolov, 1990). Rhizomata cum Radicibus Polemoni was included
in the State Pharmacopoeia of the USSR in 1961 (Maltseva,
Sorokina, 2010), and a limited number of pharmacological studies
are available (Table 12).
No toxicity was observed after treating patients with 45 mL of
an infusion of P. caeruleum (6 g of roots in 200 mL of water) per
day for two weeks; however, because some irritating effects are
possible, this infusion should be taken after a meal (Panchenkov,
1950; Turova, Sapozhnikova, 1989).
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Table 9
Summary of Pharmacological Studies for L. palustre.
Activity tested Model used Plant part
used
Extract type Admin Dosage/ duration Control Results Reference
Antibacterial in vitro. Broth dilution
method.
Shoots Aqueous extract
and isolated
polysaccharide
complex
in vitro 1/20-1/160 Tested microbes
S. aureus, E. coli,
P. aeruginosa,
Klebsiella
pneumoniae
Bacteriostatic effect at 1/160
dilution, excluding to P.
aeruginosa (1/20 dilution) for
polysaccharide complex.
Belousov et
al., 2006
Anticancer in vitro. Mouse leukemia
cells L1210,
Aerial part Methylene chloride
and MeOH extracts,
Soxhlet
96 well plate 10 μg per well Positive control
Methotrexate
Negative control
99% growth inhibition by
methylene chloride extract.
This extract is not attractive
as a potential source of drugs
because of the possibility of
causing necrosis of the cells.
71% growth inhibition by
MeOH extract.
Goun et al.,
2002
Anticancer in vitro. Human lympho-
blastoid Raji cells
Aerial part Crude EtOH (40%)
extract
in vitro 10, 50, 200 μg/mL Positive control:
methotrexate
ﬂuorouracil,
cyclophos-phamide,
vinblastine. Negative
control
99% inhibition at 200 μg/mL Spiridonov et
al., 2005
Antidiabetic in vitro. C2C12 murine
skeletal myoblasts and the
3T3-L1 murine
preadipocyte cell lines
Leaves EtOH (80%, 1:10)
extract with
153.5 μg/mg total
phenolic
in vitro. 1.1 mmol/L (glucose
deprivation) or 150 mmol/L
glucose (glucose toxicity)
Negative control.
Positive control
rosiglitazone
Cytoprotective properties
under conditions of glucose
toxicity and glucose
deprivation at 6.25 μg/mL.
Exhibited the effect on the
basal and insulin stimulated
3H-deoxy-glucose uptake in
differentiated 3T3-L1
Adipocytes at 50 μg/mL.
Triglyceride level was
increased by 3-fold. Effect
was comparable with levels
induced by10 mmol/L
rosiglitazone
Harbilas et
al., 2009
Antidiabetic in vitro. Caco-2/15 cells;
western blot analysis.
in vivo. Rats, oral glucose
tolerance test
Leaves EtOH (80%, 1:10)
extract with
153.5 μg/mg total
phenolic
25–100 μg/mL (in vitro);
250 mg/kg (in vivo)
Negative control.
Positive control:
cytochalasin B,
phlorizin, phloretin.
100 μg/mL instantaneous
inhibition of differentiated
Caco2/15 intestinal cells
glucose absorption. Reduced
SGLT1 protein expression.
in vivo reduction AUC of
blood glucose levels
compared with control in the
periods 0–30 min, 0–50 min,
0–120 min after glucose
administration.
Nistor Baldea
et al., 2010
Antifungal in vitro. Micro-broth
dilution method.
Leaves Quercetin 3-β-D-
(6-p-coumaroyl)
galactoside and
quercetin 3-β-D-(6-
p-hydroxy-
benzoyl)
96 well plate 100 μL Cryptococcus
neoformans,
Saccharomyces
Cerevisiae, Aspergillus
niger, C. albicans.
Positive control
amphotericin B,
ﬂuconazole
MIC¼16-63 μg/mL for C.
neoformans, S. cerevisiae and
A. niger. MIC¼ 0.16–10 μg/mL
for amphotericin B and
ﬂuconazole. MIC¼250 μg/mL
for C. albicans.
Jin et al., 1999
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Table 9 (continued )
Activity tested Model used Plant part
used
Extract type Admin Dosage/ duration Control Results Reference
Anti-inﬂammatory in vitro. Prostaglandin
biosynthesis assay; PAF-
induced exocytosis
Aerial part Aqueous extract,
lyophilized.
in vitro 0.2 mg/mL (for prostaglandin)
0.25 mg/mL (for PAF)
Negative control.
Positive control:
indometacin,
eugenol, quercetin,
saligenin.
Moderate inhibition of
prostaglandin biosynthesis
(50%) and platelet activating
factor (PAF)- induced
exocytosis (71%)
Tunón et al.,
1995
Anti-inﬂammatory in vitro. Prostaglandin-
synthesizing cyclooxygena-
se system from sheep
seminal vesicles and HPLC
separation
Aerial part Essential oil in vitro. 37 μMol Positive control:
eugenol, carvacrol,
thymol, guajazulen,
urushiol, curcumin,
piperin, capsaicin,
apiol, cubebin,
isoalantolacton, ledol
Ether oil inhibited
cyclooxygenase in vitro with
46.6% and carvacrol was
reported to be one of the
compounds responsible with
94% inhibition. However,
ledol, did not inhibit the
enzyme.
Wagner et al.,
1986
Anti-inﬂammatory in vivo. Carrageenan-
induced edema in rats
Shots Dry extract
aqueous, EtOH 40%,
EtOH 70%
Per oral 50 mg/kg / Single dose Negative, Positive
control: butadione,
50 mg/kg
51.574.6% inhibition of
edema by EtOH 40% extract,
comparable to butadione.
Belousov et
al., 2006
Antioxidant in vitro. DPPH assay,
Fe3þ -EDTA-H2O2
deoxyribose assay,
nonenzymatic lipid
peroxidation of rat liver
homogenate
Aerial part Essential oil. 37
compounds
identiﬁed among
them sabinene (16-
17%), terpinen-4-ol
(7.6%), myrtenal
(3.5%), β-Selinene,
α-selinene, γ-
elemene, α -caryo-
phyllene (2-6%
range)
in vitro. Not indicated Negative control. IC50¼1.6 μg/mL in DPPH
assay; IC50¼2.7 μg/mL in
Fe3þ -EDTA-H2O2 deoxyribose
system; IC50¼13.5 μg/mL in
nonenzymatic lipid
peroxidation of rat liver
homogenate
Kim, Nam,
2006
Antithrombin in vitro. Thrombin solution
from bovine plasma
Aerial part MeOH extract,
soxhlet
96 well plate 50 μL Negative control 88% thrombin inhibition Goun et al.,
2002
Hepato-protective in vivo. Rats, mice, CCl4
intoxication
Shots Dry extract (EtOH
40%)
Per oral 100 mg/kg / Single dose Negative control. Extract reduces hexobarbital
sleeping time in 1.4 (rats),
and 3.2 (mice) folds.
Improves functional-
metabolic and morphological
parameters of liver.
Belousov et
al., 2007
Radioprotective in vivo. Mice irradiated
with γ-irradiation
Aerial part Combination of
Archangelica
ofﬁcinalis and L.
palustre extracts
Single injection Not indicated, 5–15 min
before lethal dose irradiation
Negative control. 100% of animals survived
after a dose of 6 Gy (LD50/30);
70% survived after a dose of
7.5 Gy (LD90/30), and 25% after
a dose of 8 Gy (LD100/12) by
day 30.
Narimanov et
al., 1991
in vivo. 30 days albino
mongrel male mice
irradiated with
γ-irradiation (LD90/30)
Aerial part Combination of
Archangelica
ofﬁcinalis and L.
palustre extracts
Single injection Not indicated Negative control:
nonirradiated
animals
Offspring were obtained from
11 of 12 experimental males.
The number of mouse pups
was 10.270.6 and 7.470.7
in experimental and
nonirradiated groups
respectively. The number of
both sexes in the posterity of
nonirradiated parents was
equal, in offspring of
experimental groups, the
number of female pups was
2.3 times larger than that of
males.
Narimanov,
1992
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In an open clinical trial without a control group, a group of
patients with tuberculosis, acute and chronic bronchitis, and lung
abscess was treated with 0.75 mL of P. caeruleum liquid extract
(taken 3 times a day) and 45–75 mL of infusion (6 g of roots in
200 mL of water) for 30 days. Therapeutic effects were observed
in 60% of the patients, but no clear scale for primary outcome
parameters appears to have been deﬁned. Patient treatment
resulted in increased phlegm and the facilitation of its evacuation.
Catarrhal conditions of the lungs were improved, and coughing
diminished (Turova, 1955). A different group of patients with
psychiatric disorders was treated with 15 mL of an infusion of
P. caeruleum (6 g of roots in 200 mL of water) to be taken three
time a day after a meal for a 2-week period. A sedative effect was
observed in all patients (Turova, Sapozhnikova, 1989), but the
details remain lacking.
A speciﬁc method has been reported for the treatment of
patients with peptic ulcers that involves the combined adminis-
tration of infusions of P. caeruleum and G. uliginosum. The rationale
behind this therapy is due to the sedative effect provided by P.
caeruleum and a local effect of G. uliginosum that accelerates ulcer
healing. Seventy patients with ulcers were treated with 15 mL of
an infusion of P. caeruleum (6 g of roots in 200 mL of water) and
50 mL of an infusion of G. uliginosum (10 g in 200 mL of water) to
be taken three times a day after a meal for 2 weeks. No side effects
were observed. Most of the patients exhibited diminished gastric
pain and less blood in the stool. Based on radiographic examina-
tion, the gastric ulcer lesions (called ‘niches’) disappeared, and the
gastric pH was usually normalized. Treatment of patients with
either of the infusions alone was not effective (Panchenkov, 1950).
The roots and rhizomes of P. caeruleum are recommended for
internal administration at the dose of 20 mL of the infusion (6 g in
200 mL of water), 3–5 times per day, for use as an expectorant and
at the dose of 20 mL, 3 times per day, together with an infusion of
the aerial parts of G. uliginosum for use as an anti-inﬂammatory
agent for the treatment of stomach ulcers (Sokolov, 2000).
Polemonium caeruleum has been used clinically for a long time,
and the roots and rhizomes are available without a prescription.
However, the chemical and pharmacological evidence needed to
support the medical applications of this plant, especially for its use
as an expectorant, dates from the early part of the last century and
needs further conﬁrmation.
5.9. Diuretic agents
5.9.1. CORTEX VIBURNI
Viburnum opulus L. (Adoxaceae), also known as the guelder rose,
water elder, European cranberrybush, cramp bark, and snowball
tree, is a deciduous shrub growing to 4–5 m high.
An infusion of the bark is used in Russian traditional medicine
to treat scrofula in children, asphyxia, colds, and uterine, gastric
and hemorrhoidal bleeding (Vereschagin et al. 1959). The bark has
been used to treat high blood pressure, heart trouble, tuberculosis,
shortness of breath, stomach pain, digestive troubles, duodenal
ulcers and bleeding, kidney and bladder afﬂictions, and coughs
and colds, and this infusion also has astringent activity (Smirnova,
Iadrova, 1968, Velioglu et al., 2006, Zayachkivska et al., 2006;
Sokolov, 2000). The tannins of V. opulus bark bind mucous proteins
after intragastric administration, causing them to precipitate and
thereby cover and protect sensitive stomach cells. Consequently,
local pain is decreased, blood vessels are constricted, the secretion
of gastric juice is decreased, and membrane density is increased,
resulting in decreased inﬂammation. In 1952, the bark was
included in the State Pharmacopoeia of the USSR (Vereschagin
et al. 1959).
In the available literature, there is no data regarding the toxic
effects of V. opulus bark. The bark is available without a prescription
in Russian pharmacies and is considered safe in decoction form at
the dose of 18–36 mL, 3–4 times per day (Sokolov, 2000). Table 13
summarizes the pharmacological studies that have been under-
taken on V. opulus bark and that are reported in the literature.
In the literature, no clinical data are reported. The bark of V.
opulus is recommended for internal administration at the dose of
1–2 tablespoons of the decoction (10 g in 200 mL of water), taken
3–4 times per day as a diuretic or an antiseptic. The bark has been
used clinically for a long time as a non-prescription medicine.
However, the information available regarding its chemical and
pharmacological effects is insufﬁcient, and the bark should be
studied in greater detail.
5.9.2. FLORES CENTAUREAE CYANI
Centaurea cyanus L. (Compositae) also called blue cornﬂower or
bachelor’s button has grey-green branched stems. The ﬂowers are
used in Russian traditional medicine as a diuretic and for the
treatment of cystitis, coughs, nervous and gastric diseases, uterine
bleeding and in children against diarrhea and as an eye-wash
(Vereschagin et al., 1959). The ﬂowerheads are a well-known crude
drug used in European traditional medicine to treat minor ocular
inﬂammation (Bruneton, 1995), fever, gynecological problems,
digestive complaints (Kern et al., 1972; Hansel et al., 1992), and
wounds and dermatological complaints (Pieroni et al., 2004). The
dried ﬂowers of C. cyanus are used to relieve diarrhea, increase
energy and appetite, and to relieve chest tightness (Arif et al.,
2004). Centaurea cyanus is recommended as a component of
herbal mixtures for the treatment of edema associated with
kidney disease, as well as diseases of the urinary tract (nephritis,
cystitis, and urethritis), and diseases of the liver and biliary tract
(Turova, Sapozhnikova, 1989).
No data regarding the toxicity of C. cyanus is available in the
literature. In a recently published review of retrospective observa-
tional case reports of ocular side effects or systemic side effects of
eye medications involving herbal medicines and nutritional sup-
plements, Fraunfelder (2004) mentioned that cornﬂower is used
for the treatment of conjunctivitis and ophthalmia. No side effects
of C. cyanuswere found in reports submitted to the WHO, the Food
and Drug Administration, and the National Registry of Drug- Induced
Ocular Side Effects (Fraunfelder, 2004). The dry ﬂowers of C. cyanus
are available without a prescription in Russian pharmacies and are
safe in decoctions at the dose of 18 mL, administered 3 times a day
(Sokolov, 2000). Few pharmacological studies of C. cyanus are
available and summarized in Table 14.
No clinical data were found regarding C. cyanus. Flowerheads of
C. cyanus are recommended for internal administration at the dose
of 1 tablespoon of the infusion (10 g in 200 mL of water), 3 times
per day, for use as a diuretic. This material has been used clinically
for a long time without prescription. However, information
regarding the chemical and pharmacological effects of this mate-
rial is limited and warrants further study.
5.9.3. FOLIA VITIS-IDAEA
Vaccinium vitis-idaea L., (lingonberry, or cowberry, Ericaceae) is
a short evergreen shrub up to 25 cm tall, with leathery evergreen
leaves. In Russian traditional medicine, infusions or decoctions
made from the leaves have been used as an astringent and as a
diuretic for the leaching of kidney stones and in cases of stomach
pain, diarrhea, and rheumatism (Vereschagin et al., 1959; Nosal,
Nosal, 1960). Vaccinium vitis-idaea leaves are used as an anti-
inﬂammatory medicine in China to treat respiratory system infec-
tions (Wang et al., 2005). A decoction of V. vitis-idaea leaves is
recommended in modern Russian medicine for use as a diuretic, a
cholagogue, an antiseptic, and as an astringent for the treatment of
kidney and bladder diseases, gastroenteritis, diarrhea, as well as
A.N. Shikov et al. / Journal of Ethnopharmacology 154 (2014) 481–536 503
Table 10
Summary of Pharmacological Studies for T. farfara.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Anticancer in vitro. Mouse leukemia
cells L1210,
Aerial part Methylene chloride and MeOH
extracts, soxhlet
96 well
plate
10 μg per well Positive control
Methotrexate Negative
control
92% growth inhibition by methylene
chloride extract. 71% growth
inhibition by MeOH extract.
Goun et al., 2002
Anti-inﬂammatory in vitro. Murine
macrophage cell line
(RAW 264.7),
lipopolysac-charide-
activated macrophages
Flower buds Isolated 1α,5α -bisacetoxy-8-
angeloyloxy-3β,4β-epoxy-bisabola-7
(14),- 10-dien-2-one
96 well
plate
No data Negative, Positive control:
NG-monomethyl -L-arginine
Inhibition of arachidonic acid
metabolism and i-NOS (71.1%) with
IC50 ¼8.9 μM.
Ryu et al., 1999
Anti-inﬂammatory in vitro. Murine
macrophage cell line
(RAW 264.7),
lipopolysac-charide-
activated macrophages
Flower buds Isolated tussilagone 96 well
plate
0–30 μM Negative, Positive control:
zinc protoporphyrin IX,
copper protoporphyrin IX
Inhibition of production of NO, TNF-
α, and PGE2 aswell as i-NOS and
COX-2 LPS-stimulated RAW264.7
cells and murine peritoneal
macrophages
Hwangbo et al.,
2009
Antimicrobial in vitro. Liquid dilution
method
Aerial part, rhizome EtOH (80%) extract in vitro. No data B. cereus, E. coli, P. aeruginosa,
S. aureus, C. albicans. Positive
control: erythromycin,
gentamicin, amphotericin B
MIC (mg/mL) for aerial part/rhizome
B. cereus: 16.63/62.5; S. aureus:
62.50/62.5
Kokoska et al.,
2002
Antioxidant in vitro. Lipid
peroxidation in rat brain
homogenates, DPPH
assay.
Flower buds EtOAc fraction from MeOH extract in vitro. Not indicated Negative control. IC50¼6.3 μg/mL in lipid peroxidation
assay, IC50¼14.3 μg/mL in DPPH
assay
Cho et al., 2005
Antioxidant in vitro. DPPH assay,
pyrogallol autoxidation
assay
Flower buds EtOAc, BuOH, aqueous fractions from
EtOH (70% extract). Main
compounds: chlorogenic and 3, 5-O-
dicaffeoylquinic acids.
in vitro 5–8 mg/mL Negative control. EtOAc and BuOH fractions exhibited
more potent activities than aqueous
fraction in all tested concentrations.
The scavenging activity of all extracts
was found in a concentration-
dependent manner
Li et al., 2012a
Antitussive in vivo. Mice, ammonia
induced coughing.
Flower buds and
rachis
Aqueous extract Per oral Flower bud (2.8 g/
kg), rachis (3.5 g/
kg). 5 days.
Negative control. Positive
control: pentoxyverine
After treatment with ﬂower bud
extract latent period of cough was
prolonged in 47% and cough
frequency was decreased in 48%
compared to control. Rachis extract
has no signiﬁcant effect.
Li et al., 2012b
Expectorant in vivo. Mice,
intraperitoneal injection
of phenol red solution.
Flower buds and
rachis
Aqueous extract Per oral Flower bud (2.8 g/
kg), rachis (3.5 g/
kg). 5 days.
Negative control. Positive
control: ammonium chloride
Flower bud enhance tracheal
phenolsulpho-nphthalein excretion
in 42% compared to control,
indicating strong expectorant effect.
No effect for the rachis extract
Li et al., 2012b
Neuro-protective in vitro. Cortical cell
cultures
Flower buds EtOAc fraction from MeOH extract in vitro. Not indicated Negative control. Inhibition of neuronal damage
induced by arachidonic acid with
IC50¼ 0.64 μg/mL. Attenuated
neuronal damage induced by
spermine NONOate. Cell viability
increased to 30-40% at 10 μg/mL and
above. Inhibited Aβ (25-35)-induced
neurotoxicity with IC50¼ 30.9 μg/mL
and glutamate- or N-methyl-D-
aspartic acid-induced excitotoxicity
was inhibited with IC50¼ 76.3 and
53.7 μg/mL respectively. 90% of cells
were protected from Fe2þ/ascorbic
acid-induced damage at 30 μg/mL.
H2O2-induced damage was not
inhibited until 300 μg/mL. Viability of
cells exposed to xanthine/ xanthine
oxidase was increased at 30 μg/mL
and above.
Cho et al., 2005
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for rheumatism, gout and arthritis (Sokolov, 2000). The leaves of V.
vitis-idaea were included in the VIIIth Pharmacopoeia of the USSR
in 1952.
No literature data is available regarding the toxic effects of V.
vitis-idaea leaves. The acute toxicity of the polyherbal mixture
"Brusniver", which contains 50% V. vitis-idaea leaves, 20% Hyper-
icum perforatum L. (Hypericaceae) aerial parts, 20% Rosa spp. L
(Rosaceae) pseudo-fruits and 10% Bidens tripartita L (Compositae)
aerial parts, has been studied in mice. Regarding acute toxicity,
intragastric administration of the infusion was found to be safe; no
mortality was observed after administration of the extract at the
dose of 30 g/kg (equivalents of dry mixture) in mice, and the LD50
was not reached. No signs of toxicity were observed in female rats
after intragastric administration of infusions (20 and 40%) of the
mixture at doses up to 8 g/kg administered for 21 days
(Vichkanova et al., 2004). Table 15 summarizes the pharmacolo-
gical studies that have been undertaken on V. vitis-idaea and that
are reported in the literature.
The effect of an oral treatment with an infusion of Brusnivers
(200 mL/day, administered for 14 days) was studied in 31 patients
with pyelonephritis, urolithiasis, and urethritis. The report did not
give a full description of the controls used, which makes it difﬁcult to
assess the outcome of this trial. A positive effect was registered in
83.8% of patients; however, it appears that no clear primary outcome
parameters were deﬁned. All patients tolerated the treatment well,
and no side effects were observed (Vichkanova et al., 2004).
Vaccinium vitis-idaea leaves are available in Russia in pharma-
cies without a prescription and are recommended for internal use
at a dose of 1/2 - 1/3 glass of the decoction (6 g in 200 mL of
water), 2–3 times per day, for use as a diuretic, a cholagogue and
as an antiseptic (Sokolov, 2000). However, insufﬁcient information
is available regarding the chemical and pharmacological effects of
this material, which therefore warrants further study.
5.9.4. GEMMAE BETULAE
Gemmae betulae consists of the buds of Betula pendula Roth
and B. pubescens Ehrh. (Betulaceae). Birch buds are widely used
in Russian traditional medicine as a diuretic, expectorant, chola-
gogue, diaphoretic, blood-puriﬁer, and analgesic; as an anti-
infective agent and an antiseptic for wound healing; to treat
furunculosis; and as a wash to remove skin spots (Vereschagin et
al., 1959; Nosal, Nosal, 1960; Zevin et al., 1997). Infusions and
decoctions of birch buds are used in stomatology and otolaryngol-
ogy for their anti-inﬂammatory properties, to treat stomatitis,
gingivitis, periodontitis, glossitis, sore throat, chronic tonsillitis,
acute respiratory diseases, and as a rinse applied to gauze pads,
which are moistened with infusions or decoctions (Lavrenova,
Lavrenov, 1997).
Birch buds have been used for centuries; in adequate doses, this
material presents no toxicity or contraindications except for
ingestion, due to the presence of ether oils in the buds. However,
we did not ﬁnd any data regarding the toxic effects of Gemmae
betulae in the available literature. Table 16 summarizes the
pharmacological studies that have been undertaken on Gemmae
betulae and that are reported in the literature.
A group of 108 patients with purulent wounds (83 had super-
ﬁcial wounds, 10 had deep wounds, and 15 had cavitary wounds)
was treated with a 20% tincture of birch buds in 70% EtOH. The
publication did not give a full description of the controls; thus, it is
practically difﬁcult to assess the outcome of this trial. Positive
results were obtained after using the birch-bud tincture in all of
the patients, including patients with antibiotic-resistant microbial
ﬂoras; however, it appears that no clear primary outcome para-
meters were deﬁned (Zakharov et al., 1980). Birch buds have
been used in patients with edema of cardiac origin as a diuretic.
A signiﬁcant increase in diuresis (urine production) and a sharp
decrease in edema were observed. However, in case of functional
kidney failure, this type of treatment is not recommended due to
possible irritation of the renal tissue by the resinous substances
(Sokolov, 2000). Birch buds were shown to exert a beneﬁcial effect
in the treatment of patients with acute and chronic forms of
eczema (Pevzner, Raitsina, 1954).
Birch buds are available in Russia pharmacies without a prescri-
ption and are recommended for internal administration at the
dose of 1/2 - 1/3 glass of the infusion (10 g in 200 mL of water),
taken 2–3 times per day as a diuretic and a cholagogue (Sokolov,
2000). However, insufﬁcient information is available regarding its
chemical composition and pharmacological effects, and thus, this
material warrants further study.
5.10. Cardiotonic agents
5.10.1. HERBA ADONIDIS VERNALIS
Adonis vernalis L., also known as pheasant's eye, spring pheasant's
eye, yellow pheasant's eye and false hellebore, among others, is a
perennial ﬂowering plant of the Ranunculaceae. This plant is included
in the German Homoeopathic Pharmacopoeia.
In Siberia, an aqueous infusion of the aerial parts has tradi-
tionally been used against malaria, edema, cardiac edema, and
several other heart-related problems, and against kidney diseases
(Utkin, 1931; Nosal, Nosal, 1960). In 1879, alcoholic extracts of A.
vernalis were ﬁrst introduced into medicine by the Russian
medical doctor, N.O. Bubnow, who employed these extracts as a
cardiac stimulant (Heyl et al., 1918). In 1898, the famous Russian
neurologist Vladimir Bekhterev suggested using a mixture of A.
vernalis with sodium bromide (or potassium bromide) or codeine
to treat light forms of heart failure, panic disorder, dystonia, and
epilepsy (Bekhterev, 1898). The biological activity of A. vernalis
aerial parts (1:20 EtOH 95% extract) was deﬁned as 50–66 frog
units or 6.3-8.0 cat units according to the State Pharmacopoeia of
the USSR, 11th edn.
The toxicity of A. vernalis leaves was assayed using the one-
hour frog method, which is ofﬁcially used to test tinctures of
digitalis, strophanthus, and squill. The average minimum dose
producing a permanent systole (M.S.D.) of the frog’s ventricle at
the end of exactly one hour was 0.0045 mL/g frog for the A.
vernalis tincture (1:10, 95% EtOH) (Heyl et al., 1918). The LD50 of
cymarin (one of the active glycosides present) after intravenous
injection in rats was found to be 24.871.8 mg/kg (Vogel, Kluge,
1961) and the LD50 after intravenous injection in cats was found to
be 95.473.0 μg/kg (Chen et al., 1942). The M.S.D. values for
adonitoxin and cymarin are 0.62170.046 g/g and
0.88070070 g/g frog, respectively (Chen, Anderson, 1947). The
LD50 for adonitoxin after intravenous injection in cats was found to
be 191.3717.5 μg/kg (Chen, Anderson, 1947).
Preparations of Adonis slow, regulate and strengthen heart
contractions, increase blood pressure, and exert a mild diuretic
action. This material reduces dyspnea and relaxes smooth muscle
in the lungs, allowing deeper breathing, and is especially indicated
in congestive heart failure with arrhythmia, and for feeble con-
tractions with dyspnea and dropsy. In heart failure accompanied
by cardiac conduction disturbance, Adonis can be as effective as
Digitalis; however, the effects of Adonis are not cumulative and do
not cause the phenomenon of a cardiac arrest, as does Digitalis
(Turova, Sapozhnikova, 1989). Table 17 summarizes the pharma-
cological studies that have been undertaken on A. vernalis and that
are reported in the literature.
In the ﬁrst half of the twentieth century, the pharmacological
effects of A. vernalis were studied extensively in Russia; however,
the literature from that time is poorly accessible. The novo-galenic
preparation "Adonisid" (a speciﬁc extract of A. vernalis) was
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Table 11
Summary of Pharmacological Studies for I. helenium.
Activity tested Model used Plant part used Extract type Admin Dosage/
duration
Control Results Reference
Anticancer in vitro Human
lymphobla stoid Raji
cells
Root Crude EtOH (40%)
extract helenin
(40% alantolactone
and 60%
isoalantolactone)
in vitro 10, 50, 200 μg/mL Positive control:
methotrexate ﬂuorouracil,
cyclophos-phamide,
vinblastine. Negative
control
100% inhibition at 50 μg/mL by
EtOH extract; and at 10 μg/mL by
helenin. Helenin exceeded activity
cyclophosphamide and ﬂuorouracil
and approached the activity of
methotrexate.
Spiridonov et al.,
2005
in vitro. Human tumor
cell lines HT-29, MCF-7,
Capan-2 and G1. MTT
assay for adherent cell
lines and propidium
iodide staining and
FACS analysis for PBL
Root Acetone: MeOH
(2:1 v/v) extract
96 well
plate
10, 1, 0.1, 0.05,
0.01, 0.005 μL/mL
Negative control Cytotoxic effect with LD50 (μL/mL)
of 0.015 for HT-29, of 0.017 for
MCF-7, of 0.020 for Capan-2 and of
0.018 for G1 and LD90 (μL/mL) of
0.05 for HT-29, of 0.20 for MCF-7, of
0.10 for Capan-2 and of 0.10 for G1.
The cytotoxicity on healthy human
PBLs has LD50 of 2.4- 3.0 (μL/mL)
and LD90¼8.0-9.0 (μL/mL)
Cytotoxicity over 100-times higher
in tumor cell lines than in PBLs.
Dorn et al., 2006
Antihelmintic in vitro. Egg hatching
assay (eggs Ascaris
sum) larval migration
inhibition (LMI)
(Trichostron gylus
colubriformis)
Rhizomes and roots EtOH (80%) extract 96 well
plates
62.5–2000 μg/mL Positive control:
albendazole. Negative
control.
Athelmintic effect on the egg
embryo-genesis at 250-000 μg/mL.
LMI at the dose of 125 μg/mL and
higher.
Urban et al., 2008
in vivo. Rabbits infected
with Clonorchis sinensis
Root Boiled water
extract
in vivo. 30 days,
beginning at the
end of 3rd day of
inoculation.
Negative control. Recovery rates of worms from
rabbits was 2%. Degeneration,
atrophy, necrosis, dilatation, etc. of
viscera of the worms was observed
Rhee et al. 1985
Antihypoxant in vivo. Mice, single
hemic hypoxia,
repeated hemic
hypoxia, single tissue
hypoxia, repeated
tissue hypoxia, single
circulatory hypoxia,
repeated circulatory
hypoxia.
Stem Tincture (1:10) by
EtOH 40%. Contain
1.63% of ﬂavonoids,
dry residue42.25%
Injection 2.5 mL/kg, 5 days
and 1 h before
the hypoxic
exposure.
Negative control Life-span of mice increased by 35%
after single hemic hypoxia and by
76% after repeated hypoxia. Stress-
protective effect was realized
through prevention of adrenal
hypertrophy and splenic involution.
The life-span after single
intoxication with sodium ﬂuoride
was prolonged by 59%, of those
exposed to repeated hypoxia by
29%. Severity of stress decreased by
5 and 4 points, respectively,
compared to control due to the
protective effect on gastric mucosa.
Zelenskaya et al.,
2005
Antimicrobial in vitro. Broth dilution
assay
Root Helenin (a
crystalline mixture
of eudesmanolides)
in vitro. 10–750 μg/mL Negative control. Several
strains of S. aureus, E. coli, P.
aeruginosa, C. albicans
The MIC (μg/mL) against several
strains of S. aureus was 10-400, E.
coli and P. aeruginosa 200-750, C.
albicans - 200-750.
Kowalewski et al.,
1976
in vitro. Broth
microdilution method
Root Stepwise
supercritical ﬂuid
extract (SFE),
hydrodistillate
(HD). Main
compounds:
alantolactone,
isoalantolactone
and β -elemene
in vitro. 10–750 μg/mL Negative control. Positive
control: streptomycin,
bifonazole
MIC from 0.009 mg/mL to
414 mg/mL. HD and SFE extracts
active against Bacillus cereus,
S. aureus, Enterococcus faecium
clinical strain resistant to
ampicillin, erythromycin, penicillin
and tetracycline (MIC40.03 mg/
mL). Candida strains were most
Deriu et al., 2008
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susceptible, with MIC¼ 0.009–
0.12 mg/mL.
in vitro.
Radiorespirometric
bioassay against Myco-
bacterium tuberculosis
Root Isolated
alantolactone,
isoalantolactone,
11αH, 13-dihydro-
isoalanto-lactone
in vitro. Negative control. Positive
control: encelin from
Montanoa speciosa
MIC for alantolactone and
isoalantolactone was 32 μg/mL.
Cantrell et al.
1999
in vivo. Mice inoculated
with S. aureus
suspension in the left
nare
Root Isoalantolactone Subcuta-
neously
50 mg/kg, 2 h
after infection
with S. aureus
and at 12-h
intervals
thereafter for a
total of 6 doses.
Negative control:
phosphate-buffered saline
Marked alleviation of pulmonary
inﬂammation; treated mice less
accumulation of cellular inﬁltrates
in alveolar space.
Qiu et al., 2011
Anti-proliferative in vitro. MK-1, HeLa,
B16F10 cell lines, MTT
assay
Root MeOH extract ,
isolated 1,3,11(13)-
elematrien-8β,12-
olide, igalan; 5α-
epoxyalantolac-
tone; 4 β, 5α
-epoxy-1(10),11
(13)-
germacradiene-
8,12-olide;
alantolactone,
isoalantolactone,
11 α,13-dihyd-
roalantolactone,
11α,13-
dihydroisoalanto-
lactone
in vitro. Negative control. Positive
control: 5-ﬂuorouracil
GI50 (μM) for 5α-epoxyalan-
tolactone was 3.6-6.9, for
alantolactone – 4.7-6.9. 1,3,11(13)-
elematrien-8β,12-olide, igalan
exhibited almost the same potency,
but GI50 against HeLa cells was
2 folds lower.
Konishi et al.,
2002
Antithrombin in vitro. Thrombin
solution from bovine
plasma
Not speciﬁed Methylene chloride
extract, soxhlet
96 well
plate
50 μL Negative control 100% thrombin inhibition Goun et al., 2002
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produced in USSR in the form of tablets, but this preparation is
currently excluded from the State Register of drugs. "Adonisid" is
used in modern medicine as a part of the complex phytomedicine
"Cardiovalen" (which consists of 17.2 mL of the pressed juice of
Erysimum diffusum Ehrh. (Brassicaceae), 30.3 ml of "Adonisid"
containing 85 frog units in 1 mL, 48.6 mL of a tincture of Valeriana
ofﬁcinalis L. (Valerianaceae), 2.2 mL of a liquid extract of Crataegus,
0.4 g of camphor, and 2 g of NaBr).
The aerial parts of A. vernalis are prescribed in Russia for
internal use at the dose of 1 tablespoon of the infusion (7:200),
3–5 times per day, when taken as a cardiotonic. "Cardiovalen" is
prescribed at the dose of 15–20 drops, taken 1–2 times per day
(Sokolov, 2000).
5.10.2. HERBA CONVALLARIAE et FOLIA CONVALLARIAE et FLORES
CONVALLARIAE
In the Pharmacopoeia of the USSR, Herba Convallariae, Folia
Convallariae and Flores Convallariae consists of the whole or cut
dried aerial parts, leaves or ﬂowers, respectively, of Convallaria
majalis L. (syn: C. transcaucasica Utkin ex Grossh.), C. keiskei Miq.
(Asparagaceae), which are harvested during or at the beginning
(for the leaves) of the ﬂowering period. Depending on region, the
harvesting time can be shifted to obtain high-quality raw plant
material. Particularly in the St-Petersburg region, the optimal
harvesting time for Herba Convallariae is during the late budding
and early ﬂowering stages (Borisova et al., 1984). Convallaria
majalis is commonly known as the lily of the valley, and has been
recognized by clinicians for its antiarrhythmic effect. Felter found
it particularly useful for treating tachycardia and mitral insufﬁ-
ciency but found it less useful for addressing aortic valve problems
(Felter, 1922). Unlike the much stronger and more dangerous
Digitalis spp., lily of the valley glycosides do not accumulate in
the body, are safer, and produce milder effects (Yarnell, Abascal,
2003). The ﬂavonoids of C. majalis are also considered important
for the activity of the botanical drug, supporting the use of the
whole plant rather than isolated cardiac glycosides (Weiss, 1988).
The ﬂowers of C. majalis have been used in Russian traditional
medicine to treat epilepsy, cardiac dropsy, and mild congestive
heart failure (Nosal, Nosal, 1960; Gammerman et al., 1984).
Table 12
Summary of Pharmacological Studies for P. caeruleum.
Activity
tested
Model used Plant
part
used
Extract
type
Admin Dosage/
duration
Control Results Reference
Hypoglycemic in vivo. Mice,
glucose tolerance
test.
Roots
with
rhizome
EtOH 70%
extract
with 65%
saponins
Intraperitoneal 10 mg/kg Negative control.
Positive control:
extract of roots of
Beta vulgaris
Glucose concentration in the blood
decreased by half in 30 min after glucose
injection. Maximum of glucose in the blood
was in 50 min after injection.
Boyeva et
al., 2007.
in vivo. Mice,
glucose tolerance
test.
Roots
with
rhizome
EtOH 70%
extract
with 65%
saponins
Intraperitoneal 10, 30 mg/kg Negative control. Glucose concentration in the blood was
decreased by half after injection of 10 mg/kg
of extract in 30 min after glucose injection.
Sorokina
et al.,
2010.
Hypotensive in vivo. Rabbits
with experimental
atherosclerosis
Roots
with
rhizome
Isolated
saponins,
no details
Per oral Not
provided
Negative control. Decrease of cholesterol and blood pressure.
According to histological evaluation,
saponins reduce lipid cell inﬁltration of the
aortic intima and large vessels
Turova,
1955
Sedative in vivo. Mice exited
with phenamine.
Roots
with
rhizome
Infusion Per oral 0.01-0.03 g
(equivalents
of dry mass)
Negative control.
Positive control:
valerian infusion
Sedative effect was 8–10 times stronger
compared with valerian and more
pronounced in mice exited with phenamine.
Zoﬁna,
1946
Sedative in vivo. Rats,
prolongation of
soporiﬁc effect of
sodium ethaminal
Roots
with
rhizome
Dry
powder
Intragastric 30, 60,
120 mg/kg
Negative control.
Positive control: V.
ofﬁcinalis powder
Combination of P. caeruleum and V. ofﬁcinalis
(1:1, 60 mg/kg) prolonged the soporiﬁc effect
of sodium ethaminal in 2.5 fold.
Khishova
et al.,
2013
Table 13
Summary of Pharmacological Studies for V. opulus bark.
Activity
tested
Model used Plant
part
used
Extract type Admin Dosage/
duration
Control Results Reference
Antispasmodic in vitro. Single uterine
horns from virgin
Holtzman rats
Bark MeOH extract with
yield 4%.
in vitro 0.4 g/mL No data Complete relaxation of
muscle at 1 mL
Jarboe et al.,
1966
in vitro. Single uterine
horns from virgin
Holtzman rats
Bark Isolated scopoletin in vitro 0.025–
0.150 mg/mL
No data Relaxation of muscle tension
and spasms in uterus,
IC50¼0.09 mg/mL
Jarboe et al.,
1967
in vitro. Barium
stimulated rat uterus.
Bark Isolated viopudial in vitro No data No data ED50 for spasmolytic effect 24 μg/ml Nicholson et
al., 1972
Hypotensive in vivo. Rats, cats, dogs. Bark Isolated viopudial Intravenous 250 μg/kg
-2 mg/kg
Negative
control
In rats hypotensive effect at
250 μg/kg. At 1 mg/kg effects
were sustained and decrease
in blood pressure with decrease
in heart beat. In dogs and cats
effective dose 2 mg/kg.
Nicholson et
al., 1972
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According to the State Pharmacopoeia of the USSR, 11th edn., the
biological activity of C. majalis should be at least 120 frog units or
20 cat units for the aerial parts (1:20 EtOH 95% extract), 200 frog
units or 33 cat units for the ﬂowers (1:20 EtOH 95% extract), or 90
frog units or 15 cat units for the leaves (1:20 EtOH 95% extract).
Convallaria majalis has been reported to be toxic due to the
presence of the cardioactive glycosides, convallarin, and convalla-
marin. The LD50 for convallarin in rabbits after intravenous
administration was found to be 1,500 μg/kg (Marhold, 1986). The
lowest published lethal dose for convallarin in rabbits after
subcutaneous administration is 10 mg/kg, that in frogs after oral
administration is 200 mg/kg, and that after subcutaneous admin-
istration in frogs is 15 mg/kg (Abderhalden, 1935). The LD50 for
convallarin in rabbits after oral administration was found to be
320 mg/kg (Marhold, 1986). Table 18 summarizes the pharmaco-
logical studies that have been undertaken on Convallaria and that
are reported in the literature.
The novo-galenic preparation "Corglycon" (an 0.06% aqueous
solution of puriﬁed total glycosides from C. majalis leaves) was
developed in Ukraine SSR during the Soviet period. This prepara-
tion is clinically approved and standardized to 11–16 frog units, or
1.8–2.2 cat units per 1 mL. The pharmacological effect of "Corgly-
con" is similar to that of strophanthin but is more prolonged. The
preparation is prescribed for patients with acute and chronic class
II and III heart failure, cardiac decompensation, and for the
cupping of paroxysmal tachycardia (Mashkovskii, 2002).
A group of 34 patients having stage II-III atherosclerotic
dyscirculatory encephalopathy with coexisting ischemic heart
disease in the presence of stenosing and occlusive lesions of major
brain arteries were evaluated to examine the effects of pentox-
iphyllin and corglycon on the clinical course of this medical
condition and on systemic and cerebral haemodynamics. In this
series, 82.7 % of patients derived beneﬁt from a single intravenous
infusion of pentoxiphyllin and corglycon, and a course of treat-
ment with this drug preparation resulted in an improvement in
the parameters of the systemic and cerebral hemodynamics and in
the regression of the neurological symptomatology. The results of
these studies were used as a basis for recommending the use of
pentoxiphyllin in combination with corglycon for the treatment of
patients with eukinetic and hypokinetic systemic haemodynamics,
whereas the use of pentoxiphyllin alone is recommended for those
with hyperkinetic haemodynamics, considering its cardiodepres-
sive effects (Ishchenko et al., 1996). The publication did not fully
describe the controls used, which makes it difﬁcult to assess the
outcome of this trial.
Crude drug preparations of Convallaria are not available in
Russian pharmacies, but the tincture (10 g in 100 mL of EtOH 70%)
is prescribed in Russia for internal use at the dose of 15–20 drops,
taken 2–3 times per day as a cardiotonic. "Corglycon" is used for
intravenous injection at the dose of 0.5–1.0 mL in 10–20 mL of
glucose (20 or 40% solution), administered 1–2 times per day
(Sokolov, 2000).
5.11. Cardiovascular agents
5.11.1. FLORES CRATAEGI et FRUCTUS CRATAEGI
According to the Pharmacopoeia of the USSR, Flores crataegi
and Fructus crataegi consists of the ﬂowers of Crataegus sanguinea
Pall. and the ﬂowers and fruits of С. laevigata (Poir.) DC., C.
chlorosarca Maxim (syn. С. korolkowii hort. ex Dippel), C. wattiana
Hemsl. & Lace (syn. С. altaica (Loud.) Lange), С. chlorocarpa Lenn,
& K. Koch, and C. dahurica Koehne ex C.K. Schneid, С. monogyna
Jacq. (syn. С. alemanniensis Cinovskis, С. orientobaltica Cinovskis),
C. rhipidophylla Gand. (syn. С. curvisepala Lindm.), C. rhipidophylla
var. lindmanii (Hrabětová) K.I.Chr. (syn. С. Х dunensis Cinovskis),
and С. pentagyna Waldst. & Kit. ex Willd. (all Rosaceae).
Dried false fruits and the whole or cut, dried, ﬂower-bearing
branches of Crataegus monogyna Jacq. (Lindm.), C. laevigata (Poir.)
D.C. (synonym: C. oxyacantha L.) or their hybrids or a mixture of
these false fruits and the whole or cut, dried, ﬂower-bearing
branches of other European Crataegus species, including C. penta-
gyna Waldst. et Kit. ex Willd., C. nigra Waldst. et Kit., C. azarolus L.,
are included in the European Pharmacopoeia.
The pharmacological proﬁle and indications of Crataegus are
similar in Russia and Europe. Therefore, these plants will be not
discussed further in this review.
5.12. Haemostatic agents
5.12.1. HERBA POLYGONI HYDROPIPERIS
Persicaria hydropiper (L.) Delarbre (syn. Polygonum hydropiper L.,
Polygonaceae), also known as water pepper, is an annual that grows
to 0.8 m tall; in Russian popular medicine, the leaves are used to stop
bleeding and to treat haemorrhoids (Turova, Sapozhnikova, 1989).
Water pepper has been used for a long time as a haemostatic agent in
uterine bleeding, and for heavy and painful menstruation, abortion,
and postpartum bleeding (Kravkov, 1912, Rossijsky, 1934). The leaves
of this plant have been used to treat cancer, colds, and coughs
(Onitsev, 1962). The infusion has been prescribed for treating
rheumatism, chronic ulcers, haemorrhoid, tympanitis, and erysipelas
(Yang et al., 2012). Women in Assam (India) have traditionally used
the powdered dry root of P. hydropiper to prevent unwanted
pregnancies (Hazarika, Sarma, 2006). Water pepper is a hot-tasting
spice known in China, Japan, and Europe. The sprout of water pepper,
called "mejiso" or "benitade" in Japanese, is a well-known relish for
"sashimi," and the seeds were occasionally used as a substitute for
pepper in Europe (Matsumoto, Tokuda, 1990). "Hydropiperinum", a
chemically characterized extract of P. hydropiper leaves containing
ﬂavonoid glycosides, increases blood clotting, reduces the duration of
bleeding, and strengthens uterine contractions (Fedukovich, 1960).
Since 1946, the aerial parts and a liquid extract of P. hydropiper have
been included in the State Pharmacopoeia of the USSR (Vereschagin
et al. 1959).
The LD50 for the chloroform extract of P. hydropiper leaves was
determined to be 760 mg/kg in male albino mice. Subcutaneous
injection of a sub-lethal dose of extract into male mice once a
week for 6 weeks failed to show any signiﬁcant inﬂuence on white
and red blood cell counts or blood cholesterol levels (Rahman et
al., 2005). A subchronic toxicity study of water pepper extract
(WPE) was conducted in groups of 10 male and 10 female F344
rats fed powdered diets containing 62.5, 250, 1,000 or 4,000 ppm
concentrations of WPE for 13 weeks. WPE was prepared using a
two-step extraction method from leaves of P. hydropiper; the
leaves were ﬁrst extracted with N-hexane and then with EtOH,
resulting in a solution containing 7.0% polygodial as the main
component. Suppression of body weight gain due to decreased
food consumption was observed in both sexes at concentrations of
4,000 ppm of WPE. At this dose, slight increases of blood urea
nitrogen in both sexes and of serum alanine aminotransferase, Na
and Cl in females were observed; these increases are suggestive of
weak hepatic and renal toxicity, at least in females. The same
females also exhibited slight decreases in the number of red blood
cells and haematocrit, slight increases in mean corpuscular
volume and mean corpuscular haemoglobin, and minimal
increases of splenic haemosiderin deposition, providing evidence
of slight haemolytic anemia. In addition, an enhanced mast cell
accumulation in the mesenteric lymph nodes induced by WPE
treatment might be related to the complex biological effects of
polygodial and/or related ingredients included in this extract on
the gastrointestinal environment. The no-observed-adverse-effect
level of WPE was 1,000 ppm, which corresponds to 57.4 and
62.9 mg/kg/day for male and female rats, respectively (Kuroiwa
A.N. Shikov et al. / Journal of Ethnopharmacology 154 (2014) 481–536 509
et al., 2006). Table 19 summarizes the pharmacological studies
that have been undertaken on Polygonum hydropiper and that are
reported in the literature.
No clinical data were found regarding P. hydropiper in the
available literature. The aerial parts and an extract (70% EtOH) are
available in Russia in pharmacies without a prescription and are
recommended for internal administration at the dose of 1/3 of a
glass of the infusion (10 g in 100 mL of water), 3–4 times a day, or
30–40 drops of the extract, 3–4 times a day, when used as a
haemostatic agent (Sokolov, 2000). Polygonum hydropiper is a
popular herb in Russia, and its safety and efﬁcacy are conﬁrmed
by its long history of use. However, there is lack of information in
the literature regarding the efﬁcacy of this material. Further
clinical studies are required to evaluate the claimed activity in
patients, and more details on the safety of this drug would be
desirable.
5.13. Spasmolytic agents
5.13.1. FRUCTUS ANETHI GRAVEOLENTIS
Anethum graveolens L (dill, Apiaceae) grows to a height of
40–60 cm. The fruits (seeds) of A. graveolens have had diverse
uses in Russian traditional medicine: in powder and tincture forms
as a carminative, expectorant, and diuretic; in decoction form as
an antispasmodic, sedative, and galactagogue; and in infusion
form as a hypotensive agent (Gammerman et al., 1984;
Lavrenova, Lavrenov, 1997). Dill is a common household plant
with a history of more than 2,000 years of use as a spice and a
condiment in food because of its ﬂavor and preservative qualities.
Dill water is believed to have a soothing effect and is given to
babies to treat inﬂuenza and relieve hiccups and colics. Chewing
the seeds reduces bad breath. Dill is a galactagogue that is known
to increase the ﬂow of milk in nursing mothers and is passed to
the baby via the milk to help prevent colics. Dill can be used to
help regulate the menstrual cycle and has been reported to
possess antihyperlipidaemic and antihypercholesterolaemic activ-
ity (Heamalatha et al., 2011).
The toxicity of A. graveolens has been studied in mice after
intraperitoneal injection. The maximum non-fatal doses of aqueous
and EtOH extracts of A. graveolens seeds were 0.45 g/kg and 5 g/kg
(i.p.), respectively. The LD50 values of the aqueous and EtOH extracts
were 3 g/kg, and 7 g/kg, respectively (Hosseinzadeh et al., 2002).
Table 20 summarizes the pharmacological studies that have been
undertaken on A. graveolens and that are reported in the literature.
A prospective randomized clinical trial was carried out on 30
hyperlipidemic patients of both sexes with an age range 44–63
years and a disease duration of 5–10 years. Patients were allocated
into two groups: Group A comprised 15 patients who were treated
with lovastatin tablets at the dose of 20 mg once daily for four
weeks; Group B comprised 15 patients who were treated with
500 mg of ﬁnely powdered leaves of A. graveolens, which was
administered twice daily for four weeks; in addition, 15 healthy
subjects served as a control group. Treatment of the patients with
powdered dill leaves resulted in highly signiﬁcant (Pr0.01)
decreases in the values of total cholesterol (TC) (19.9%), triglycer-
ide (29.5%), LDL-Chol (22.2%) and VLDL-Chol (25.2%). Statistically
signiﬁcant (Pr0.05) decreases were observed in TC/HDL-Chol and
LDL-Chol/HDL-Chol levels after four weeks of treatment, and TG/
HDL-Chol was decreased to less than that of the healthy control
group. In contrast, treatment with lovastatin signiﬁcantly
(Pr0.05) decreased all lipid ratios in hyperlipidemic patients
after four weeks. During the course of treatment, no side effects
were recorded, indicating the safety and tolerability of the admi-
nistered agent (Sahib et al., 2012).
Considering the literature data and the common use of Fructus
anethi graveolentis in Russia and other countries, the drug and itsTa
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Table 15
Summary of Pharmacological Studies for V. vitis-idaea.
Activity tested Model used Plant part used Extract type Admin Dosage/
duration
Control Results Reference
Antidiabetic in vitro. Caco-2/15
intestinal cells; western
blot analysis. in vivo.
Rats, oral glucose
tolerance test (OGTT)
Not indicated EtOH (80%, 1:10)
extract
in vitro 96-
well plate.
in vivo per
oral
25–100 μg/mL
(in vitro);
250 mg/kg
(in vivo)
Negative control. Positive
control: cytochalasin B,
phlorizin, phloretin.
100 μg/mL instantaneous inhibition
glucose absorption inCaco2/15
cells. in vivo No effect in OGTT.
Nistor Baldea et
al., 2010
Anti-inﬂammatory in vitro. Prostaglandin
biosynthesis assay;
PAF-induced exocytosis
Leaves Aqueous extract,
lyophilized.
in vitro 0.2 mg/mL (for
prostaglandin)
0.25 mg/mL (for
PAF)
Negative control. Positive
control: indometacin,
eugenol, quercetin,
saligenin.
Moderate inhibition prostaglandin
biosynthesis (45% ) and strong
inhibition PAF- induced exocytosis
(96% )
Tunón et al., 1995
Anti-inﬂammatory in vivo. Mice, acetic
acid-induced vascular
permeability test.
Stems and leaves EtOH extract,
isolated arbutin,
fraxin
Per oral. 5 g/kg (extract),
0.25 g/kg,
0.5 g/kg
(arbutin, fraxin)
Negative control. Positive
control: dexamethasone
Decrease in vascular permeability
by fraxin (0.5 g/kg) similar
todexamethasone (1 g/kg).
Wang et al., 2005
Antimicrobial in vitro. Agar dilution
assay, Porphyromonas
gingivalis, Prevotella
intermedia
Leaves Isolated
procyanidin B-1,
procyanidin, B-3,
proanthocyanidin
A-1, cinnamtannin
B1, epicatechin-
(4β-8)-epicatechin-
(4β-8, 2β-O-7)-
catechin,
epicatechin-(4β-6)-
epicatechin-(4β-8,
2β-O-7)-catechin.
in vitro. 0–100 μg/mL Negative control. Positive
control: tetracycline
Epicatechin-(4β-8)-epicatechin-
(4β-8, 2β-O-7)-catechin, had strong
antimicrobial activity against
Porphyromonas gingivalis and
Prevotella intermedia with MIC of
25 μg/ml.
Ho et al., 2001
Antimicrobial in vitro. Tube dilution
assay, eleven strains of
E. coli.
Leaves Aqueous, EtOAc,
EtOH extracts
in vitro. 0–100 μg/mL Negative control. Positive
control: amoxicillin
MIC¼5 mg/mL for aqueous extract.
MBC¼ 5 mg/mL for nine strains.
Vučić et al., 2009
Antioxidant in vitro. Anti-lipid
peroxidation activity
(thiobarbituric acid
test). Anti-superoxide
formation: xanthine
oxidase inhibition test.
Free radical scavenger
activity: cytochrome C
test
Leaves. Isolated
procyanidin B-1,
procyanidin B-3,
proanthocyanidin
A-1, cinnamtannin
B1, epicatechin-
(4β-8)-epicatechin-
(4β-8, 2β-O-7)-
catechin,
epicatechin-(4β-6)-
epicatechin-(4β-8,
2β-O-7)-catechin.
in vitro. No data Negative control Cinnamtannin B1 strongest anti-
lipid peroxidation activity
IC50¼2.25 μM, proanthocyanidin
A-1 strongest superoxide
scavenging activity IC50¼10.14 μM,
picatechin-(4β-6)-epicatechin-(4β-
8, 2β-O-7)-catechin strongest
antisuperoxide formation effect
IC50¼308 μM
Ho et al., 1999
Antithrombin in vitro. Thrombin
solution from bovine
plasma
Not speciﬁed MeOH extract,
soxhlet
96 well
plate
50 μL Negative control 94% thrombin inhibition Goun et al., 2002
Antiviral in vitro. Cells infected
with HSV-2. XTT assay.
Plaque reduction assay
Dried whole plants Isolated
proanthocyanidin
A-1
96 well
plate, 24
well plate
0.5–200 μMol Negative control. Positive
control: acyclovir
Proanthocyanidin A-1 anti-HSV-2
activity. IC50¼73.3 μMol for XTT
assay. IC50¼41.9 μMol
IC90¼62.8 μMol for plaque
reduction assay 100.0 μMol
proanthocyanidin A-1 completely
suppressed HSV-2 replication when
added at 12 h post-infection.
Cheng et al., 2005
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preparations should be considered safe and effective. Seeds of A.
graveolens are available in Russia in pharmacies without a pre-
scription and are recommended for internal administration at the
dose of 1/3 of glass of the infusion (10 g in 200 mL of water), 3–4
times per day, as a spasmolytic (Sokolov, 2000). However, pub-
lications regarding clinical trials are far too limited to allow
conclusions regarding the therapeutic potential of this plant. This
botanical drug exhibits clear potential and warrants further
clinical testing.
5.13.2. RHIZOMATA ET RADICES RUBIAE
In a monograph in the Pharmacopoeia of the USSR, Rhizomata
et radices Rubiae is described as the rhizome and roots of Rubia
tinctorum L. (syn. R. iberica (Fish. ex DC) K. Koch). Rubia tinctorum,
the common madder or dyer's madder, is a perennial plant species
in the Rubiaceae that grows to a height of 60-100 cm. Roots of R.
iberica have been used in traditional medicine in the Caucasus
region and Middle Asia as a diuretic (Gammerman et al., 1984).
Extracts of Rubia have been reported to decrease the tension and
increase the amplitude of renal pelvic and ureter contractions. This
extract promotes the motility of stones and their elimination from
the kidney and the urinary tract (Turova, Sapozhnikova, 1989).
The safety of R. tinctorum was evaluated in mice, rats, and cats.
The acute toxicity of an aqueous extract of madder root was
studied during 14 days of administration by gavage to (C57Bl/
6C3H)F1 mice. The maximum tolerated dose of extract was
between 3,500 and 5,000 mg/kg body weight. A subacute toxicity
test was performed using 62 mice of each sex, mixing their diets
with R. tinctorum extract at concentrations of 0, 0.3, 0.6, 1.25, 2.5,
and 5% for 90 days. All mice tolerated these doses well. The body
weight gains of either sex were not affected by the treatment.
None of the mice treated with the extract exhibited clinical signs
of toxicity. Histopathological examination showed retention cysts
of the kidneys and epidermal vaginal cysts in a few of the treated
and control mice. No hyperplastic, preneoplastic, or neoplastic
lesions and no pathological ﬁndings of toxicity were found. It was
concluded that dietary exposure to madder root extract at the
doses tested had no signiﬁcant acute or subacute toxic effects on
mice (Ino et al., 1995). Acute intragastric administration of the dry
extract of R. tinctorum root at doses of 125–15,000 mg/g in mice
was safe, and no side effects were observed. No side effects were
registered after 12 days of intragastric administration of the dry
extract of madder roots (100 mg/kg) in rats. The extract was safe
for cats at doses of 20–200 mg/kg (intragastric). However, an
increased dose of up to 400 mg/kg was followed by vomiting,
excitation for 3 hours, and subsequent sleeping. The physiological
conditions became normalized after 5 hours (Vichkanova et al.,
2009).
Male and female ACI/SegHsd rats weighing 150–200 g received
a diet supplemented with 1 or 10% R. tinctorum root for 780 days.
This root contained lucidin (0.34%), alizarin (0.67%; 1,2-dihydrox-
yanthraquinone) and the primeverosides of both compounds. In
the groups receiving the 10% madder root diet, 2/16 males and 3/
17 females developed hepatocellular adenomas, whereas none
were observed in the controls or the 1% madder root group of
either sex. Renal tubule-cell adenomas were observed in 1/16
males and in 2/16 females in the 10% madder root group, and a
renal tubule-cell carcinoma was observed in 1/14 males in the 1%
madder root group (Westendorf et al., 1998). Male and female
F344 rats were fed diets containing 0%, 2.5%, and 5.0% of a 50%
EtOH extract of madder root for 104 weeks. Body weights were
signiﬁcantly decreased in the treated groups of both sexes
throughout the feeding period. However, survival rates at week
104 were higher in the treated groups of both sexes than in the
controls. The relative weights of the kidneys and liver wereTa
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Table 16
Summary of Pharmacological Studies for Gemmae betulae.
Activity
tested
Model used Plant
part
used
Extract type Admin Dosage/
duration
Control Results Reference
Anticancer in vitro. Human lympho-blastoid Raji
cells
Buds Crude EtOH
(40%) extract
in vitro 10, 50, 200 μg/
mL
Positive control:
methotrexate
ﬂuorouracil, cyclophos-
phamide, vinblastine.
Negative control
63% inhibition at 50 μg/mL and 95% inhibition at 200 μg/
mL,
Spiridonov et
al., 2005
Anticancer in vitro. Mouse leukemia cells L1210 Not
speciﬁed
Methylene
chloride, MeOH
extracts, soxhlet
96 well plate 10 μg per well Positive control
Methotrexate Negative
control
99% growth inhibition by m ethylene chloride extract and
91% growth inhibition by MeOH extract.
Goun et al.,
2002
Antimicrobial in vitro. B. subtilis, S. aureus, E. coli,
P. aeruginosa. Agar diffusion assay,
agar dilution assay.
Buds Acetone extract
(1:5), re-
extracted with
MeOH,
decoction (1:10)
in vitro. 0.039- 5% Negative control.
Positive control:
ciproﬂoxacin,
gentamicin sulphate,
penicillin
Inhibition zones for MeOH extract and decoction were
against S. aureus: 11.2 and 10.2 mm, against B. subtilis: 11
and 8 mm, against P. aeruginosa: 11.6 and 0 mm. MIC for
MeOH extract against P. aeruginosa: 1.25%, against B.
subtilis: 2.5%, against S. aureus: 2.5%.
Duric et al.,
2013
Antimicrobial in vitro. Agar dilution assay, antibiotic-
resistant forms of 144 strains of
Staphylococci isolated from patients with
mastitis, furunculosis, abscesses,
peritonitis.
Buds EtOH (70%)
tincture (1:5)
in vitro. Negative control. Antibacterial activity was observed for all strains with MIC
in dilution 1:90-1:100
Nikolaeva,
Khokhlova,
1981
Antioxidant in vitro. DPPH assay, ABTSþ assay, Buds EtOH extract in vitro 0.01–1.0 mg/mL Negative control.
Positive control: trolox,
ascorbic acid
IC50¼0.511 mg/mL in DPPH assay, IC50¼0.290 mg/mL in
ABTSþ  assay.
Mashentseva
et al., 2011
Antioxidant in vivo. Mice, acute hypoxia.
Phospholipids level in brain.
Buds EtOH extract Per oral 5.0 mg/kg, 20
days
Negative control.
Positive control:
tocopheryl acetate.
Preventive administration of extract resulted in
normalization of phospholipid level. Effect was comparable
with tocopheryl acetate.
Mashentseva
et al., 2011
Diuretic in vivo. Wistar rats, after NaCl solution
load (25 mL/kg)
Buds 6% aqueous
extract
Intraperitoneal 1 mL per animal,
single injection
Negative control.
Positive control:
furosemid
Increase of uric acid elimination in 5 folds comparing to
control group and effect was similar compared to
furosemid.
Peev et al.,
2010
Heavy metals
binding
in vivo.Wistar rats, feed normal diet with
additional 25 mg/kg of Pb and 25 mg/kg
of Cd during 10 days
Buds. EtOH extract, no
details about
concentration
and method.
Per oral. 0.5 mL/kg, 32
days after 10
days of
intoxication by
heavy metals
Negative control. The Pb concentration in animal organs and tissues was
decreased by 45.7-71.3% and Cd, by 10.4-92.2% compared
with control.
Bokova,
Vasil’tsova,
2011
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signiﬁcantly increased in the treated groups of both sexes. Histo-
pathologically, karyomegaly and atypical tubules/hyperplasias, as
well as renal cell adenomas and carcinomas were signiﬁcantly
increased in the treated groups of both sexes, and this result was
dose-dependent. The obtained results indicate that the extract has
carcinogenic potential in the kidney and liver, even at the lower
dose studied (Inoue et al., 2009).
A number of genotoxicity studies of madder color (50% EtOH
extract of madder root) and its constituents have been conducted.
Madder color (MC) was found to give negative results in bacterial
DNA repair assays but positive results in reverse mutation assays
with or without an S9 mix in TA98, TA100 and TA1537 strains
(Hachiya et al., 1985). The anthraquinone constituents of MC,
such as lucidin-3-O-primeveroside and its deglycosylated meta-
bolite, lucidin, caused the formation of DNA adducts in rodents
(Westendorf et al., 1998). Mollugin, 1-hydroxy-2-methylanthr-
aquinone, 2-ethoxymethyl-anthraquinone, rubiadin, 1,3-dihydrox-
yanthraquinone, 7-hydroxy-2-methylanthraquinone, lucidin,
1-methoxymethylanthraquinone, and lucidin-3-O-primeveroside,
which were isolated from the roots of R. tinctorum, exhibited
mutagenicity with Salmonella typhimirium TA 100 and/or TA 98
(Kawasaki et al., 1992). Alizarin, a metabolite of 1-hydroxyanthra-
quinone, was weakly mutagenic in S. typhimurium TA1537 in the
presence of S9 and in rat hepatocyte DNA-repair assays but was
consistently inactive in transformation experiments conducted with
C3H/M2 mouse ﬁbroblasts and in Hprt mutation assays conducted
with Chinese hamster V79 cells (Westendorf et al., 1990).
Considering the literature data, the International Agency for
Research of Cancer (IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans, 2002) has concluded that limited
evidence in experimental animals exists for the carcinogenicity of R.
tinctorum; thus, this material is not classiﬁable with regard to its
carcinogenicity in humans (Group 3). However, 1-hydroxyanthra-
quinone is possibly carcinogenic to humans (Group 2B). Nevertheless,
the possibility of a human cancer hazard must be considered when
madder is used chronically for therapeutic purposes. Table 21
summarizes the pharmacological studies that have been undertaken
on Rhizomata et radices Rubiae and that are reported in the literature.
Alizarin, a constituent of madder root, is employed in phy-
totherapy to prevent recurrences of calcium-containing urinary
stones. Pharmacokinetic studies have been carried out in human
subjects. After a single oral dose of 210 mg of alizarin was
administered, two maxima were observed in the serum concen-
tration curves: the ﬁrst at 2–4 h and the second at 6–8 h. Alizarin
and its glucuronide conjugate were detected in both maxima using
TLC. The mean elimination half-life was 12 h. The amounts
excreted in the urine within 6 days ranged from 18.1 to 36.3%,
and the amounts excreted in the feces within 6 days ranged from
21.6 to 33.0% (total recovery: 40-60%). In bile from a patient who
had undergone cholecystectomy, only 0.6% of the dose was
recovered. To exclude any possibility that alizarin might be bound
to calcium ions in bone, bone trephine specimens were examined
from patients with oxalate stones who had previously been
treated with alizarin for several years. No alizarin was detectable
in these samples (Lorenz et al., 1985).
A group of patients (15 male and female, 29–63 years old) with
renal pelvis stones (1.5–7 cm) was treated with 0.5 g of R.
tinctorum root extract, to be taken three times a day for 30 days.
The resulting therapeutic results were observed in 11 patients. The
report did not give a full description of the controls, which makes
it difﬁcult to assess the outcome of this trial. The treatment of the
patients resulted in the removal of sand and small stones and in
the reduction of pyuria. However, the extract was not effective in
4 patients who had large stones. In another study, tablets (0.25 g)
of the dry extract of R. tinctorum were used in a clinical trial to
treat 22 patients with nephrolithiasis with various urinary stoneTa
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Table 18
Summary of Pharmacological Studies for Convallaria.
Activity tested Model used Plant part used Extract type Admin Dosage/
duration
Control Results Reference
Anti-tumor in vivo, Balb/c mice
induced by human
kidney tumor cells and
by sarcoma L1 cells
Rhizomes and roots Convallamaroside,
the steroidal
saponin.
Per oral 5, 10, 20, 50,
100 μg of
convallamaroside
/ 3 days
Negative control. Antitumor effect on human kidney
tumors, and mouse sarcoma
through inhibition angiogenesis
Nartowska et al.,
2004
Antiviral in vitro. Agar diffusion,
method. HeLa cells
Leaves Aqueous extract
(1:10)
in vitro 0.02 mL Herpes virus Hominis HVP
75 (type 2), inﬂuenza virus
A2 (Manheim 57), Vaccini
virus, poliovirus type 1.
Negative control.
Cytotoxic effect with inhibition
zone 15-30 mm, virustatic effect
with inhibition zone over 30 mm
for all viruses excluding poliovirus
May, Willuhn,
1978
Cardiac inotropic in vivo, beating rabbit
atria
Aerial part Aqueous extract
(1:5), dry,
convallatoxin
ex vivo 0.003; 0.03 mg/
mL for extract
and 0.0001 mM
for convallatoxin
Negative control. Extract signiﬁcantly increased atrial
stroke volume, pulse pressure, and
cAMP efﬂux. and markedly increase
the Kþ concentration in the
beating atria-derived perfusate.
Convallatoxin increased atrial
stroke volume and pulse pressure
but did not alter the cAMP efﬂux
level.
Choi et al., 2006
Cardiac inotropic in vitro. Rabbit
erythrocytes,
(NaþþKþ)-ATPase,
from hog cerebral
cortex
Not speciﬁed Convallatoxin. in vitro. 0.01–10 μM Negative control. Positive
control: ouabain, digoxin,
digitoxin.
Inhibition of palytoxin-induced Kþ
release with IC50¼0.9 μM.
Inhibition of NaþþKþ ATPase with
IC50¼0.84 μM. No inhibition by
aglycones, even at 10 μM
Ozaki et al. 1985
Cardiac inotropic and
constrictor
in vivo. Cats Not speciﬁed. SCOA, a product
which contains
extracts from Scilla,
Convallaria,
Oleander and
Adonis
Intravenous 21.5–100 GPU/kg Positive control: cymarin,
convallatoxin,
proscillaridin, and scillaren
Positive inotropic and moderately
strong vasoconstrictor effect on
veins and arteries. Pure glycoside
convallatoxin, exert equal effects.
Lehmann, 1984
Cardiotonic in vivo. Cats wit
modulated ischemia
Leaves Tincture, no details
about preparation
Intravenous 0.2 mL Negative control. Positive
control: tinctures of A.
vernalis, Digitalis purpurea,
Narium oleander.
The maximal increase in the
amplitude of ischemic skeletal
muscle contractions and has lower
lethal dose comparing with
positive control.
Pardo et al., 1951
Cardiotonic in vivo. Cats, and
isolated papillary
muscle of the cat heart.
Leaves Convara – an
aqueous extract,
treated with ferric
hydroxide,
concentrated under
reduced pressure
until 1 g was
equivalent to 30 g
of dried leaves.
Extract
direct
addition to
the Locke’s
solution.
0.1 g Negative control. Increased strength isometric
contractions of isolated papillary
muscle.
Weeks, Holck,
1943
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localizations: kidney (11 patients), urethra (9 patients), and
bladder (2 patients). The tablets were administered 3 times per
day at the dose of 0.5 g (2 tablets) for 25 days. Positive effects were
observed in 5 patients. The treatment led to the removal of sand
with the urine and to pain reduction. However, no size decrease of
large stones was seen in X-ray examinations. No side effects were
recorded during either trial (Vichkanova et al., 2009).
Tablets (0.25 g of dry extract standardized with a minimum of
8% of ruberitrinic acid) of R. tinctorum root are available in Russian
pharmacies without a prescription and are recommended for
internal administration at the dose of 1 tablet to be taken 3 times
per day (maximum 3 tablets, 3 times per day) in 100 mL of warm
water as a spasmolytic (Sokolov, 2000). However, the information
regarding the chemical composition and pharmacological effects
of this material is insufﬁcient and warrants further study.
5.14. Sedatives
5.14.1. HERBA LEONURI
According to the Pharmacopoeia of the USSR, Herba Leonuri
(motherwort) consists of the aerial parts of Leonurus cardiaca L.
and Leonurus quinquelobatus Gilib. (syn. Leonurus cardiaca L. subsp.
villosus (Desf. ex d'Urv.) Hyl.), Lamiaceae, as collected during the
ﬂowering season. The two species are similar in morphology, the
only difference being the degree of hairiness. L. quinquelobatus has
hairs all around the stem, not only on the angles, and the hairs are
1 mm in length and erect. Because the pharmacological effects of
both plants are similar and L. cardiaca is included in the European
Pharmacopoeia, the pharmacological effects of L. quinquelobatus
will not be discussed in this review.
5.15. Polyvitamins
5.15.1. FRUCTUS SORBI
Sorbus aucuparia L. (rowan, European rowan, mountain-ash, or
European mountain-ash), is a small to medium deciduous tree
typically growing to 8–10 m tall and is a member of the Rosaceae.
The fruit is a small pome of ca. 6–9 mm (rarely up to 14 mm) in
diameter. The edible fruits of S. aucuparia have been traditionally
used in Russia for their diuretic, anti-inﬂammatory, anti-diarrheal,
vasoprotective, and vasorelaxant properties and as a vitamin
source (Turova, Sapozhnikova, 1989; Sokolov, 2000). In Central
and Lower Valais (Switzerland), rowan fruits are used for the
treatment of the gastrointestinal tract as antiﬂatulent and anti-
bloating agents and against colics (Abbet et al., 2014). As docu-
mented in the VOLKSMED database, the fruits of S. aucuparia are
used in Austria as teas, syrups, jellies or liqueurs for the treatment
of respiratory tract-related ailments, such as infections, colds, and
inﬂuenza, as well as fever, rheumatism and gout (Vogl et al., 2013).
Rowanberry is a good source of vitamin C (up to 490 mg/kg)
(Häkkinen et al., 1999) and has been used to prepare dietary jellies
and jams, as a component of syrups and polyherbal mixtures
(Shass, 1952).
Rowanberry is considered of low toxicity. The toxicity is related
to the cyanogenic glycoside amygdalin and to parascorbic acid,
which irritates mucous membranes. These compounds are present
in very low concentrations and therefore rarely cause more than
gastrointestinal effects (Campbell, Chapman, 2000). Table 22 sum-
marizes the pharmacological studies that have been undertaken
on S. aucuparia and that are reported in the literature.
A capillary protective effect of S. aucuparia when taken
in combination with vitamin C and rutin was shown in patients
with myocardial infarct and angina pectoris (Golubenko, 1967).
However, no details are available. No other clinical data were
found in the literature.
Dry fruits of S. aucuparia are available in Russia in pharmacies
without a prescription and are recommended for internal admin-
istration at the dose of 1/2 of glass of the infusion (10 g in 200 mL
of water), taken 2 times a day as a polyvitamin (Mashkovskii,
2002). S. aucuparia fruits can be regarded as a promising and
under-explored fruit that has been used in food in Europe and Asia
and that might ﬁnd wider application for medicinal purposes.
However, the pharmacological effects of this fruit are not well
documented and warrant further study.
5.16. Regulation of metabolism and anti-inﬂammatory agents
5.16.1. INONOTUS OBLIQUUS
According to systematic classiﬁcation methods, Chaga - also
known as birch fungus (Fungus betulinus) - is the terrestrial
polypore fungus Inonotus obliquus (Pers.) Pil (Polyporaceae). Chaga
must be collected only from living or freshly cut old birch trees. On
dry standing and fallen trees, Chaga is destroyed, and the content
of active compounds decreases dramatically (Shashkina et al.,
2006).
Since the 12th century, chaga has traditionally been used in
Russia for the treatment of gastrointestinal disorders, cardiovas-
cular diseases, diabetes, and even cancer. Allegedly, the Russian
duke Vladimir Monomach was cured of lip cancer using chaga
(Artemova, 2001). Chaga (in various combinations with other
medicinal plants) has been used for the treatment of gastric and
duodenal ulcers and for various forms of gastritis (Artemova,
2001; Kaukin, 2002). Chaga tea increases general stamina, relieves
pain and is used to treat heart, stomach, and liver diseases
(Gammerman et al., 1984; Saar, 1991).
The safety of chaga extract was tested in mice, rabbits, dogs,
and cats. The extract was well tolerated in large doses; the LD50 for
mice was 6.5 g/kg body weight. The extract administered per os in
doses up to 1.0 g/kg did not cause any change in the behavior
of rabbits, dogs, and cats (Lazovskaya, 1959). In a chronic
administration test, rats and rabbits received a chaga extract in a
daily dose of 1.0 and 0.3 g/kg body weight, respectively, over
5–6 months. It was concluded that chaga is tolerated well in the
doses indicated and does not exhibit accumulative toxic effects.
The same tests showed no evidence of pyrogenicity upon per
oral administration of chaga in rabbits (Lazovskaya, 1959). Table 23
summarizes the pharmacological studies undertaken on I. obli-
quus and reported in the literature.
Clinical data indicate that when chaga is administered for
extended periods, it has beneﬁcial effects in the treatment of
patients with stage III – IV of cancer, irrespective of the tumor
location. In most of these patients without pronounced cachexia, a
3- to 4-week administration of chaga led to a decrease and a
termination of the pain syndrome, which allowed the administra-
tion of narcotic drugs to be stopped (Bulatov et al., 1959;
Pyaskovskii, Rikhter, 1961; Shashkina et al., 2006).
The commercial chaga extract Befungins contains an EtOH
(10%) extract of chaga with 1.76% of cobalt chloride or 2.0% cobalt
sulfate and is manufactured in 8 factories in Russia. A group of 50
patients (14 women and 36 men) suffering from psoriasis were
treated with Befungins and chaga extract paste. In 37 of these
patients, the development of psoriasis was preceded by diseases of
the gastrointestinal tract or liver (hyperacid or hypoacid gastritis,
hepatocholecystitis, gastric ulcer or duodenal ulcer, or colitis). In
9 patients, these gastrointestinal tract problems appeared during
the existing psoriasis condition, and another 4 patients had
accompanying chronic pharyngonasal cavity conditions. Almost
all patients with gastrointestinal disorders complaining regarding
pyrosis, belching, unstable stool, intolerance to fatty foods, pain in
the right upper quadrant of the epigastric area etc. The patients
noted that the exacerbation of psoriasis often coincided with the
A.N. Shikov et al. / Journal of Ethnopharmacology 154 (2014) 481–536516
Table 19
Summary of Pharmacological Studies for P. hydropiper.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Anticancer in vivo. Mice initiated
with 7,12-dimethylbenz
[α]anthracene (DMBA)
and promoted with 12-
O-tetradecanoyl-
phorbol-13-acetate
(TPA)
Fresh sprouts Isolated
warburganal and
polygodial
Transder-
mal
1.7, 17, 170 nM /
1 h prior to each
promotion with
TPA
Negative control. Positive
control: Salicylaldehyde
Delayed the formation of
papillomas, and markedly reduced
rate of papilloma-bearing mice and
the number of papillomas per
mouse.
Matsumoto,
Tokuda, 1990
Antifertility in vivo. Pregnancy rats. Roots EtOH (90%) extract Per oral 100–200 mg/kg/
single dose
Negative control. 66% antifertility in early pregnancy Prakash, 1985
Anti-inﬂammatory in vitro. Murine
macrophage cell line
(RAW 264.7),
lipopolysac-charide-
activated macrophages
Leaves Commercial MeOH
extract (99% purity)
96 well
plate
0–200 μg/mL Negative control. Suppressed release of NO, TNF-α,
and prostaglandin PGE2. Inhibited
mRNA expression of pro-
inﬂammatory genes such as iNO
synthase, COX-2, and TNF-α by
suppressing the activation of NF-κB,
activator protein (AP-1), and cAMP
responsive element binding protein
(CREB), and simultaneously
inhibited its upstream inﬂammatory
signaling cascades, including
cascades involving Syk, Src, and
IRAK1
Yang et al., 2012
Anti-inﬂammatory in vivo. Mice with
dextran sulphate
sodium (DSS)-induced
colitis
Leaves Commercial MeOH
extract (99% purity)
Per oral 100 mg/kg/ 7 days Negative control,DSS Extract strongly ameliorated the
DSS-induced decrease in colon
length that had been triggered by
DSS-induced colon inﬂammation
Yang et al., 2012
Antimicrobial in vitro. Broth
microdilution method.
Leaves Confertifolin
isolated from
essential oil.
in vitro. Initial
concentration
0.5 mg/mL
Negative control. Positive
control: ﬂuconazole,
ketoconazole, streptomycin
MIC (μg/mL ) was 1.56 against
Erwinia sp, 6.25 against S. aureus and
K. pneumoniae, 7.82 against E.
ﬂoccosum, C. Lunata, and
Scopulariopsis sp., and 16.62 against
T. mentagrophytes and T. rubrum
Duraipandiyan et
al., 2010
Antinociceptive in vivo. Mice, acetic
acid-induced writhing
Aerial part Hexane, EtOAc
MeOH extracts
(yield 1.22, 1.81,
2.28% of dried plant
material).
Per oral 250, 500 mg/kg, Negative control. Positive
control: aminopyrine
50 mg/kg
Suppression of the number of
writhing in 19-55%. Maximal effect
for EtOAc extract at 500 mg/kg.
Rahman et al.,
2002
Antioxidant in vitro. DPPH assay Aerial part Hidropiperoside B
and vanicosides A
isolated from MeOH
extract
96 well
plate
No data Negative control. IC50¼23.4 μg/mL for
hidropiperoside B, 26.7 μg/mL, for
vanicosides A.
Kiem et al., 2008
in vitro. Ferric
thiocyanate method
Leaves Isolated 7,4'-
dimethylquercetin,
3'-methylquercetin
in vitro. 0–10 ppm Negative control. Positive
control: α-tocopherol
ID50¼ 1.5 ppm for 4’-
dimethylquercetin and 3.0 ppm for
3'-methylquercetin.
Haraguchi, 1992
Citotoxic in vitro. Sensitized sheep
erythrocytes and guinea
pig serum
(complement)
Leaves Isolated drimane-
type sesquiterpene
dialdehyde
polygodial.
Microtiter
plates
No data Negative control. Anticomplement activity at 10.5 μg/
mL.
Fukuyama et al.,
1980
Estrogenic in vivo. Ovary-intact and
ovariectomized (OVX)
rats
Roots MeOH extract Per oral 1000 mg/kg / 12
days
Negative control. Positive
control: estradiol-17β (E2)
In uterine tissues of ovary-intact and
OVX rats, extract induced
hyperplasia in places of luminal
epithelium and degeneration of
endometrial glands. In OVX rats, the
effect of extract on uterine
endometrium was corroborative
with the effect of E2.
Hazarika, Sarma,
2006
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Table 20
Summary of Pharmacological Studies for A. graveolens.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Antibacterial in vitro Agar
diffusion assay.
Seeds Aqueous, hexane,
EtOAc, acetone,
EtOH extracts
in vitro. 0.1 mL Negative control.
Positive control:
ampicillin, ceﬁxime,
chloramphenicol, co-
trimoxazole,
gentamicin, imipenem,
pipericillin/tazobactam,
tobramycin
Antibacterial activity
against E. faecalis, S. aureus,
E. coli, P. aeruginosa, S. typhi,
S. typhimurium, S. ﬂexneri
with MIC¼5-10 mg/mL for
acetone extract and 20-
50 mg/mL for aqueous
extract.
Kaur, Arora, 2009
Antibacterial in vitro.
Microdilution
assay. E. coli, P.
aeruginosa, Proteus
mirabilis, K.
pneumoniae,
Acinetobacter
baumannii S.
aureus,
Enterococcus
faecalis, B. subtilis,
and clinical
isolates. C. albicans,
C. parapsilosis
Aerial part Essential oil by
hydrodistil-lation
Microplates No data. Negative control.
Positive control:
ampicillin, gentamicin,
oﬂoxacin, levoﬂoxacin,
ketoconazole,
ﬂuconazole;
MIC¼1-4 μg/mL for all
microbes (excluding
clinical isolates) and
9-18 μg/mL for all fungi.
Erdoğan Orhan et
al., 2012.
Antibacterial in vitro. Broth
dilution method. S.
aureus, E. coli.
Not speciﬁed Commercial
essential oil
96 well
plate
0-0.5% (v/v) Negative control. MIC(v/v)¼0.37% against S.
aureus and 0.47% against E.
coli
Delaquis et al.,
2002
Anticancer in vitro. Mouse
leukemia cells
L1210,
Aerial part Methylene chloride
and MeOH extracts,
soxhlet
96 well
plate
10 μg per well concentration
of the extract
Positive control
Methotrexate Negative
control
98% growth inhibition by
methylene chloride extract,
Goun et al., 2002
Anti-inﬂammatory in vivo, Mice,
formalin induced
inﬂammation
Aerial part, seeds Hydroalchoholic
extract
Intraperito-
neal
300 mg/kg Negative control.
Positive control:
morphine.
Analgesic effect 15–45 min
after formaline injection by
both extracts.
Rezaee-Asl et al.,
2013
in vivo, Rats,
formalin induced
edema
Fresh aerial part Sesame oil extract
(10:4)
Topical
application
on paw
100 mg/ 8 days Negative control.
Positive control:
diclofenac gel 0.01%.
Reducing of the paw
inﬂammation even
stronger than application of
diclofenac.
Naseri et al., 2012
Antispasmodic in vitro. Rats
isolated ileum
contractions
induced by KCl,
acetylcholine and
BaCl2
Seeds EtOH (70%) extract Direct
addition of
extract to
the media
with ileum
0.1, 1, 2, 4 mg/mL /cumulative Negative control. Maximal spasmolytic effect
was for BaCl2 induced
contraction with
IC50¼0.96 mg/mL.
Gharib Naseri,
Heidari, 2007
Antiviral in vitro, antiviral Aerial part Essential oil by
hydrodistil-lation
96 well
plate
0.025–0.8 μg/mL Herpes simplex viruses
HSV-1, parainﬂuenza
type-3 (PI-3). Positive
control: acyclovir,
oseltamivir
Antiviral activity against
HSV-1 at 0.025–0.8 μg/mL
and against PI-3 at 0.4–
0.8 μg/mL.
Erdoğan Orhan et
al., 2012.
Diuretic in vivo. Mongrel
dogs.
Seeds EtOH (70%) extract.
Volatile oil by
steam distillation.
Intrave-
nous.
Volatile oil 0.004 mL/kg.
Extract 12.5, 25 mg/kg.
Negative control. Increase in urine ﬂow
2.2 folds at 12.5 mg/kg no
effect on blood pressure.
25 mg/kg produced a
further but insigniﬁcant
increase in urine ﬂow
accompanied by a marked
hypotension that lasted for
1 h. Volatile oil increased
Naþ and Cl excretion
Mahran et al.,
1991).
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Gastroprotective in vivo. Rats, EtOH
and HCl-induced
gastric ulcer
Seeds Aqueous and EtOH
(70%) extracts
Per oral,
intraperito-
neal.
0.05–0.45 g/kg aqueous extract,
0.5–5 g/kg EtOH extract.
Negative control.
Positive control:
sucralfate, cimetidine
Decreased gastric lesions
induced by HCl with ED50¼
0.12 g/kg for both extracts,
induced by EtOH with
ED50¼0.34 g/kg for
aqueous and 1.73 g/kg for
EtOH extracts. Both
extracts at higher doses
antisecretory activity as
effective as cimetidine.
Hosseinzadeh et
al., 2002
in vivo. Rats,
indomethacin
induced gastric
ulcer after ligation
of pylorus. in vitro
pepsin binding.
Seeds Dry powder,
aqueous and EtOH
(95%) extracts.
Per oral. 1, 1.5, 2 g/kg of powder. Aqueous
and EtOH extracts equivalent of
2 g/kg of powder. 14 days.
Negative control.
Positive control:
indomethacin
The powder of seeds dose
dependent decrease gastric
acid output, increase pH,
and reduce gastric ulcer
index. Effects of aqueous
and EtOH extracts were
signiﬁcant but lower.
Pepsin binding capacity of
powder was 70.4%
at 0.5 g/mL.
Rifat-uz-Zaman
et al., 2004
Hypolipidemic in vivo. Rats fed
with high
cholesterol (Chol)
diet, rats with
normal diet.
Aerial part Essential oil by
hydro-distillation
with α-
phellandrene (32%),
limonene (28%) and
carvone (28%). Dry
powder.
Per oral Essential oil: 45, 90, 180 mg/kg
for high Chol diet rats. Dry
powder: 10%
(w/w) addition for normal diet
rats / 2 weeks
Negative control.
Positive control:
cloﬁbrate
Treatment with essential
oil resulted in dose-
dependent reduction of
total Chol, triglyceride and
LDL-Chol and increase of
HDL-Chol by 24- 33%.
Addition of powder
reduced the total Chol in
20%, LDL-Chol in 2 folds
and triglyceride in 14% and
increased the HDL-Chol
concentration in 30%
compared to control.
Hajhashemiand
Abbasi, 2008
Regulation of
menstrual cycle
in vivo. Rats in
estrus phase of
estrous cycle.
Seeds Aqueous and EtOH
(80%) extracts.
Per oral 0.045, 0.45 g/kg of aqueous and
0.5, 5 g/kg EtOH extracts. 10 days
Negative control. Increase in duration of
estrous cycle and in
diestrus phase and
progesterone concentration
in high dose extract
treatment.
Monseﬁ et al.,
2006.
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exacerbation of gastrointestinal tract disorders. The duration of
the psoriasis condition before treatment with Chaga preparations
was 1 year in 5 patients, up to 3 years in 7 patients, 7 to 5 years in
8 patients, up to 10 years in 13 patients, from 10 to 15 years in
7 patients, and more than 15 years in 10 patients. Among the
patients, 3 were suffering from psoriatic erythroderma, 1 had
psoriatic arthritis, 18 had extensive psoriasis with a massive
inﬁltration of plaques, 20 had extensively spread small plaque
rashes, and 8 had localized psoriatic plaques. Forty-three patients
started the treatment with Chaga during the acute stage of
psoriasis, and 7 started during the steady-state. Chaga extract
was heated au-bain-marie, and 1 tablespoon of the extract was
diluted in a glass of boiled water at room temperature. One
tablespoon of this solution was taken orally, 3 times a day,
20–30 minutes before meals. Water solutions of Befungins were
prepared by mixing 1 dessertspoon of Befungins in 100 mL of
boiled water (after cooling to room temperature). The intake
instructions were the same as those described above. Both Chaga
preparations have no unpleasant odor or taste and were tolerated
well by the patients even after several months of continuous
intake. Most of the patients (42) only used a Chaga preparation for
internal use, although 8 also used ointments and one of the
preparations for internal use. Twenty-four patients used the Chaga
preparations for 3–6 months, 18 patients used them for up to 12
months, and 8 patients used them for more than 2 years. The
therapeutic effect of the Chaga manifested slowly, reaching a
maximum at the 3rd month of regular intake. In most cases, the
psoriatic rashes disappeared starting at the torso, then on the
scalp, upper limbs and ﬁnally, on the hips and lower legs. The
normalizing effect of Chaga treatment was observed on the nail
plates after 2–3 months. Extensive psoriasis with massive plaques
was completely cured in 14 patients, and improvements were
mentioned for 2 patients. Extensive psoriasis with localized plaques
was completely cured in 16 patients, and improvements were
mentioned for 3 patients. Limited psoriasis lesions and erythroder-
mic lesions were completely cured in 5 and 3 patients, respectively.
Psoriasis-therapy with Chaga was especially successful where psor-
iasis occurred in combination with chronic inﬂammatory diseases of
the gastrointestinal tract, liver and biliary system. The maximum
efﬁciency of treatment was noted after 9 to 12 weeks of continuous
intake. Additionally, improvement in gastrointestinal functions,
increased vitality and general tonus was noted in all patients after
long and regular chaga intake, demonstrating the adaptogenic
properties of I. obliquus (Dosychev, Bystrova, 1973).
Chaga and Befungins are available in Russia in pharmacies
without a prescription and are recommended for internal admin-
istration at the dose of 100 mL of the infusion (10 g in 100 mL of
water), 6 times a day, or 20 mL of Befungins, 3 times a day for 3–5
months as a regulator of metabolism and as part of the complex
therapy of gastrointestinal diseases (Mashkovskii, 2002). Chaga is
well known and popular in Russia, and its safety and some evidence
for its efﬁcacy is based on a long tradition of empirical use.
However, there is a lack of information in the literature regarding
its efﬁcacy under controlled conditions. Further clinical studies are
required to evaluate the claimed activity in patients, and more
details on the drug’s safety would be desirable. Given the recent
ﬁndings of the importance of the GI-tract microbiome, studies of
the effect of Chaga on this biome would be of great interest.
5.17. Tonics
5.17.1. RADICES ARALIAE MANDSHURICAE
Aralia elata (Miq.) Seem. syn A. mandshurica Rupr. & Maxim,
also known as Japanese angelica tree (Araliaceae), is an upright
deciduous small tree or shrub growing up to 6 m in height, native
to eastern Russia, China, Korea, and Japan. The stem and root barks Ta
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Table 22
Summary of Pharmacological Studies for S. aucuparia fruits.
Activity tested Model used Plant part used Extract type Admin Dosage/
duration
Control Results Reference
Anticancer in vitro. Mouse
leukemia cells L1210,
Fruits Methylene chloride
extract, soxhlet
96 well
plate
10 μg per well Positive control
Methotrexate Negative
control
98% growth inhibition Goun et al., 2002
Anti-inﬂammatory in vitro. PPARα or PPARγ
activation in human
embryonic kidney
(HEK) 293 cells.
Fruits Detanniﬁed MeOH
extract
96 well
plate
10 μg/mL Negative control. Positive
control GW7647 and
pioglitazone
Strong activation (75-100%) of
PPARα and PPARγ
Vogl et al., 2013
Antimicrobial in vitro. Liquid culture. Fruits Polyphenol-rich
fraction
in vitro. 1 mg/mL Negative control. Strong growth inhibition of Bacillus
cereus. Bacteriostatic effect
against Campylobacter jejuni and
S. aureus.
Nohynek et al.,
2006
Antimicrobial in vitro. Liquid culture.
Inhibition of bacterial
hemag-glutination
Fruits Polyphenol-rich
fraction with
anthocyanins,
ﬂavonols,
5-caffeoylquinic
and 3-
caffeoylquinic
acids.
in vitro. 1 mg/mL. 0.5-
2.0 μg of total
phenolics/mL for
hemag-
glutination
Negative control. Weak inhibition of Salmonella
enterica, and E. coli. Inhibitory effect
on hemag-glutination of E. coli
HB101 (pRR7), which expresses the
M hemagglutinin.
Kylli et al., 2010
Antioxidant in vitro. Liposome and
emulsion oxidation
assays.
Fruits Polyphenol-rich
fraction with
anthocyanins,
ﬂavnols,
5-caffeoylquinic
and 3-
caffeoylquinic
acids.
in vitro. 2.1, 4.2, 8.4 μg/mL
of phenolics for
liposomes. 25, 50,
and 100 μg/g of
phenolics for
emulsion
Negative control. In liposome model 90-97%
inhibition of hexanal formation;
68-77% inhibition formation of
conjugated diene hydroperoxides.
In emulsion oxidation model 86-
95% inhibition hexanal formation;
80-87% inhibition
formationconjugated diene
hydroperoxides.
Kylli et al., 2010
in vitro. Ferric reducing
antioxidant power
(FRAP). DPPH assay.
Fruits Acetone (70%)
extracts of fresh
fruits
96 well
plate
30 μL of 1/40
diluted samples
for FRAP assay
and 50 μL for
DPPH assay
Negative control. The FRAP value 61–105 μM Fe2þ/g
of fresh weight and the DPPH
radical scavenging activity: 9.7-21 g
of berries/g of DPPH radical.
Hukkanen et al.,
2006
in vitro. DPPH assay. Fruits Water soluble
polysaccharides
(yield 4.2%).
in vitro. 0.5 mg/mL Negative control. Positive
control: trolox
35-53% of the activity of trolox
taken as100%
Zlobin et al., 2012
Anti-proliferative in vitro. HeLa cell
viability assay
Fruits Polyphenol-rich
fraction
96 well
plate
50 μg/mL Negative control. Reduced viability of HeLa cell to
50% of control
McDougall et al.,
2008
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of Aralia elata have been used as a traditional and local medicine in
East Asian countries and in Russia to treat coughs, diabetes, gastric
ulcers, hepatitis, and inﬂammatory diseases such as rheumatoid
arthritis (Namba, 1980; Perry, 1980; Turova, Sapozhnikova, 1989;
Ma et al., 2005). The Nanai (“nanaitsy”in Russian), a Tungusic
people of the Russian Far East, have used the roots of A. elata for
toothache and stomatitis, as a tonic, and to treat liver diseases
(Vostrikova, 1973). The Ainu, aboriginal peoples who once domi-
nated Hokkaido in Japan, have used the roots of A. elata (Ayus-ni or
enenkeni in Japan) as a stomachic (Mitsuhashi, 1976). In Russian
codiﬁed medicine, Aralia belongs to the group of classical adapto-
gens (Brekhman, Dardymov, 1969).
The toxic acute and subchronic effects of a A. mandshurica dried
root extract (standardized to a minimum of 3% of aralosides) were
studied in Sprague-Dawley rats of both sexes after per oral
administration. In the acute toxicity experiment, an extract was
administered twice a day at various concentrations. The LD50 was
estimated as 16.5 g/kg and 16.8 g/kg for male and female rats,
respectively. Before death, the animals exhibited nervous depres-
sion, diminished motor activity, frequent micturition, respiratory
difﬁculty, and diarrhea. In a subchronic toxicity assay, the extract
was administered per oral at the doses of 0.2, 1.7, 3.4 g/kg over 90
days. Depression of the CNS response was not observed. An
increase in the levels of aspartate aminotransferase (AST) and
serum alkaline phosphatase (SAP) were observed at the dose of
3.4 g/kg in both sexes on day 90 of administration, but no changes
were observed in urea and serum protein levels. A signiﬁcant
decrease in body weight was recorded in both sexes at the dose of
3.4 g/kg. Moreover, the animals treated with doses of 1.7 and 3.4 g/
kg showed a diminished fecal consistence. An increase in liver
weight was produced with all doses of A. mandshurica, but neither
macroscopic nor histological alterations were observed in the liver
or in other organs. The authors concluded that the extract of Aralia
might accumulate, causing a toxic effect over the long term
(Burgos et al., 1994). The hepatotoxic effect of a dried root extract
of A. mandshurica (standardized to a minimum of 3% of aralosides)
was studied over 60 days (0.16 g/kg, 1.5 g/kg and 3 g/kg) in Land-
race pigs of both sexes. No changes in behavior, external appear-
ance, food consumption, or body weight were observed. The levels
of alanine aminotransferase (ALT) and γ-glutamyl transpeptidase
(gGT) were increased signiﬁcantly at all concentrations of A.
mandshurica at day 60. SAP levels did not signiﬁcantly differ
throughout the experiment. Subclinical hepatitis, which was
characterized by the presence of lymphocytes and polymorpho-
nuclears in the portal and periportal region, was observed (Burgos
et al., 1997). The LD50 for mice after per oral administration of a
combination of aralosides (A, B, and C) was 0.47 g/kg (Brekhman,
Dardymov, 1969). The acute toxicity of araloside A (chikusetsusa-
ponin IV), as isolated from A. elata, was studied in ICR male mice.
The LD50 after 1 week of oral administration was 3.22 g/kg (Lee et
al., 2005). Table 24 summarizes some pharmacological studies that
have been undertaken on Aralia and that are reported in the
literature.
In an open, single-arm study including 106 patients who were
treated for various asthenic conditions, a success rate of approxi-
mately 90% was reported using Aralia. The administration (3 times
per day for 30 days) of 2 mL of A. mandshurica tincture (1:15, EtOH
70%, standardized for aralosides) to patients aged 23 to 60 years
with a diagnosis of long-term effects of traumatic brain injury
with associated asthenic syndrome and neurotic reactions, depres-
sion, neurasthenia, and psychasthenia, signiﬁcantly increased their
working capacity, appetite, and sleep. A decrease in the number of
complaints of fatigue, headache, and general weakness was
observed. Some patients have reported increased sexual potency
and libido (Gubina, 1988). Positive effects in patients with
myasthenia syndrome accompanied by chronic post-inﬂuenza
arachnoiditis were registered after 2 weeks of treatment with
Aralia tincture (Gubina, 1959). Normalization of body function is
one of the main attributes of adaptogens. There were no statisti-
cally signiﬁcant effects of Aralia tincture on patients with normal
blood pressure, although a normalization of blood pressure was
observed in patients with hypotension (Turova, Sapozhnikova,
1989). Aralia exhibits a pronounced positive effect in clinical trials
on introverts and on people with high levels of neuroticism. The
maximal positive effect was observed during the ﬁrst 4 months of
treatment (Markin, Markina, 2007; Markina, Markin, 2008).
The effects of oral treatment with the phytopreparation Aralox
(which contains A. mandshurica and Engelhardtia chrysolepis Hance
(Juglandaceae) extracts) on some parameters of lipid metabolism
were studied. A randomized placebo-controlled study was con-
ducted over 15 weeks and included 32 women with nondiabetic
obesity. The patients received Aralox (main group, n¼16) or
placebo (control group, n¼16) 3 times daily, 30–45 min before
meals. A single dose of Aralox included 150 mg of A. mandshurica
extract containing at least 20% triterpene saponins (aralosides)
and 150 mg of an extract of Engelhardtia chrysolepis leaves contain-
ing at least 20% ﬂavonoid (dehydroquercetin-3-rhamnoside). Thir-
teen women from the main group and 14 controls completed the
15-week study. No appreciable differences were detected in the
physical characteristics and nutrition of the examined patients
between the two groups before Aralox/placebo treatment. The
patients receiving Aralox 3 times daily lost 4.370.7 kg (po0.001)
over 15 weeks vs. 0.770.2 kg for the placebo group. Body weight
loss due to Aralox was almost exclusively (95%) due to fat loss.
Perilipin content in the adipocytes of patients treated with Aralox
decreased by 27%. A course of Aralox treatment promoted an
increase in adipocyte HSL activity from 5.271.1 to 8.171.4 U/mg
protein, whereas controls exhibited virtually no change in this
parameter. Aralox decreased the plasma triglyceride content from
3.670.2 to 1.870.7 mmol/L; in the controls, the triglyceride level
did not change (Abidov et al. 2006).
Since 1975, Saparal tablets containing a mixture of ammonium
salts of aralosides A, B, and C (0.05 g) have been on the market in
the USSR / Russia. Aralosides (A, B and C) stimulate the central
nervous and immune systems, possess anti-stress properties, and
protect against unfavorable environmental conditions, such as
hypoxia or viral infections. After swimmers trained while taking
Saparal at the dose of 50 mg/day for 35 days, a variety of effects
was observed; the level of tissue hypoxia decreased after physical
loading due to an increase in the level of oxidation-reduction
processes in the tissue, the protective properties of an organism
were promoted, and the cytophagous activity of leukocytes was
increased. The decrease in work capacity during the ﬁrst two-three
days after high physical loading was also reduced (Sokolov et al.,
1971). Aralia is a popular plant in the traditional medical systems
in Russia and Asia and has the reputation of being an adaptogen.
Aralia tincture and Saparal tablets are available in Russia in
pharmacies by prescription and are recommended for internal
administration at the dose of 30–40 drops, 2–3 times a day, or
1 tablet, 2–3 times a day, for 10–15 days for use as a CNS stimulant
and as an adaptogen (Sokolov, 2000). However, it is important to
reproduce and conﬁrm the non-clinical studies and to perform
clinical trials according to Good Clinical Practice (GCP).
5.17.2. RHIZOMATA ET RADICES RHODIOLAE ROSEAE
Rhizomata et radices Rhodiolae roseae consists of the dried roots
and rhizomes of Rhodiola rosea L. (syn. Sedum roseum (L.) Scop.),
(Crassulaceae), which is commonly known as golden root, rose
root, roseroot, and arctic root, a perennial plant with shoots
reaching 5-35 cm in height.
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Table 23
Summary of Pharmacological Studies for I. obliquus.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Antiallergic in vivo. Mice Fruiting bodies Aqueous extract Intraperito-
neally Per
oral.
0.1, 0.5, 2.5, 0.1, 1,
10 mg/mouse
Negative control 100% inhibition anaphylactic shock
induced by compound 48/80 at
2.5 mg Oral administration reduced
total IgE levels and slightly affected
production of IgG1. Spleen cell
cultures from OVA-sensitized mice
that had received extract orally
showed an increase in IFN-γ
Yoon et al., 2013.
Anti-astmathic in vivo. Asthmatic mice. Sclerotium EtOH extract Intraperito-
neally
No data. Negative control. Inhibition expression of phosphor-
p38 MAPK, balancing IFN-γ/IL-4 ratio
and decreasing number inﬂammatory
cells
Yan et al., 2011
Anticancer in vitro. Mouse leukemia
cells L1210
Not speciﬁed Methylene chloride
and MeOH extracts,
soxhlet
96 well
plate
10 μg/well Positive control:
Methotrexate Negative
control
100% growth inhibition by Methylene
chloride and 92% by MeOH extracts.
Goun et al., 2002
Anticancer in vivo. Mice with
melanoma. in vitro.
Melanoma B16-F10 cells.
Sclerotium Aqueous extract Intraperito-
neally, per
oral 48 well
plates
Initial concentration
50 mg/mL
20 mg/kg/day (i.p)
200 mg/kg/day
(p.o) during 10 days
Negative control. Positive
control
Intraperitoneal administration
reduced tumor growth to 33% of
positive control. Inhibited growth of
B16-F10 cells by causing cell cycle
arrest at G0/G1 phase.
Youn et al., 2009
Antidiabetic in vitro. 3T3-L1
Preadipocytes.
Fruiting bodies Aqueous extract
with glucose-rich
polysaccharides
149 kDa
96 well
plate
10, 25, 50,
100 μg/mL
Negative control. Positive
control: insulin
Extract enhanced differentiation of
3T3-L1 preadipocytes, and dose-
dependent increased TG
accumulation. It stimulated gene
expression of CCAAT/enhancer-
binding protein α and PPARγ during
adipocyte differentiation, and
induced the expression of PPARγ
target genes such as aP2, LPL and
CD36.
Joo et al., 2010
Anti-inﬂammatory in vivo. Acetic acid-
induced abdominal
constriction, hot plate
tests in mice.
Carrageenan-induced
edema in rats.
Sporophores MeOH extract (29.8%
yield)
Per oral 100, 200 mg/kg/
7 consecutive days
(in rats), 100,
200 mg/kg /single
dose in mice
Negative control. Positive
control: aspirin, ibuprofen.
Dose dependant reduction of paw
edema in rats and analgesic activity in
mice
Park et al., 2005
in vivo. Mice with
dextran sulphate sodium
(DSS)-induced colitis
Fruiting bodies Aqueous extract Per oral 50, 100 mg/kg /
twice a day, 7 days
before and during
DSS admini-stration,
for 14 days. Twice a
day 7 day concur-
rent with DSS
administration
Negative control, DSS Diminishing colitis by suppressing
expression of inﬂammatory
mediators TNF-α, IFN-γ, IL-1β and IL-
6, and iNOS in colonic tissues.
Mishra et al., 2012
Anti-inﬂammatory in vitro. Murine
macrophage cell line
(RAW 264.7),
lipopolysac-charide-
activated macrophages
Sporophores MeOH extract (29.8%
yield)
96 well
plate
45, 90, 135 μg/mL Negative control. Positive
control: l-N6-(1-iminoethyl)
lysine
Inhibition of iNOS and COX-2
expression via the down-regulation of
NF-κB binding activity and reduction
in nuclear p65 protein levels
Park et al., 2005
Antimutagenic in vitro. Ames test Sclerotium Subfractions from
MeOH extract
Agar plates 50 μg /plate Negative control Inhibition of mutagenesis induced in
Salmonella typhimurium strain TA100
by the directly acting mutagen MNNG
(0.4 μg /plate) by 77.3-80.0%.
Inhibition of 0.15 μg /plate 4NQO-
induced mutagenesis in TA98 and
TA100 by 52.6–62.0%. Mutagenesis in
TA100 by Trp-P-1 and B(α)P was
reduced by 70.5–87.2%.
Ham et al., 2009
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Table 23 (continued )
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Antioxidant in vitro. DPPH assay Sclerotium Subfractions from
MeOH extract
in vitro. 5–500 μg/mL Negative control. Positive
control: ascorbic acid,
tocopherol, BHA
IC50¼69 μg/mL for subfraction 1 Ham et al., 2009
in vitro. DPPH, hydroxyl
radicals, superoxide
anion radicals, H2O2
assays
Sclerotium Polysaccharide
fractions IOP40,
IOP60, IOP80 with
yield 2.2%, 11.6%,
0.84%,
in vitro. 62.5–1000 μg/mL Negative control. Positive
control: ascorbic acid
Order of reducing power in DPPH,
H2O2, and hydroxyl-scavenging
activity was IOP604 IOP404 IOP80
Du et al., 2013
in vitro. ABTS, DPPH,
superoxide anion
radicals assays
Fruiting bodies Isolated inonoblins
A, B, and C,
phelligridins D, E,
and G.
in vitro. No data Negative control. Positive
control: trolox, caffeic acid
Inonoblin C was most active in ABTS
assay (0.65 TEAC), phelligridin D in
superoxide anion radicals assay
(IC50¼85.5 μM), Phelligridin E in
DPPH assay (1.57 TEAC)
Lee et al., 2007
Immunomodulatory in vivo. Balb/c mice Sclerotium Aqueous extract Per oral 1–100 mg/kg/ up to
8 weeks
Negative control. Increased in 1.5-3.5 fold the
proliferative activity of splenocytes
transformed in vitro by a polyclonal
Con A mitogen or an alloantigen in a
mixed culture of lymphocytes (MCL)
from allogenic mice spleen. Induced
formation of additional T-killers in
the MCL. 8 weeks administration
stimulated cytotoxic activity of
peritoneal macrophages.
Shashkina et al.,
2006
Immunomodulatory in vivo. Ovalbumin
(OVA)-sensitized BALB/c
mice. ex vivo. LPS-
stimulated peritoneal
macrophages.
Sclerotium Aqueous extract Per oral Daily 50, 100,
200 mg/kg
Negative control. IgG2a was suppressed after the second
immunization with OVA. ConA
stimulation in spleen cells isolated
from OVA-sensitized mice treated
with 100 mg/kg resulted in 5.2%
decrease in IL-4 production and a
102.4% increase in IFN-γ, compared to
controls. IL-4, IFN- γ, and IL-2 were
reduced after ConA stimulation in
isolated CD4þT cells. Extract inhibits
the secretion of NO from LPS-
stimulated peritoneal macrophages
ex vivo.
Ko et al., 2011
Radioprotective in vivo. Rats irradiated
with cesium (2.0 Gy)
Sclerotium Chromogenic
complex
Per oral. 4.0 mg/kg /30 days Negative control. Between 3 and 10 days after
exposure, recovery of hemopoietic
tissue function and bone marrow
cellularity. Stimulation of cells
participating in the immune
protection of neutrophils
(microphages) and lymphocytes.
Gavrilov et al.,
2003
Radioprotective in vivo. Wistar rats Balb/c
mice γ-irradiated
(0.025 sGr/min) 30 days.
Sclerotium Aqueous, EtOH
extracts, aqueous
suspension
Per oral Dose not indicated/
single
administration in
rats 2–3 min after
the intravenous
injection of 90Sr
isotope irradiation.
30 days
administration of
suspension in mice
Negative control. Decrease in the extent of radionuclide
deposition in the bone and soft
tissues and increase of radionuclide
elimination in 33-35% in rats.
Extension of average lifespan of mice
up to 305 days (against 186 days in
the untreated control group) and
prevented a sharp drop of leukocytes
and lipid peroxidation.
Rasina, 2002
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Rhodiola rosea is one of the most popular classical plant adapto-
gens utilized in Russia. In traditional and popular Russian medicine, R.
rosea is used to increase physical endurance, work productivity,
longevity, and resistance to altitude sickness and to treat fatigue,
depression, anaemia, impotence, gastrointestinal ailments, and infec-
tions and disorders of the nervous system (Turova, Sapozhnikova,
1989). In Linne’s Materia Medica (Linne, 1749), the root of Rhodiola is
recommended for the treatment of headaches, "hysteria", hernias,
and discharges and for use as an astringent. A monograph on the root
is also found in the ﬁrst Swedish national pharmacopoeia (Panossian
et al., 2010). Alm (Alm, 2004) mentioned the use of Rhodiola in
popular medicine against scurvy, and this root was also used
medically as a stimulant and, in France, as an astringent (as described
by Virey in a medical textbook published in 1811).
This plant was ﬁrst recommended in 1969 by the Pharmacological
Committee of the Ministry of Health of the USSR for use as a
stimulant against fatigue by patients who suffered asthenic states
and for healthy people with astheny during periods of high mental
exertion or after intensive physical work. The drug can also be used to
treat borderline nervous-mental diseases, neuroses, neurotic disor-
ders, and psychopathies. In psychiatric practice, extracts of R. rosea
are indicated for the correction of neurological side effects associated
with psychopharmacological therapy, and for the intensiﬁcation and
stabilization of remissions in cases of asthenic and apathistical-
aboulic type schizophrenia (Saratikov, Krasnov, 1987, 2004:
Panossian et al., 2010). Since 1975, Rhodiola liquid extract (1:1, EtOH
40%) has been produced industrially in Russia on a large scale, and
since 1985, Rhodiola tablets containing R. rosea SHR-5 extract have
been on the market in Sweden. In April 2009, the ﬁrst R. rosea
product Vitano (based on the R. rosea extracts WS 1375, which was
registered as a traditional herbal medicinal product), was introduced
in the UK (Hung et al., 2011) for use as an adaptogen (Box 1) to treat
decreased performance due to fatigue and the sensation of weakness
(Panossian et al., 2010).
The safety of R. rosea extract was tested in rats, mice, dogs, and
humans. Rhodiola rosea has a very low level of toxicity. The LD50
after intraperitoneal injection of the liquid extract in mice was
found to be 28.6 mL/kg, equivalent to approximately 3,360 mg/kg.
The equivalent dosage in a 70 kg human would be approximately
235 g. Because the usual clinical dose is 200–600 mg/day, there is
a very large safety margin (Brown et al., 2002). No toxic signs were
observed after administration of the glycoside salidroside at the
dose of 1,000 mg/kg (equivalent to 50 mL/kg of extract). Intragas-
tric administration of the extract (1 mL/kg) or salidroside (20 mg/
kg) for 14 days was found safe in rabbits. In a dose range of 10–
40 mg/kg, salidroside does not affect arterial blood pressure in
rabbits after intraperitoneal or intravenous injection. The values of
LD50 for p-tyrosol, another of the main compounds present in R.
rosea,were found to be 2,700 mg/kg and 1,700 mg/kg in mice after
intragastric and intraperitoneal injection, respectively, and
7,079 mg/kg in rats after intragastric administration. No toxicity
was observed after 3 months of chronic intragastric administration
of p-tyrosol at the doses of 200 mg/kg in male rats and 10 mg/kg
in dogs (Saratikov, Krasnov, 2004). Salidroside did not exhibit
genotoxicity in a reverse mutation assay (up to a maximal dose of
5,000 mg/plate), in a chromosomal aberration assay (at doses up to
2,000 μg/kg, and in a mouse micronucleus assay (at doses up to
1,500 mg/kg) (Zhu et al., 2010). No induction of mutations in the
sexual and somatic cells of rats was observed after intragastric
administration of p-tyrosol at the dose of 2,500 mg/kg (Saratikov,
Krasnov, 2004). After the per oral administration of an EtOH
extract from the roots of R. rosea in mice (10-316 mg/kg), sig-
niﬁcant reductions in exploratory behavior and in the number of
rearings and head dippings were observed, but no changes were
seen in the sedative-hypnotic and anticonvulsant response. More-
over, R. rosea reduced licking time in the formalin test. Rhodiola
rosea extract (1,000 mg/mL) was not toxic for Artemia salina. These
results all conﬁrm the very low toxicity risk of Rhodiola (Montiel-
Ruiz et al., 2012).
Rhodiola rosea extract WSs 1375 was safe and generally well
tolerated at a dose of 200 mg twice daily for 4 weeks in subjects
with life-stress symptoms. Two hundred milligrams of dry extract
from R. rosea roots and rhizomes is equivalent to 300–1,000 mg of
R. rosea roots and rhizomes (Edwards et al., 2012).
The results of several hundred pharmacological studies of R. rosea
are assessed in several review articles and books (Saratikov, Krasnov,
1987, 2004; Kelly, 2001; Brown et al., 2002; Panossian, Wagner,
2005; Panossian, Wikman, 2009; Panossian et al., 2010, Hung et al.,
2011; Ishaque et al., 2012). The main pharmacological effects sum-
marized in these reviews include adaptogenic and stress-protective
(neuro-cardio and hepato- protective) effects; stimulation of the CNS,
including cognitive functions such as attention, memory, and learn-
ing; anti-fatigue, antidepressive and anxiolytic effects; increases in
lifespan; cardioprotective effects; and the normalization of endocrine
activity. It is interesting that the effect of Rhodiola on the CNS does
not depend linearly on the dose. The dose-dependent activity curve is
bell-shaped; in small doses, Rhodiola is inactive; at intermediate
doses, Rhodiola is active; and at high doses, it becomes inactive again
(Kurkin et al., 2003; Perfumi, Mattioli, 2007; Wiegant et al. 2009;
Panossian et al., 2010). Table 25 summarizes some pharmacological
studies that have been undertaken on Rhodiolae roseae and that are
reported in the literature.
A systematic review of randomized clinical trials of R. roseawas
published by Hung et al. (2011). Orally administered for 2–6
weeks, a dry SHR-5 extract prepared with EtOH 70% (v/v) and
administered in daily doses of 288–680 mg (1–4 tablets) has been
shown to improve mood (Darbinyan et al., 2007), cognitive
performance and attention, and to relieve fatigue (Darbinyan et
al., 2000; Spasov et al., 2000; Shevtsov et al., 2003; Olsson et al.,
2009) in stress-related conditions. In an endurance exercise
performance test, 24 healthy volunteers who were treated with
100 mg of R. rosea extract (containing 3% rosavinþ1% salidroside)
exhibited signiﬁcant (po0.05) increases in time to exhaustion,
VO2, VCO2, peak O2 output, and peak CO2 output (De Bock et al.,
2004). Recovery after exercise was facilitated after the treatment
of untrained subjects with 340 mg RHODAX (a preparation con-
taining 30 mg of the active substances of R. rosea extract) twice a
day for 30 days before and 6 days after exhausting physical
exercise (Abidov et al., 2004).
Based on the abovementioned studies and other data, the
EMA’s Community herbal monograph on Rhodiola rosea L. rhizoma
et radix (EMA/HMPC/232091/2011) approved its use in 2011 for the
temporary relief of symptoms associated with stress, such as
fatigue, exhaustion and mild anxiety for traditional use only.
R. rosea is a popular plant in traditional medical systems in the
Nordic countries, Eastern Europe, and Asia, and has a very well-
documented reputation as an adaptogen. No major risks have been
associated with R. rosea. An extract of Rhodiola is available in
Russia in pharmacies without a prescription and is recommended
for internal administration at the dose of 5–10 drops, 2–3 times a
day, for 20 days (1–2 months in psychiatric praxis) as a CNS
stimulant and as an adaptogen (Sokolov, 2000). However, it is
important to reproduce and conﬁrm the pre-clinical studies and to
perform large-scale clinical trials according to GCP.
5.18. No pharmacological group is stated in the Pharmacopoeia
5.18.1. HERBA POLYGONI PERSICARIAE
Persicaria maculosa Gray (syn. Polygonum persicaria L.), Poly-
gonaceae, also known as lady's thumb, is a perennial plant that
grows up to 1 m high and has narrow, lancet-shaped leaves that
are 8–10 cm long. A decoction and an infusion have been used in
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Table 24
Summary of Pharmacological Studies for Aralia.
Activity tested Model used Plant part used Extract type Admin Dosage/ duration Control Results Reference
Antiarrhythmic in vivo. Rats, coronary
occlusion and
reperfusion
Roots Aqueous extract Intragastric 16 mg/kg, 5 days Negative control Improvement heart resistance to
arrhythmogenic effect of ischemia
and reperfusion. 86% of animals
receiving extract before coronary
occlusion developed no
arrhythmias, vs. 19% in controls.
Severity of arrhythmia in treated
rats was 74% lower during ischemia
and coronary blood ﬂow recovery
than controls.
Maslov et al.,
2009
Anticancer in vitro. Human kidney
cancer cell lines GRC-1
and 786-O
Roots Isolated araloside A in vitro 1, 3, 10, 30, 100 μM Negative control Reduction of cellular viability of
booth cells in a dose- and time-
dependent manner. Number of
Tunnel-positive cancer cells was
higher in cells treated with
Araloside A than untreated cells.
Araloside A increased expression of
bax mRNA and inhibited expression
of bcl-2 mRNA.
Yu et al., 2011
Anticataract ex vivo. Rat lenses from
male Sprague-Dawley
rats. Sugar cataract was
induced by adding of
(þ)-xylose to media
Bark Aqueous extract
with 7% yield
24 well
plate
0.5, 1 mg/mL Negative control After treatment at 1 mg/mL lens
opacity was lowered by 36.4 and
31.3% after 24 and 48 h,
respectively
Chung et al.,
2005
Anticataract in vivo. STZ-induced
diabetic rats
Bark Aqueous extract
with 7% yield
Per oral 300, 600 mg/kg
daily, 11 weeks
after STZ
administration
Negative control After treatment with 300 or
600 mg/kg extract the opacities of
lenses decreased by 15% and 12%
respectively.
Chung et al.,
2005
Anti-inﬂammatory in vitro. Murine
macrophage cell line
(RAW 264.7),
lipopolysac-charide-
activated macrophages
Roots Isolated saponin
elatoside F
96-well
plates
24-well
plates
0.96, 9.6, 48, 96 μM Negative, Positive control:
tosyl phenylalanyl
chloromethyl ketone,
Inhibition of LPS-induced NO
production in 28.8, 43.2, 67.9, and
81.2% at 0.96, 9.6, 48, and 96 μM.
Inhibition of NF-κB activity in 20.4,
and 33.7% at 48 μM, and 96 μM
respectively.
Lee et al., 2009
Antiulcer in vivo. Aspirin-induced
ulcer. HCl-EtOH
induced gastric lesions.
Root bark Isolated araloside A Per oral 50, 100 mg/kg Negative control. Positive
control: cimetidine.
Reduction of HCl-EtOH-induced
gastric lesions and aspirin-induced
gastric ulcers. Antiulcer action may
be due to the inhibition of gastric
acid secretion
Lee et al., 2005
Cardioprotective in vivo. Cardiac
dysfunction in STZ
induced diabetes rats.
Roots Total aralosides, no
details about
isolation.
Per oral 4.9, 9.8, 19.6 mg/kg,
for 8 weeks
Prevents diabetes-induced cardiac
dysfunction by increased absolute
value of left ventricular systolic
pressure and maximum rates of
pressure development, and
enhanced amplitude of ICa2þ-L in
cardiac cells and decreasing
connective tissue growth factor
expression. High dose, but not low
prevented cardiac ultrastructural
changes in diabetic rats, indicated
by closely lining up of
myoﬁlaments and almost normal
structure of mitochondria
Xi et al., 2009
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Russian traditional medicine for the treatment of hemorrhoidal
bleeding and as a laxative and a diuretic (Vereschagin et al., 1959).
The infusion of P. persicaria is recommended to treat patients with
atonic constipation (Sokolov, 2000). The infusion and an EtOH 70%
extract of the aerial parts increase gastrointestinal motility, induce
vasoconstriction in blood vessels, increase blood viscosity and
activate blood coagulation in rabbits (Samarina, 1950). Antihyper-
tensive properties were demonstrated in frogs and guinea pigs
(Samarina, 1948). A laxative effect and increased diuresis were
observed in mice after administration of an EtOH (70%) extract of
P. persicaria (Belikova, 1944).
Reportedly, the aerial parts of P. persicaria have very low
toxicity (Sokolov, 2000); however, no details are available. A
limited number of pharmacological studies regarding Herba poly-
goni persicariae are available (Table 26).
A single-arm, uncontrolled, non-blinded study was performed
on a group of 34 patients suffering from hemorrhoids. The patients
were treated with an infusion of P. persicaria three times a day
before meals for 7–21 days at doses 20-100 mL. Positive results
were observed in 27 patients. Subjective complaints decreased,
bowel movements became regular, bleeding stopped completely
or decreased, and a diuretic effect was observed (Turova,
Sapozhnikova, 1989).
Aerial parts of P. persicaria are available in pharmacies without
a prescription and are recommended at the dose of 20 mL of
infusion (20 g in 200 mL of water) taken 3 times per day to treat
chronic atonic constipation and hemorrhoids (Sokolov, 2000).
However, the chemical and pharmacological evidence to support
these medical applications, especially as a antihypertensive, dates
from the early 1940s and needs further conﬁrmation.
5.18.2. HERBA THERMOPSIDIS LANCEOLATAE
Thermopsis lanceolata R. Вr. (bush pea, Leguminosae) is a
perennial plant attaining 40 cm in height. The aerial part is
harvested before ﬂowering. Decoctions are used in Russia to treat
respiratory catarrh, ﬂu, bronchitis, pneumonia and headaches
(Akopov, 1990; Mamedov, Craker, 2001). In China, T. lanceolata is
used to stimulate breathing and prevent coughs (Li et al., 2007).
The dry extract of Thermopsis (using 25% EtOH as an extragent)
was proposed in USSR in 1933 as an expectorant and to promote
the thinning and removal of secretions (Vereschagin et al., 1959).
The standardized extract Cytiton (containing 0.15% cytosine and
obtained from the seeds of T. lanceolata) has been prescribed to
stimulate respiratory function, improve blood circulation and treat
asphyxia (Khalmatov et al., 1984; Gammerman et al., 1984).
Various extracts of T. lanceolata have all shown to be toxic. The
toxicity of a MeOH extract was studied in mice after per oral
administration. All mice died within 2–2.5 min after the single
acute administration of 300 mg/kg of extract. After 60 days of
chronic administration at the dose of 50 mg/kg, this material was
found to be toxic (Zhu et al., 2003). Toxicity resulted in paroxysmal
supraventricular and ventricular tachycardia and extrasystoles
(Chatval, 2009). In low doses, dry extracts of T. lanceolata excite
the respiratory center; in high doses, these extracts can cause
vomiting and paralyze the centers of the brain and the medulla
oblongata. The maximal single dose of the aerial part for adults is
0.1 g, and the maximal daily dose is 0.3 g (Sokolov, 2000). The
acute toxicity of cytisine (the main quinolizidine alkaloid in T.
lanceolata) was studied in rats and mice. The LD50 was estimated
at 5–50 mg/kg body weight in rats after per oral administration. In
repeated dose toxicity studies, cytisine was administered to the
rats for 30 and 90 days at the doses of 7.6 mg/kg and up to
1.35 mg/kg, respectively. No changes were observed in clinical
laboratory parameters or histomorphology in experimental ani-
mals. When applied chronically in mice (3.3 mg/kg) for 45 days
C
ar
di
op
ro
te
ct
iv
e
In
vt
rv
o.
In
ju
ry
in
d
u
ce
d
by
H
2
O
2
,i
n
H
9c
2
ce
lls
Ro
ot
ba
rk
W
at
er
-s
ol
u
bl
e
p
ol
ys
ac
ch
ar
id
e
A
EP
-w
1
(M
r
4.
5

10
4
D
a)
.
M
on
os
ac
ch
ar
id
e
co
m
p
on
en
ts
:
ar
ab
in
og
al
ac
ta
n
,
co
n
si
st
in
g
of
ar
ab
in
os
e,
ga
la
ct
os
e
an
d
tr
ac
e
gl
u
co
se
w
it
h
m
ol
ar
ra
ti
os
of
6.
3:
3.
5:
0.
2.
96
-w
el
l
p
la
te
s
10
0,
20
0,
40
0
μg
/
m
L
N
eg
at
iv
e
co
n
tr
ol
A
EP
-w
1
su
p
p
re
ss
ed
ca
rd
io
m
yo
cy
te
ap
op
to
si
s,
th
e
m
it
oc
h
on
d
ri
al
m
em
br
an
e
p
ot
en
ti
al
ch
an
ge
an
d
cy
to
ch
ro
m
e
C
re
le
as
e
in
H
2
O
2
-
tr
ea
te
d
H
9c
2
ce
lls
.I
n
tr
ac
el
lu
la
r
re
d
u
ce
d
gl
u
ta
th
io
n
e
(G
SH
)
re
d
u
ct
io
n
ca
u
se
d
by
H
2
O
2
in
H
9c
2
ce
lls
w
as
re
st
or
ed
by
A
EP
-w
1
p
re
tr
ea
tm
en
t.
Zh
an
g
et
al
.,
20
13
G
as
tr
op
ro
te
ct
iv
e
in
vi
vo
.R
at
s,
co
ld
-
re
st
ra
in
t
st
re
ss
(C
R
S)
,
py
lo
ru
s
lig
at
io
n
Ro
ot
s
Et
O
H
(5
0%
)
ex
tr
ac
ts
In
tr
ap
er
it
o-
n
ea
l
50
m
g/
kg
,3
0
m
in
p
re
tr
ea
tm
en
t
N
eg
at
iv
e
co
n
tr
ol
.
Pr
et
re
at
m
en
t
re
d
u
ce
d
in
ci
d
en
ce
an
d
se
ve
ri
ty
of
C
R
S-
in
d
u
ce
d
ga
st
ri
c
gl
an
d
u
la
r
le
si
on
s.
G
as
tr
ic
se
cr
et
or
y
vo
lu
m
e
w
as
re
d
u
ce
d
,i
n
cr
ea
se
d
in
tr
al
um
in
al
ga
st
ri
c
p
H
an
d
d
ec
re
as
ed
ac
id
ou
tp
u
t.
H
er
n
an
d
ez
et
al
.,
19
88
H
yp
og
ly
ce
m
ic
in
vi
vo
.R
at
s,
gl
u
co
se
to
le
ra
n
ce
te
st
(G
TT
)
Ro
ot
ba
rk
Is
ol
at
ed
ol
ea
n
ol
ic
ac
id
an
d
9
ol
ig
og
ly
os
id
es
Pe
r
or
al
10
0
m
g/
kg
,s
in
gl
e
ad
m
in
is
tr
at
io
n
N
eg
at
iv
e
co
n
tr
ol
.
3-
O
-m
on
od
es
m
o-
si
d
es
el
at
os
id
es
A
an
d
E,
st
ip
u
le
an
o-
si
d
e
R
1
an
d
ol
ea
n
ol
ic
ac
id
3-
O
-g
ly
co
si
d
es
sh
ow
ed
p
ot
en
t
in
h
ib
it
or
y
ac
ti
vi
ty
in
G
TT
Yo
sh
ik
aw
a
et
al
.,
19
96
H
yp
og
ly
ce
m
ic
in
vi
vo
.R
at
s,
ra
bb
it
s
w
it
h
h
ig
h
ch
ol
es
te
ro
l
d
ie
t.
Ro
ot
Sa
p
ar
al
(m
ix
tu
re
of
am
m
on
iu
m
sa
lt
s
of
ar
al
os
id
es
A
,B
,C
)
Pe
r
or
al
10
,2
3,
58
m
g/
kg
,
3
d
ay
s
(r
at
s)
,
58
m
g/
kg
(r
ab
bi
ts
)
N
eg
at
iv
e
co
n
tr
ol
.
B
lo
od
se
ru
m
ch
ol
es
te
ro
li
n
ra
ts
w
as
re
d
u
ce
d
by
29
.8
%
co
m
p
ar
in
g
to
co
n
tr
ol
at
58
m
g/
kg
.L
ev
el
of
ch
ol
es
te
ro
l
in
th
e
ao
rt
a
w
as
re
d
u
ce
d
by
31
.7
%
.I
n
ra
bb
it
s
bl
oo
d
ch
ol
es
te
ro
l
w
as
re
d
uc
ed
by
61
.4
%
.
V
os
ka
ny
an
et
al
.,
19
83
A.N. Shikov et al. / Journal of Ethnopharmacology 154 (2014) 481–536 527
Table 25
Summary of Pharmacological Studies for R. roseae.
Activity tested Model used Plant
part
used
Extract type Admin Dosage/
duration
Control Results Reference
Adaptogenic
and CNS
in vivo. Mice, forced-swimming
test, swimming to exhaustion,
light/dark exploration, open
ﬁeld, tail-ﬂick
Roots Commercial EtOH
extract (containing
3% rosavin and 1%
salidroside)
Intragastric 10, 15, 20 mg/
kg / single
dose
Negative control Induction antidepressant-like, adaptogenic, anxiolytic-like and
stimulating effects. Bell shaped dose-activity curve
Perfumi,
Mattioli,
2007
Adaptogenic in vivo. Rats, exhaustive
swimming
Rhizome
and roots
EtOH (60% v/v)
extract with 3.02%
rosavines and 0.89%
salidroside
Intragastric 50 mg/kg/
single dose
Negative control Prolonged duration of swimming (by 24.6%).
Activated the synthesis or resynthesis of ATP in mitochondria.
Abidov et
al., 2003
Anticancer in vitro. Human lymphoblastoid
Raji cells
Roots Crude EtOH (40%)
extract
in vitro 10, 50, 200 μg/
mL
Positive control:
methotrexate
ﬂuorouracil, cyclophos-
phamide, vinblastine.
Negative control
99% growth inhibition at 200 μg/mL; 75% inhibition at 50 μg/mL with
formation of giant polyploid cells.
Spiridonov
et al., 2005
Antiarrhythmic in vivo. Rats, isolated heart. Roots EtOH (40%) extract Per oral 3.5 mL/kg,
8 days
Negative control,
Positive control:
Naloxone, ICI 174,864
Prevention reperfusion arrhythmias and elicitation protective effect
in experiments on isolated heart in interrupting the perfusion with
Krebs–Henseleit solution followed by reperfusion. Antiarrhythmic
effect was mediated through activation of μ-opiate receptors in
myocardium.
Maslov et
al., 1997
Antiviral in vitro. Plaque reduction assay
in vivo. BALB/c mice, Sprague-
Dawley (SD) rats
Coxsackievirus B3 (CVB3)
Roots Salidroside (purity
99%)
Per oral 20, 60, 80 mg/
kg / 7 days
Negative control.
Positive control:
ribavirin
Antiviral effects both in vitro and in vivo. Salidroside modulate the
mRNA expression of interferon-γ, interleukin-10 (IL-10), TNF-α, and
interleukin-2 (IL-2).
Wang et al.,
2009
Antiviral in vitro.Virus-induced cytopathic
effect (CPE) in Madin-Darby
canine kidney (MDCK) cells
Viruses: H1N1 (A/PR/8/34)
and H9N2 (A/Chicken/
Korea/ MS96/96).
Roots Aqueous, EtOAc
extracts.
Isolated kaempferol,
herbacetin,
rhodiolinin,
rhodionin, and
rhodiosin
in vitro. Initial
concentration
5 mM
Negative control.
Positive control:
oseltamivir (Tamiﬂu)
EtOAc extract EC50¼ 102.1 μg/mL against H1N1 and 145.4 μg/mL
against H9N2.
Aqueous extract EC50¼78.5 μg/mL against H1N1 and 139.7 μg/mL
against H9N2. For kaempferol, herbacetin, and rhodiolinin
EC50¼ 30.2, 35.0, and 41.7 μM against H1N1- and 18.5, 23.0, and
29.3 μM against H9N2.
Jeong et al.,
2009
Antiviral in vitro. HIV-1 protease
inhibition
Roots MeOH extract in vitro. 100 μg/mL Negative control.
Positive control: acetyl
pepstatin
70.4% inhibition of HIV-1 protease Min et al.,
1999
Hypotensive in vivo. SHR rats. Roots Aqueous extract with
salidroside (8.4 mg/g)
and p-tyrosol
(1.9 mg/g).
Per oral 35, 50, 75 mg/
kg
Negative control Dose-dependent decrease systolic blood pressure and increase β-
endorphin release.
Lee, et al.,
2013.
Neurotropic in vivo. Mice, thiopental-induced
sleep
Roots EtOH extract Per oral 10–500 mg/kg Negative control Stimulation at 10 mg/kg (sleep period reduced by 12.5 times),
sedation at 500 mg/kg (sleep period was increased 3-fold)
Kurkin et
al., 2003
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and in rats (0.45 and 0.9 mg/kg) and dogs (0.45 mg/kg) for
6 months, cytisine was not found to cause any changes in clinical
laboratory and histomorphological parameters in the animals;
however, some light liver dystrophic changes were observed
(Tzankova and Danchev, 2007). Overall, very limited pharmaco-
dynamics data are available.
No clinical data on T. lanceolata were found. Currently, the
aerial parts of T. lanceolata are not available in pharmacies. "Cough
tablets" (containing 0.0067 g of powdered aerial parts of T.
lanceolata and 0.25 g of NaHCO3) are available in Russia in
pharmacies without a prescription and are recommended for use
as an expectorant at the dose of 3 tablets per day taken for 3–5
days. Tablets containing 0.05 g of a standardized dry extract of T.
lanceolata (1% of alkaloids) are recommended for adults as an
expectorant at the dose of 2–3 tablets per day (Sokolov, 2000). The
dry cough mixture, containing 0.045 g of a standardized dry
extract of T. lanceolata per dose, is recommended for use by adults
as an expectorant at 1 dose dissolved in a tablespoon of water, to
be taken 3–4 times per day (Mashkovskii, 2002). The information
available regarding the chemical and pharmacological effects of
this material is insufﬁcient, and use of the drug use cannot be
recommended until more detailed studies (especially on its safety)
become available.
6. Conclusions
This review article examines the data on medicinal plants
included in the Russian Pharmacopoeia, which have been used
for many years in the ofﬁcinal Russian medicine; these plants
are not very well known as medicines outside of their region of
origin. Only 83 medicinal plants are referenced in the State
Pharmacopoeia of the USSR (11th ed.), which provides the results
of sophisticated scientiﬁc investigations and practical evaluation.
All medicinal plants were evaluated by professionals involved in
drug regulatory affairs based on state standards. The in vivo and
in vivo effects and, in some cases, the effectiveness and safety of
HMPs have been studied in considerable detail. However, our
analysis is limited, for example, by the fact that many unpublished
documents are deposited in the regulatory archive that are not
available to the public.
During most of the Soviet period, the country was closed not
only from a political point of view, but also scientiﬁcally. Many
scientiﬁc articles were never translated into English, and much
information collected by scientists was not made available for the
international community. In this review, we summarize and
critically assess data that were published in Russia and other
countries on medicinal plants that have a long history of often
well-studied application in the Russian Federation; the review
highlights the potential for further developing these herbal
medicines.
Most importantly, Soviet / Russian scientists contributed sig-
niﬁcantly to the development of plant-derived adaptogens – tonics
that play an important role in the regulation of metabolism. Aralia,
Rhodiola, and Chaga are good examples of adaptogens that have
been studied extensively (especially in the USSR / Russia). Modern
research on the molecular mechanisms of action of these drugs are
essential to improving our understanding of the effects of adapto-
gens and their potential to improve many aspects of neuropsy-
chiatric disorders, including perceived energy levels, cognitive
function, memory, attention, and mental and physical perfor-
mance, particularly under stress.
Great potential is exhibited by the group of plants with
expectorant effects. However, further studies are required to
develop the potential of these plants to yield more efﬁcientTa
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treatments. In this and other cases, the risks of adulteration must
be monitored carefully.
Four plants mentioned in the Pharmacopoeia of the USSR are
diuretics and three are astringents. It is interesting that the
rhizomes of Bergenia crassifolia are known as astringents but the
leaves appear to meet the criteria required for being an adaptogen.
A number of positive effects, especial antihypertensive effects,
are attributed to G. uliginosum. However, publications regarding
the chemistry and pharmacological effects of this material are
fragmentary.
We hope that this analysis will foster more detailed research
and development on some of these medicinal plants. It is impor-
tant to reproduce and conﬁrm the non-clinical studies and to
perform clinical trials of the mentioned medicinal plants according
to GCP.
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